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ABSTRACT
Type 1 diabetes affects over 108,000 children, and this number is
steadily increasing. Current insulin therapies help manage the disease but are not
a cure.
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to
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complications of type 1 diabetes. This autoimmune disease destroys beta cells
located in the pancreas, which are used to regulate glucose levels in the body.
Because there is no cure and many children are affected by the disease there is a
need for alternative therapeutic options that can lead to a cure.
Human mesenchymal stem cells (hMSCs) are an important cell source for
stem cell therapeutics due to their differentiation capacity, self-renewal, and
trophic activity. hMSCs are readily available in the bone marrow, and act as an
internal repair system within the body, and they have been shown to differentiate into
insulin producing cells. However, after isolation hMSCs are a heterogeneous cell
population, which requires secondary processing. To resolve the heterogeneity issue
hMSCs are separated using fluorescent- and magnetic-activate cell sorting
with

antigen

viability

after

labeling.

This

techniques

are

efficient

but

reduce

cell

separation due to the cell labeling. Therefore, to make

hMSCs more readily available for type 1 diabetes therapeutics, they should
be

separated

without

diminishing

there

functional

capabilities.

Dielectrophoresis is an alternative separation technique that has the capability
to separated hMSCs.
xxiv
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UDWKHUWKDQthe antigen labeling implemented with FACS and MACS. DEP has
been used to characterize other cell systems, and is a viable separation technique
for hMSCs.
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Chapter 1 Introduction
Stem cell therapy has gained popularity in medical research especially as a
therapeutic option for chronic disease treatment. This chapter will overview the main
topic of this dissertation, which is utilizing dielectrophoretic technology to purify
human mesenchymal stem cells for type 1 diabetes treatment. The sections to follow
will motivate the work with statistics on the prevalence of type 1 diabetes in the U.S.
and world, briefly describe human mesenchymal stem cells differentiation toward
insulin producing cells, dielectrophoresis, microfluidics, and the combination of the
technologies.

1.1 Motivation: Stem Cell Therapy and Diabetes Mellitus
Heart disease, stroke, and diabetes mellitus are chronic diseases that 27.3
million Americans (or 8.7% U.S. population) live with and these diseases claim
800,000 lives each year [1-4]. Many chronic diseases are treatable by diet and
exercise [5, 6] while others like type 1 diabetes (0.8 % of all diabetes mellitus cases)
require therapeutic options [7]. Type 1 diabetes, mostly diagnosed in children, is a
result of the pancreas not producing insulin and thus requiring insulin therapeutics
[8]. This means that young children, through their entire life, inject themselves with
insulin multiple times a day, making the disease difficult to manage. More than
108,000 children between 0-14 years have type 1 diabetes with 16,000 new cases
diagnosed each year [9]. In 2007, it cost ~$116 billion to treat diabetes, and as
children become adults complications include heart disease, stroke, blindness, kidney
1

disease, hypertension, amputations, dental disease, and pregnancy complications
[10]. Insulin therapy is in place as a management tool, but does not solve the main
issue of beta cell destruction in type 1 diabetes. This necessitates the development of
treatment options that can potentially cure type 1 diabetes rather than just
intermittently managing it. The International Diabetes Federations tracks the shows
the prevalence of diabetes in adults and children worldwide. For the western
hemisphere, diabetes in most prevalent in Mexico with > 12% of the population
affected. The U.S. and Brazil come in second with 9-12% of the population affected.
It is projected that 592 million people will suffer from diabetes in 2035 compared to
382 million people in 2013 [9], (see http://www.idf.org/diabetesatlas ).
Human mesenchymal stem cells (hMSCs) are an interesting cell source to
researchers because of their regenerative [11, 12] and immunological properties [13].
hMSCs are exciting in medical research because they can serve as an internal repair
system in the body. Upon injury, signals are sent to hMSCs and they migrate to those
specific injured areas, differentiate, and promote healing [12, 14]. hMSCs are
unspecialized cells isolated primarily from bone-marrow [15] demonstrating
significant properties such as high differentiation capacity (adipocytes, chondrocytes,
osteoblasts, etc.) [14, 16, 17], self-renew [18, 19], and secretion of bioactive
molecules (trophic activity) [12, 13, 20, 21].

Trophic activity is significant to

hMSCs function because signals are sent to surrounding cells and trigger them to
perform specific roles such as tissue regeneration [20, 21].

2

One problem associated with hMSC bone-marrow isolation is that they are
obtained as a heterogeneous mixture [22, 23]. In order for hMSCs to be used as an
effective therapeutic, they must first be purified. For therapeutic treatments,
obtaining hMSCs is a multistep process. Following bone-marrow isolation, hMSCs
are centrifuged via density gradient solution (step 1), adhered to a plastic cell culture
dish (step 2), and separated using trypsinization (step 3) [24]. This method is
inefficient and time consuming taking days to complete [25], so other separation
techniques have been employed. Fluorescent- and magnetic-activated cell sorting
(FACS and MACS) use unique cell-surface recognition elements to tag target cells.
This cell labeling alters cellular function, which is not desirable in therapeutics. Cell
culture purification, FACS, and MACS approaches all require expensive raw
materials and are labor intensive [25-27].
Other drawbacks with hMSCs are that their natural inherent biological
functions are not well understood, and within one population hMSCs, cells express
different membrane surface proteins [28]. Currently there is not one unique marker
(surface proteins, differentiation pathway, plasticity in cell culture, etc.) that
distinguishes hMSCs from other cell populations [22, 29] or identify their disposition
to differentiate to specific cell types. The minimum requirements established by the
International Society for Cellular Therapy to name a cell population hMSCs are: (1)
plastic adherence (generic cellular property [14]); (2) positive expression of
biosurface markers CD105, CD73, and CD90; (3) negative expression for CD34,
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CD45, CD11a, CD19, CD14, and HLA-DR; and (4) adipogenic, osteogenic, and
chondrogenic differential potential [17, 30].
Additionally, hMSCs morphology varies creating subpopulations [31], which
adds another dimension to overcome for effective purification. From this point
forward, purification and separation terminology will be used interchangeably.
According to Haasters et al., hMSCs can be assigned three morphological
subpopulations: (1) rapidly self-renewing cells, triangular or star-like shape; (2)
elongated, fibroblastic-like, spindle-shaped cells; and (3) slowly-replicating, large
cuboidal or flattened cells [31]. These subpopulations are dependent on cytoskeleton,
cell adhesion, and active pathways that directly determine cell fate and
differentiation [31]. Others have looked at hMSCs viscoelastic properties, the
tendency to exhibit viscous and elastic characteristics under deformation, because it
plays an important role in a cell’s biological response [32]. In the study completed by
Darling et al., the elasticity and viscoelasticity of two distinct spherical and spread
star-like hMSC morphologies were examined. The elasticity was found to be 2.5kPa
for spherical and 3.2kPa for spread star-like hMSCs, while the viscoelasticity of the
spherical morphology was 0.47kPa the spread star-like was 2.2kPa. These results
show how hMSC morphology changes subpopulation properties.
Elastin-like polypeptide (ELP) polyethyleneimine (PEI) is a positively
charged water soluble block copolymer that directs cells morphology, and can be
used to remove variations in cellular population/subpopulations [33]. ELP is a
mammalian elastin made from amino acids including valine, proline, and glycine; it
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has previously been used in drug delivery and tissue engineering applications [34,
35]. Recent studies have shown that ELP-PEI successfully induces spheroid
formation of rat hepatocytes [36]. The potential benefit of using ELP-PEI is to
eliminate variations in hMSCs morphology as discussed in Chapter 4 [37]. Despite
the shortcomings of currently available separation technologies, hMSCs therapeutics
have demonstrated their healing potential.

1.2 Successful hMSC Therapies and Insulin Producing MSCs
The purpose of this section is to contextualize the power of using hMSCs for
disease treatment. Medical researchers have focused on hMSCs impact on chronic
diseases suffered by children. An 11-year-old and 2-year-old were both treated with
hMSCs [30] for dilated cardiomyopathy, heart muscle disease in which the left
ventricle becomes enlarged and cannot sufficiently pump blood to the body [38].
For the 11-year-old, 6mL of autologous, meaning derived from the child’s own
tissue, therapeutic solution containing 4.8 x 106 cells/mL of hMSCs were
transplanted into the child using a catheter. hMSCs were transplanted into the
proximal left main coronary artery and cardiac function improved from IV (initial) to
II [30]. The 2-year-old’s treatment differed slightly, a coronary balloon dilation
catheter was placed in the left anterior artery, and low pressure was used for
inflation. 270 million bone-marrow derived hMSCs were autologously transplanted
into the child by an intracoronary bolus injection. The left ventricular injection
fraction improved heart function from 24% to 45% 6 months after the hMSC therapy
5

[30]. These studies illustrate that hMSC therapies have been successful in children,
and it is key to point out that a large number of cells were used for treatment, so
extensive cell culture magnification and purification were conducted.

Figure 1.1 Flow diagrams outlining the steps necessary to achieve hMSC isolation
using (a) density centrifugation with FACS or MACS and (b) the presently explored
dielectrophoretic separation.
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Researchers from Tehran University in Iran have examined hMSCs
differentiation into insulin producing cells, which would directly benefit children
afflicted with type 1 diabetes. Their approach was to direct adipose-derived hMSCs
toward insulin producing cells in a three-step cell culture protocol. In each step, the
cell culture media was enhanced with glucose, alcohol, vitamin B3, and an insulin
promoter peptide, exendin-4. The cells were treated with this enhanced media over
the course of 24 days. Verification of insulin producing hMSCs was completed using
dithizone staining, RT-PCR, immunochemistry, and morphology evaluation [39].
This work is important because it adds scientific evidence that hMSCs can
potentially be used as a therapeutic option for diabetes treatment. A full review of
hMSCs and their potential medical impact is in Chapter 2. Although hMSCs are
promising in diabetes treatment, the current separation methods are labor and
resource intensive, and have been shown to reduce viability such that extremely large
concentrations of cells are required for effective therapies [40].
In summary, hMSCs have the potential to be used in clinical applications for
disease treatment, but new methods for cell separation are needed to selectively
isolate hMSCs from diverse cell populations. Therefore, the objective of this body of
work is to develop a first generation technology for label-free, one-step, rapid
hMSCs separation and purification without altering cellular function or reducing
cell viability. This work outlines a new separation technique for improved hMSCs
treatment efficacy that couples dielectrophoresis (DEP) and microfluidics to more
efficiently separate hMSC populations. Additionally, this work developed a new
7

DEP data collection approach by frequency sweeping which enables an automated
data analysis method. These tools can work in tandem in a noninvasive manner to
interrogate the exterior and interior cell structure and then cause translational motion
harness-able for separations. These technologies also reduce the number of steps
needed to achieve hMSC separation, as shown in Figure 1.1.

1.3 Dielectrophoresis and Electrokinetics
Dielectrophoresis (DEP) is a subset of a larger phenomenon called
electrokinetics, which uses electrical energy as a driving force to induce particle
motion [41]. DEP is polarization of neutral or charged particles or cells due to spatial
non-uniformities in applied alternating current (AC) or direct current (DC) electric
fields. For this work, DEP can function as a spatial separation technique that has
potential to overcome the shortcomings of density gradient centrifugation, FACS,
and MACS and could provide a rapid electrical signature for hMSCs. DEP
technologies enable a variety of particle polarizations and manipulations with
nonuniform AC electric fields on microchips [42, 43] to study cell systems such as
red blood cells [44, 45], cancer cells [46, 47], white blood cells [48], and yeasts cells
[49, 50]. The advantages to coupling DEP with microfluidics are microliter sample
size, quick analysis (~minutes to achieve results), little sample preparation, and
minimal waste production. Disadvantages are that extended electric field exposure
times (>5mins) can negatively affect cell properties and viability [51].
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DEP, also known as dielectric dispersion, is unique because in AC electric
fields at specific frequencies, dipoles can be induced in or around particles and the
permittivity of that particle changes with frequency [41, 52]. At low frequencies, this
permittivity change is attributed to the polarization at the interface of the suspended
particle, and for hMSCs this interface is equivalent to its membrane [42, 52]. At
higher frequencies, the dielectric dispersion is influenced by the internal composition
and structure of the particle; for hMSCs, cytoplasm properties play a critical role [42,
52, 53]. This frequency-dependent phenomenon allows for biological cell systems,
such as hMSCs to be optimized for property-specific separations.
DEP utilizes nonuniform electric fields for cell movement based on the
polarizability and dielectric properties (permittivity and conductivity) of their
membrane, cytoplasm, and organelles [52]. Cells have distinct dielectric dispersions
that can be used as an identification tool for cell purification, as depicted in Figure
1.2. A cell’s complex permittivity is frequency dependent and charaFWHUL]HGE\WKHĮ
ȕDQGȖGLHOHFWULFGLVSHUVLRQUHJLRQV ȦĮ Ȧȕ ȦȖ) [37]. At radio frequencies in the
ȕ-region, 0.10 – 10MHz, the dielectric dispersion of cells is most heavily affected by
their membrane; high frequencies penetrate a cell’s surface and interrogates the
internal structure [54]. Therefore, a variety of information can be obtained about a
cell population, especially surface biomarkers, LQWKHȕ-region.
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Figure 1.2 Nonuniform dielectrophoretic particle polarization. Cells with different
membrane (crudely illustrated) and internal properties have different polarizations;
as a consequence, spatial particle separations can be achieved.

In the ȕ-region, Maxwell-Wagner interfacial polarizations dominate the
overall cell polarization phenomena. Based on permittivity and conductivity,
polarized cells will exhibit either positive DEP (pDEP) force Figure 1.2b, whereby
cells move up the electric field gradient to high electric field gradient, or negative
DEP (nDEP) force Figure 1.2c whereby cells are repelled from areas of high electric
field density to move down the electric field gradient [53, 55]. This cell motion in the
spatially non-uniform electric field is defined by the Clausius-Mossotti factor, fCM,
for core-shell spherical particles [52, 53, 56].
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f CM

H~i
where

H~cell  H~med
,
H~cell  2H~med
Hi 

(1)

Vi
,
jZ

(2)

is the complex permittivity of the cell (i = cell) and of the medium (i =

med  ZKLFK DUH GHSHQGHQW RQ WKH FRQGXFWLYLW\ ı  SHUPLWWLYLW\ İ  DQG DQJXODU
frequency (

) [53]. fCM is dependent on the complex permittivity of the cell and the

medium, equation 2. If a cell experiences pDEP, then fCM (equation 1) is positive
indicating the cell is more polarizable than the suspending medium, H~cell > H~med , and
the cell moves toward areas of high electric field density [53]. For nDEP, the fCM is
negative and the cell is less polarizable than the suspending medium, H~med > H~cell ,
and the cell moves towards areas of low electric field density [53]. When fCM is zero,
known as the cross-over frequency [52], cells transition from experiencing nDEP to
pDEP or pDEP to nDEP and demonstrate little or no motion in the electric field. This
cross-over frequency is an important component of a cell’s DEP spectra because
initial estimates of cell dielectric properties can be estimated from this number.
Equation 1 assumes a homogeneous, spherical particle, but more complex cell
structures can be modeled for DEP polarizations by changing the shape and cell
layers. A full review of DEP with modeling is in Chapter 3.
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1.4 Microfluidic Technology
Microfluidics is the manipulation of fluids and aqueous suspensions on the
microscale [57]; devices can have many different components such as channels,
chambers, reaction chambers, pumps, multiple layers, and electrodes.

For this

project, electrodes are utilized to induce cell motion as a means to simply and
directly examine biological cell properties [57, 58]. Microfluidic systems are easily
mounted on glass microscope slides or other optically transparent platforms using
polydimethylsiloxane (PDMS) elastomeric castings of microscale features [59].
Microfluidics can be used for biosensors [60], cell separation [61], cell lysis [62],
protein analysis [63], bacteria detection [64], and droplet formation [65].
Microfluidics can also be used to mimic organs for drug therapy optimization [66].
The overlap of these techniques with biological cell analysis enables new dimensions
bioprocessing, characterizations, and separations. Each of these example processes
can be performed on individual microdevices or combined together into one device
to achieve multistep bioprocessing. Devices such as these are referred to as lab-on-achip and are increasingly more prevalent due to reduced costs and user-friendly
operation. Lab-on-a-chip microdevices have already been developed to achieve cellbased assays like cell migration, proliferation and cell-to-cell signaling [58], and
could be extended to quickly and effectively separate hMSCs.
The strategic combination of dielectrophoresis and microfluidic technology is
a powerful tool to study cellular behavior because the microdevice can facilitate
beneficial micro-environments for the cells. Other advantages to microdevices that
12

incorporate dielectrophoretic phenomena are precise control on applied external or
chemical forces, no mechanical parts necessary, small reagent consumption, rapid
response time, reduced risk of sample contamination, higher reliability,
reproducibility, low cost and the ability to run multistep processes in series or
parallel on one device [16]. Many microdevices are being developed that incorporate
both electrokinetic and microfluidic technologies that enable property measurements
of specific biological cell systems and stem cells are an underexplored area in this
field. Thus, this work explores the utility of electrokinetic and microfluidic
technology as a solution to the challenges with current hMSC cell population
purifications.

1.5 Dielectrophoretic Microfluidic Devices and Diabetes Treatment
To summarize, hMSCs are a potential therapeutic treatment for diabetes
mellitus. The main challenge associated with hMSCs and other types of stem cells is
the lack of a rapid, simple method to purify desired subpopulations from
heterogeneous cell samples without altering cell function or reducing cell viability
[40]. Also, hMSCs are a newly explored cell system so explorative studies are
underway to understand their diverse functions within the body. Further, a database
has not yet been developed to correlate cell surface biomarkers to differentiation
behaviors or cell types. A microfluidic device utilizing DEP to discern differences in
cell dielectric properties (and thus surface biomarker expression) has the potential to
resolve the purification problems associated with hMSCs.
13

Therefore the objectives of this body of work is to:
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the
DEP spectra including the cross-over frequency.
Objective 1a:

Standardize hMSCs morphology with ELP-PEI to

reduce size-dependent DEP variations. Characterize the DEP spectra
of ELP-PEI treated hMSCs, then compare to native hMSCs in order
to identify conditions for cell separations. Subpopulation variations
are expected to be based on molecular level expression.
Objective 2: From the experimentally derived DEP spectra obtained in Objective 1,
model the dielectric properties of human mesenchymal stem cells using MATLAB
and the Core-Shell Spherical DEP Polarization models.

Use these models to

calculate the dielectric properties of hMSCs.
Objective 2a: Correlate these properties with known phenotypical
molecular expressions of hMSCs.
Objective 2b: Compare dielectric properties with other cell systems.
Objective 3: Develop a new frequency sweep rate data collection technique for rapid
compilation of the frequency dependent DEP spectrum. Optimize sweep rate
parameters with polystyrene beads and verify on red blood cells.

The two themes of this dissertation are to establish the dielectric signature of
the novel hMSCs biological system and develop an alternative DEP experimental
characterization and ultimately separation technique. The next chapters are literature
14

reviews on hMSCs (Chapter 2) and dielectrophoresis (Chapter 3). The DEP spectra
for hMSCs were determined and K06&Vİmembraneımembrane, and Cmembrane (dielectric
properties) were quantified in Chapter 4. ELP-PEI was used to standardize hMSCs
morphology and the effects of the polymer treatment were also explored in Chapter
4.

This portion of the work demonstrates the first steps necessary toward the

development of a continuous cell sorting microdevice. Chapter 5 demonstrates the
development of a new rapid DEP data collection technique with semi-automated data
analysis tested on polystyrene beads and red blood cells; a patent disclosure has been
filed on this work, with the full patent application to be submitted in July 2014.
Finally, conclusions and a summary of the main findings of this work are
summarized in Chapter 6. A side project not central to the theme of this dissertation
was completed and published as a book chapter – this is included as Appendix A.
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1

Chapter 2 Human Mesenchymal Stem Cells and Type 1

Diabetes
2.1 Key Properties of Human Mesenchymal Stem Cells
Stem cells are distinct unspecialized cells classified as embryonic or somatic
(adult) and are of interest due to their ability to differentiate into specific cell types
[1-3]. Embryonic stem cells are derived from embryos and somatic stem cells
(mesenchymal, hematopoietic, neural, epithelial, and skin) are derived from other
cells in the body excluding gametes. Stem cells are characterized by their
differentiation potential with totipotent cells, being capable of differentiated into all
cell types; pluripotent stem cells being capable of differentiating into almost all cells
types; human embryonic stems cells most strongly demonstrate pluripotency.
Somatic stem cells are multipotent meaning they only differentiate into closely
related families of cells. Human mesenchymal stem cells (hMSCs) are somatic and
ideal to work with because they are readily obtained from bone marrow and they
have the ability to self-renew while undergoing differentiation [2]. hMSCs are an
abundant source of cells found in various locations in the body including the
umbilical cord [4-6], adipose tissue [4, 5, 7, 8], synovium [5, 7, 9, 10], periosteum [5,
11, 12], and dental pulp [5, 13, 14]. hMSCs have the potential to differentiate into
osteoblasts (bone cells), adipocytes (fat cells), chondrocytes (cartilage cells),

1

The material contained in this chapter will be submitted for publication.
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astrocytes (neural cells), myoblasts (muscle cells), and Langerhans islets (pancreatic
cells) based on environmental promoters [2, 13, 14].
Presently there is not a database of unique biosurface markers that distinctly
defines hMSCs or their progeny [9, 15, 19-22], which is necessary for cell separation
and purification to occur after sample isolation from the body. As a result,
researchers have minimal understanding of the biological mechanisms that hMSCs
display in therapeutics. Samples of hMSCs are isolated from bone marrow as
heterogeneous mixtures [15]. In order for hMSCs to be highly efficient in cell
therapy, isolated cells need to be purified. Therefore, new technology is needed that
can accurately characterize hMSCs subpopulations and virility as well as reveal more
information about their cellular function and biological mechanisms. Before
proceeding to the technology for separating hMSCs, this chapter will review hMSCs
key physical properties, elastin-like polypeptide polyethyleneimine (a morphology
standardizing agent), current hMSC separation technologies, type 1 diabetes
background, and set the foundation for dielectrophoresis as an alternative and
superior separation technology.

2.1.1 hMSC Self-Renewal, Differentiation Potential And Trophic
Activity
hMSCs are characterized by three key properties: (1) ability to self-renew, (2)
trophic activity, and (3) differentiation potential, all of which are critical to their
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therapeutic potential. Figure 2.1 illustrates the three key properties of hMSCs and
each is discussed separately in the following paragraphs.
Self-renewal is the process that hMSCs go through to create new stem cells
[16]. Specifically, during self-renewal hMSCs divide to generate daughter cells with
the same developmental potential as the mother cell. This property is not unique to
stem cells, many cell types have similar self-renewal capabilities. There are two
mechanisms for hMSC self-renewal division, symmetric and asymmetric [17].
During mitosis, the internal organelles of cells are equally parsed between two
daughter cells to achieve symmetric division. The daughter cells have identical
characteristics to the mother cell. In contrast, asymmetric division is the unequal
parsing of cellular internal organelles between two daughter cells, resulting in
cellular polarization [18]. The daughter cells display different characteristics from
the mother cell. hMSCs continually undergo self-renewal [18]; differentiation into
other cell types can concurrently occur.
Potency describes stem cell’s ability to differentiate into other cell types.
Cells are typically classified into one of three important levels of potency: totipotent,
cells develop into any cell type; pluripotent, cells can form most cell types with the
exception of placental tissues; and multipotent, cells can differentiate into many cells
types, i.e. totipotent > pluripotent > multipotent [2]. The more potent a cell is, the
more versatile and valuable it is for medical treatments. hMSCs are multipotent and
differentiate into adipocytes, osteoblast, chondrocytes, and many other cells types
[2]. For stem therapeutics, hMSCs can be selectively differentiated into specific cell
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types using growth factors. Controlling and subsequently purifying hMSC-derived
cell types enables tailored autologous hMSCs disease treatment, are from and used to
treat the same individual, disease treatments [3]. For example, osteogenic
differentiation of hMSCs is accomplished by supplementing cell culture media with
dexamethasone, ascorbic acid, DQGȕ-glycerolphosphate [19]. Adipocytes have been
produced by treating hMSCs cell culture media with insulin, dexamethasone,
isobutyl methyl xanthine, and rosiglitazone [20, 21]. There is a different protocol
utilized to direct hMSCs differentiation toward specific cell types. This type of cell
manipulation can and has been implemented to make hMSCs an attractive cell
source for diabetes mellitus treatment, as discussed in section 2.3.
The third key property of hMSCs is trophic activity, which is their ability to
migrate to sites of injured tissues or to participate in response to injury by secreting
growth factors [22]. Some examples of growth factors that hMSCs secrete are
granulocyte colony-stimulating factor (G-CSF), a glycoprotein that stimulates bone
marrow to produce granulocytes and stem cells and release them into the blood;
leukemia inhibitory factor (LIF), a protein that influences cell growth; and
transforming growth factor-beta 2 (TGF-ȕ , a protein that performs many cellular
functions [23-25]. Figure 2.1 illustrates the three key properties of hMSCs.
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Figure 2.1 Important properties of hMSCs (a) trophic activity, (b) self-renewal, and
(c) differentiation potential. Adapted from [2, 18, 23].

2.1.2 hMSC Morphology
hMSC morphology must be carefully considered when designing a
microdevice to employ dielectrophoretic cell purification. According to Haasters et
al., hMSCs can be assigned three morphological subpopulations: (a) rapidly selfrenewing cells, triangular or star-like shape; (b) elongated, fibroblastic-like, spindleshaped cells; and (c) slowly-replicating, large cuboidal or flattened cells [26]. Figure
2.2 shows microscope images of these subpopulations. The observed morphology is
dependent on the cytoskeleton, cell adhesion, and active pathways; therefore the
cell’s morphology reveals information about cell fate and differentiation [26].
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2.1.3 Elastin-Like Polypeptide Polyethyleneimine
To reduce variation in hMSCS morphology, elastin-like polypeptide (ELP)
polyethyleneimine (PEI) was explored, and this cell shape variation reduction will
assist with hMSCs separation. ELP-PEI is a postively charged block copolymer that
directs cell morphology to a spheroidal shape. ELP is synthesized from amino acids
valine, proline, and glycine, and has been previously used to produce H35 rat
hepatocyte spheroids. ELP-PEI has also been used in studies to determine the affects
of free fatty acids and cytokines in 2D and 3D rat hepatoma cell cultures [27, 28].
The affects of ELP-PEI on hMSCs are described in Chapter 4.

Figure 2.2 hMSCs morphological subpopulations (a) rapidly self-renewing, star like
shape, (b) elongated fibroblastic-like spindle shaped cells, and (c) slowly-replicating
flattened cells. Reprinted with permission from [26].

2.1.4 hMSCs Surface Biosurface Markers
Additionally, hMSCs can be characterized by a variety of surface proteins,
which are major determiners of the cell phenotype, or the expressed individual cell
characteristics. Scientists have extensively studied hMSCs phenotypes, but scientific
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publications do not provide a consistent catalog of surface proteins expressed on
hMSCs surfaces. Currently, there is not a panel of unique surface proteins capable of
characterizing hMSCs or distinguishing them from other cells. Flow cytometry has
been used as a means to determine the phenotype of hMSCs using CD surface
proteins. CD stands for cluster of differentiation and is the standard system by which
newly discovered surface proteins are named [29].
Karaoz et al., conducted immunophenotyping on hMSCs using fluorescent
tags for the following surface proteins CD3, CD4, CD5, CD7, CD8, CD10, CD11b,
CD13, CD14, CD15, CD19, CD29, CD34, CD44, CD45, CD71, CD73, CD90,
CD106, CD117, CD123, CD146, CD166, HLA-DR, HLA-ABC, and HLA-G. The
results of this immunophenotyping yielded that hMSCs positively expressed CD10,
CD13, CD29, CD44, CD73, CD90, CD106, CD146, CD166, and HLA-A,B,C. The
hMSCs did not express the other 18 surface proteins examined (CD3, CD4, CD5,
CD7, CD8, CD11b, CD14, CD15, CD19, CD34, CD45, CD71, CD90, CD106,
CD117, CD123, HLA-DR, and HLA-G). Other researchers have done similar studies
looking at the phenotype of hMSCs and Table 1 summarizes their findings. The
proteins summarized in Table 1 are those that researchers had prior knowledge of
and are not meant to be all-inclusive. The major conclusions from Table 1 are that
hMSCs have a diverse phenotype with varying numbers and types of proteins
expressed on their cell membrane surface. Figure 2.3 cartoons this phenotype
diversity in hMSCs within one population; all cells do not exhibit the same surface
proteins creating subpopulations. Further, a different technology is needed that can
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provide an alternative measure to distinguish hMSCs from other cells. Since there is
not one unique surface protein, or group of proteins for hMSCs, it is advantageous to
explore opportunities with dielectrophoresis that utilizes an electrical signature
versus a protein signature.

Table 2.1 Summary of the hMSCs immunophenotyping [15, 30-33].
Function
Cell Adhesion Molecule
Bone Metabolism/
Mineralization

Bone Mineralization
Structural Protein of
Cartilage
Structural Protein of
Cartilage
Glycoprotein
Integrin
Leukocyte Antigen
Anti-adhesive Molecule
Activated Leukocyte
CALLA
TGF-ȕ5HFHSWRU
5,.2-5HFRJQLWLRQ
Aminopeptidase 5HFRJQLWLRQ

Marker
CD44, CD54, CD106,
CD146, CD90
Osteonectin,
Osteopontin,
Osteoprotegerin,
Osteocalcin
Biglycan
Procollagen-1, Collagen-I,
Collagen-III, Collagen-V,
Collagen-VI
Collagen-II, Collagen-IX,
Collagen-X, Aggrecan,
Decorin
CD9, CD59, CD161
CD29, CD73
HLA-A, HLA-B, HLA-C
Veriscan
CD166
CD10
CD105
CD55
CD13
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Figure 2.3 Illustration of differentiation surface proteins present within one hMSCs
population [33, 34].

At this point, the three main properties of hMSCs that make them ideal
candidates for stem cell therapeutics, differentiation capacity, self-renewal, and
trophic activity have been described. However, there is not one single or
combination of unique physical hMSC properties that make them easily identifiable
after bone marrow isolation. To achieve this goal, the International Society for
Cellular Therapy put in place minimum requirements to label a cell population as
hMSCs, which are [1, 34]:
1) Plastic adherence,
2) Positive expression of CD105, CD73, and CD90,
3) Negative expression of CD34, CD45, CD11a, CD19, CD14, and HLA-DR,
4) Adipogenic, osteogenic, and chondrogenic differentiation potential.
The plastic adherence is a general property common in many cells and the specific
surface proteins listed overlap with other cells, like hematopoietic stem cells.
Further, it isn’t possible to identify the propensity of individual cells toward the
specialized cell type. Therefore, a more descriptive property would be beneficial for
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hMSC characterization and a separation tool to achieve quantification of the property
would empower researchers to tailor cell populations for therapies.
The currently known mechanical and electrical properties of hMSCs are
discussed in the following section. Knowledge of these key properties is critical for
any hMSCs purification and identification efforts.

2.1.5 hMSCs Mechanical Properties
Mechanical properties typically measured on cells include elasticity,
viscoelasticity, and strength (Young’s modulus, tensile, compression, and stiffness).
Thus far, hMSCs mechanical property studies have been dominated by elastic,
viscoelastic, and Young’s modulus measurements. These properties are exploited for
separation and are important for therapeutic considerations. Elasticity is the measure
of a cells tendency to return to its original form after deformation, similarly in
viscoelasticity cells exhibit viscous and elastic characteristics under deformation
[35]. In reviews [36-40], it’s been concluded that the viscoelastic behavior of
biological cells plays an important role in biophysical and biological responses to
stimuli.
The goal of outlining the viscoelastic properties here is to demonstrate that
hMSCs have unique physical properties that are useful for characterization and lends
support to hMSCs having unique electrical markers. In the study completed by
Darling et al. [35], the elasticity and viscoelasticity of two hMSC morphologies were
examined: spherical and spread star-like. Spherical hMSCs deformation was
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measured at the cell’s center, and the spread-like hMSCs deformation was measured
over the cell’s nucleus. The spread star-like hMSCs studied here are similar to those
in Figure 2.2a, and the results are summarized in Table 2.2.

Table 2.2 Elasticity and Viscoelasticity of hMSCs with spherical and spread star-like
morphologies [35].
Morphology

Cell Type

n

Elasticity (kPa)

Viscoelasticity (kPa)

Spherical

hMSC

53

2.5 ± 1.8

0.47 ± 0.52

Spread Star-like

hMSC

67

3.2 ± 2.2

2.2 ± 1.9

From Table 2.2, the elasticity for each hMSC morphology tested was a
similar order of magnitude, 2.5 kPa (spherical) versus 3.2kPa (spread star-like).
However, the viscoelasticity changed by an order of magnitude, from 0.47kPa
(spherical) to 2.2kPa (spread star-like). Titushkin et al. [41] corroborated hMSC
spread star-like morphology with atomic force microscope indentation, and found the
Young’s Modulus to be 3.2kPa.
Just as growth factors can be added to cell culture media to direct hMSCs
differentiation, Kim at al.[42], found that hMSC populations are sensitive to
mechanical vibrations. Stimulation at 30Hz and 0.3g of acceleration induces
osteogenic differentiation. This mechanical vibration increased the alkaline
phosphatase activity and calcium depositions, which are consistent with osteoblast
differentiation. Similarly, Subramony et al. [43], coupled nanofiber alignment with
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tensile loading to induce fibroblastic

differentiation.

Controlling

hMSCs

differentiation using mechanical or other cues after purification is a powerful tool
that can be utilized in hMSC therapeutics.
Lastly, supporting evidence by Alexopoulos et al. [44] and Guilak and Mow
[45], illustrate that the mechanical properties of cells can affect their physical
interactions with surrounding extracellular matrices (ECM). ECM is a complex
arrangement of polysaccharides and proteins secreted by cells for structural support
[29]. The interaction of hMSC derivatives with ECM is an important consideration
as these cells move toward therapeutic applications.
These results show that mechanical properties may serve as a basis of
characterization for cell subpopulations without necessitating cell tagging. The
disadvantage to using elasticity measurements is that they may serve as a mechanical
cue that triggers differentiation. Thus, mechanical characterizations can be classified
as a more invasive tool. Further, it is necessary to perform individual cell mechanical
property measurements in order to identify subpopulations prior to separation. The
tools to conduct these individual cell measurements followed by separation do not
currently exist. In slight contrast, electrical measurements can determine similar
properties as mechanical, but are much more amenable to being conducted on
individual cells.
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2.1.6 hMSCs Electrical Properties
The measurement of hMSC electrical properties, and their link to physical
properties has included impedance measurements. In the last 20 years, minimal
literature has been published on hMSCs electrical properties. For example, a search
of ‘human mesenchymal stem cells electrical properties’ in Web of Science yields
only 24 articles; only two articles directly measure hMSCs electrical characteristics.
The remaining articles relevant to hMSCs can be categorized in the following
manner: biocompatible materials (applications in scaffolds, nanofilms, nanotubes,
polyimide electrodes) [46-50], electrical stimulation (to monitor membrane
mechanics and calcium dynamics) [51-53], and hMSC differentiated progeny
impedance measurements [54-56]. The most relevant publications to this dissertation
involve impedance measurements of the hMSCs and are more reviewed in this
section.
Impedance is a measure of the opposition to AC current flow in a circuit.
When cells or cell suspensions are embedded into the circuit, information can be
acquired about cell function and morphology. Hildebrandt et al., used impedance as
an hMSC osteogenic differentiation indicator, and found that undifferentiated
hMSCs and osteocytes have different impedance values, as reproduced in Figure
2.4a. The impedance of undifferentiated hMSCs is particularly relevant to this
research; hMSC suspensions in cell culture media (roughly 1.7 S/m) yield impedance
values of 7.5-7.9 x104ȍEHWZHHQ-1.3MHz [55]. Cho et al., also used impedance
to monitor hMSC differentiation but was interested in adipocytes rather than
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osteocytes. Cho’s work corroborates Hildebrandt’s by also demonstrating an increase
in impedance for hMSCs derived adipocytes as reproduced in Figure 2.4b; average
hMSC impedance was ȍ [54]. It’s important to note that while these studies
quantify an electrical property of hMSCs, that property is not translatable to cell
separations. Impedance is a sensor tool, but does not induce any motion so is not
amenable to use as a separation technique. These experimentally determined
impedance values are correlated to hMSCs membrane capacitance in Chapter 4 as a
comparison to our own hMSC experimental work.

Figure 2.4 Impedance measurements for (a) [55] undifferentiated hMSCs (red) and
osteocyte differentiated hMSCs (blue) (yellow is a nonrelated mikrozid liquid
treatment to induce cell necrosis), and (b) [54] undifferentiated hMSCs (labeled
control) and adipocyte differentiated hMSCs (labeled differentiation). Impedance
increases in differentiated cells indicating differing morphology and physiological
properties from the mother cells. Reprint permission requested from [54, 55].
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This review has thus far been restricted to hMSCs. However, other electrical
measurements have been performed on other stem cell lines.

Stem cell

dielectrophoretic measurements are organized into Chapter 3, section 3.5 for
continuity purposes.
In summary, there are no direct measurements of hMSCs membrane
capacitance and permittivity, which are key properties for designing cell separations.
This dissertation research seeks to fill this gap in knowledge by quantifying hMSCs
membrane capacitance and permittivity using dielectrophoresis, a noninvasive
electrical tool capable of cell translation and thus cell population sorting. Further, a
polymeric membrane treatment, ELP-PEI is utilized to reduce hMSCs morphology
variations in order to better isolate the contributions from mechanical and electrical
properties and thus yield a more efficient hMSC purification technique for type 1
diabetes therapeutics.

2.2 Human Mesenchymal Stem Cells Separation Technology
2.2.1 Research Motivation Statement
hMSCs therapeutics are especially important for the continued advancement
of medicine due to their differentiation capacity, self-renewal, and trophic activity.
Highly purified hMSC samples are necessary for therapies to be effective and
efficient. Thus, separation after bone marrow isolation is critical and has relied upon
flow cytometry and centrifugation. The following subsections describe current
technologies that are used to separate hMSCs from heterogeneous cell populations.
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Current technology disadvantages leave room for improvement and provide a
motivation to explore other separation techniques.
Current hMSCs separation techniques can be generalized into two categories:
affinity-based and physical-based.

Affinity-based techniques utilize hMSCs

biological properties, like membrane surface proteins (CD’s), to selectively purify
the cells. Technologies that implement this separation scheme are fluorescentactivated cell sorting (FACS) and magnetic-activated cell sorting (MACS).
Physical-based techniques, like density gradient centrifugation, utilize hMSCs size
and plastic adherence to achieve separations.

2.2.2. Fluorescent and Magnetic Activated Cell Sorting for Cell
Separations
Fluorescent-activated cell sorting (FACS) and magnetic-activated cell sorting
(MACS) are separation techniques employed after hMSC extraction from the body
and cell culture to then achieve purification. FACS uses unique cell-surface antigens
as recognition elements to tag target cells. This cell labeling alters cellular function,
which is not desirable for medical applications [57]. More specifically, FACS is a
specialized type of flow cytometry that uses a laser beam to capture emergent light
from passing cells. Based on the signal, fluidics are used to direct and sort cells into
channels. The data collected reports information on cell size, complexity, phenotype,
and health [58]. FACS has six main components: fluidic, laser, optic, detector,
electronic and computer system.
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In a typical hMSC separation, cells are first labeled by incubating them with
fluorescent conjugated antibodies (CD34, CD45, CD73, CD105 and CD166;
conjugated with phycoerythrin or fluorescein isothiocyanate) [59] and then
transported through the fluidic system for single cell laser analysis (for accurate data
collection) via mechanical vibrations and hydrodynamic focusing [60]. The
individual cells pass through the laser causing light to scattering in two ways:
forward light scatter, where light is sent in the forward direction as it hits a cell; or
side light scatter, where light is sent at a 90° angle from the cell. Side scatter is
caused by cell granularity and structural complexity [61]. Forward and side light
scatter provide a one-dimensional and two-dimensional graphical representation of
cell population, respectively [62]. Separate detectors translate the scattered light
intensity into a voltage pulse, which is proportional to cell size. In the final step,
hMSC FACS separations involve directing the cells into channels based on the
scattered light signal. The fluidic stream containing the laser-interrogated cells flows
past electrodes that selectively activate to induce cell electrophoretic motion so the
cells can be selectively collected in separate tubes. FACS enables multiparametric
analysis of hMSCs [63-65]. Figure 2.5 illustrates the FACS system.
There are some disadvantages associated with using FACS for separation
including low throughput of 5000-70,000cells/s [58], high cost ($75,000+) [66],
large electronic system (Becton Dickson FACSJazz, 125lbs, 21x20x20in) [67],
skilled technician necessary for operation [60], sample contamination risk (due to
sample preparation) [66], processing time (3-6hrs) [58], altered cell function/viability
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from antibody tagging [68]. Nevertheless, this method is one of the best available
and has been used to successfully separate hMSCs by many researchers [69-73].

Figure 2.5 (a) Schematic of Fluorescent-Activated Cell Sorting and (b) illustrates
labeling of two hMSCs progenitor cells. Adapted from [63-65]. Cells of interest are
labeled with antigens and separated based on charge.
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MACS uses the same separation principles as FACS whereby target cells are
labeled with antibodies (anti-immunoglobulin, anti-biotin, streptavidin, or antifluorochrome) conjugated with magnetic beads approximately 50 nm in size [74].
The cells are labeled through incubation that lasts approximately 30 mins [75]. After
incubation, the cell suspension goes through a steel column placed in a magnetic
field that impacts the magnetic beads bound to the cell surfaces. Cells are either
positively or negatively selected based on the magnetic beads attached to the cell
surface antibodies. Labeled cells stay in the column while the magnetic field is
applied [76]. With the magnetic field on, the nonlabeled (unattached) cells pass
through the column and are collected in a test tube; once the magnetic field is turned
off, the labeled cells are eluted from the column and collected in a separate test tube
[74, 75]. Figure 2.6 shows a schematic of the MACS system.
The advantages to using MACS are high throughput [76], easy use [58], and
lower cost than FACS [60]. The disadvantages associated with this separation
technique are cell labeling alters cell function [57] and long process time [77].
Despite the drawbacks, MACS has been widely implemented as a separation method
for hMSCs population control [78-82].
To summarize, FACS and MACS can achieve hMSC separation based on
biosurface marker membrane expression; this approach is referred to as
immunophenotyping [58]. FACS and MACS are widely used because there is not a
better alternative. The disadvantages associated with them, namely cost, throughput
and altered cell function, are widely acknowledged and underscore the need for
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improvements in cell separation. Microfluidic devices utilizing dielectrophoresis are
technologies with the ability to discern cell types without any chemical labeling and
without altering cell function [57]. These tools are explored within this work to
improve hMSC, motivated in part by the success of other cell separations for clinical
applications [83]. Before discussing dielectrophoresis in detail (Chapter 3), other
separation techniques that do not incorporate cell antibody labeling are reviewed.

Figure 2.6 (a) Schematic of Magnetic–Activated Cell Sorting, and (b) cell labeled
with magnetic beads, (c) unlabeled cell. Adapted from [74-76]. Target cells are
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labeled with antigen conjugated magnetic beads and with magnetic field on labeled
cells are retained inside column, unlabeled cells pass through.

2.2.3 Density Centrifugation and Membrane Filtration
Density centrifugation is another separation technique employed to extract
select hMSCs from a heterogeneous cell population. This method separates hMSCs
from other cells based on their cellular density. A centrifuge tube is prepared by
layering Percoll or Ficoll-Paque solutions from high density at the tube bottom to
low density at the top, producing a gradient. After the gradient is poured, an hMSC
suspension is placed in the centrifuge tube on top of the Percoll and centrifuged.
During centrifugation, hMSCs migrate through the gradient until each cell reaches its
isopycnic position [58], the position where the solution density equals the cell
density. Increasing the number of density gradient layers increases separation
efficiency [84].
Disadvantages with this method include: a) fluctuations in pH and osmolarity
of density gradient solutions, which affect cell viability (changes may kill or reduce
cell efficacy) [58], b) density gradient preparation is laborious and tedious (layering
in centrifuge tube) [85], and c) low selectivity (this is mainly employed as a
preparative step before other separation methods are employed) [60].
Another physical based separation technique that has been used for hMSC
separation is membrane filtration. This technique has been employed due to its fast
processing time, easy use, and low cost. Separations are achieved based on cell size
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and affinity for adherence to a membrane surface [8, 86], as illustrated in Figure
2.7a. A membrane composed of rayon and polyethylene has been successfully used
to filter hMSCs from mononuclear cells [87] as reproduced in Figure 2.7b.

Figure 2.7 (a) Schematic of density gradient centrifugation [86] and (b) electron
micrograph of nonwoven rayon and polyethylene with hMSCs attached. Permission
requested for reuse [87].

The main objective of each of these technologies is to enrich hMSCs after
bone marrow isolation. Each of the separation methods mentioned above have
disadvantages that reduce efficiency in processing hMSCs for therapeutics, thus
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leaving room for improvement in hMSCs separation. Therefore, dielectrophoretic
(DEP) microdevices are explored in this research as an alternative separation
method. A review of DEP microdevice systems is given in Chapter 3 before
presenting the experimental results of this dissertation (Chapter 5 and 6). In
conclusion, the technology employed for hMSCs purification needs to be dynamic
for scalability for higher throughputs and achieve high resolution for clinical
therapeutic applications (one application is reviewed next), which require high
concentrations of pure hMSCs.

2.3 Type 1 Diabetes Mellitus
2.3.1 Definition
Globally, there are 16,000 new cases of type 1 diabetes diagnosed each year
[88]. Type 1 diabetes mellitus is a chronic autoimmune disease that diminishes the
body’s ability to produce the insulin hormone [89], as a resultant of beta cell
destruction in the pancreas [90] as illustrated in Figure 2.8. Autoimmune diseases are
ones where the immune system perceives the body’s own cells as foreign and
destroys them [91]. The beta cells are specialized cells in the body that produce
insulin in direct proportion to glucose in the blood stream [92]. The mechanism
responsible for this autoimmune destruction of beta cells is currently unknown, but it
leads to absolute insulin deficiency mediated by the immune system or it may be
idiopathic [89]. This autoimmune destruction of beta cells in Type I is very different
from Type II diabetes where food and body habits disrupt the balance and slowly
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wear out the functionality of the beta cells. hMSC therapies for autoimmune diseases
are effective because they can replace destroyed cells and sometimes avoid being
recognized as foreign by the immune system.
At the center stage of this disease is insulin production. The pancreas, a gland
behind the stomach, secretes insulin into the blood stream and the insulin controls
the amount of glucose in the blood via metabolic reaction pathways. Glucose is
necessary for cells and tissues through the body to get the energy they need; an easily
metabolized source of energy for the cells come from glucose consumed through
food (bread, pasta, milk, rice, etc.). In type 1 diabetes, there is not enough insulin
present to metabolize and transport the glucose from the blood into cells therefore,
blood glucose concentrations increase causing complications [93].

Figure 2.8 Schematic of Type 1 Diabetes (a) normal functioning pancreas and (b)
diminished pancreas function, beta cells destruction. Beta cells within the pancreas
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do not produce the insulin necessary to reduce glucose concentrations in blood [89,
90].

Although the mechanism is unknown, researchers have tried to determine
genetic predispositions to type 1 diabetes. 80% of children with IPEX (immune
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), characterized
by a mutation in the Foxp3 transcription factor (protein involved in regulating the
immune system [94]), develop type 1 diabetes [95-97]. Another gene mutation
example is with autoimmune polyendoocrine syndrome type 1, qualified by a
mutation in the AIRE transcription factor, resulting in 20% of children with this
disease developing type 1 diabetes [98]. Other gene mutations that have shown
susceptibility to type 1 diabetes are HLA (human leukocyte antigen) [99], INS
(insulin) [100], PTPN22 (protein tyrosine phosphatase, non-receptor type 22) [101],
IL2RA (interleukin-2 receptor alpha chain) [102], and CTLA-4 (cytotoxic Tlymphocyte antigen 4) [103]; all of these genes are associated with the function of
the immune system.
Environmental factors have also been explored to understand more about
type 1 diabetes. Data suggests that viral infections may precipitate type 1 diabetes,
and correlations have been made between coxsackievirus (CVB4) [104], a virus that
lives in the digestive tract and is a subset enterovirus. Increased amounts of
neutralizing antibodies as a result of CVB4 were found in patients newly diagnosed
with type 1 diabetes [105], and was confirmed with PCR (polymer chain reaction)
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genetic matching [106]. Yoon et al. [107], demonstrated with mouse subjects that
CVB4 can infect beta cells causing insulitis and diabetes.

In addition, Yoon also

isolated CVB4 from a child with recent type 1 diabetes onset [108]. A contrasting
study looked at the Pribilof Islands in Alaska after a CVB4 epidemic, and found that
type 1 diabetes incidence was similar between infected and uninfected individuals
[109], suggesting no connection between the diseases. Testing in the Finnish
population provided positive links between individuals with enterovirus and type 1
diabetes [110, 111]; this is corroboration in Figure 1.1 where incidence in Finland is
greater than 24%. Other viral infections linked to type 1 diabetes are rotavirus [112],
cytomegalovirus [113, 114], parvovirus [115], and encephalomyocarditis [116],
although all of these still need to be confirmed in larger patient populations [117].
Evidence has also shown that antibiotic and probiotic consumption may alter
the gastrointestinal tract microbiota creating imbalance, which may lead to type 1
diabetes depending on intestinal composition [118]. It has also been found in the
Sardinian population, that mycobacterium avium subspecies paratuberculosis, shed
in infected cow’s milk, was present in type 1 diabetes patients confirmed with blood
tests [119]. In conclusion, there is growing evidence that links gene mutations,
viruses, and bacteria to autoimmune disruption that causes type 1 diabetes. These
factors and others require more exploration.
Although concrete factors that contribute to types 1 diabetes are still under
investigation, diagnosis is well understood and completed via blood glucose
assessments. A person with type 1 diabetes is characterized as having a casual blood
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glucose level >200mg/dL, fasting blood glucose level 126mg/dL, or blood glucose
level >200mg/dL 2 hours after eating [89]. Currently, type 1 diabetes management
requires insulin pens, shots, or pumps [120, 121]. Type 1 diabetes complications
include cardiovascular disease [122], neuropathy (nerve damage) [123], nephropathy
(kidney damage) [124], retinopathy (eye damage) [125, 126], osteoporosis (bone
degradation) [127], hearing impairment [128], and high-risk pregnancies [129].

2.3.2 hMSCs as a Type 1 Diabetes Treatment Option
Currently, there is no cure for type 1 diabetes, and the various complications
necessitate the need for a curative therapeutic option, which is much more than
simply an insulin management strategy. An effective cure will preserve remaining
beta cells [130], and protect newly produced beta cells from autoimmune destruction
in the pancreas [34]. Demonstration of this beta cell replacement therapy concept has
been achieved through human pancreas transplantation in type 1 diabetes patients,
which reestablished their insulin-independency [130]. However, this method cannot
be widely implemented for all type 1 diabetes patients due to the number organs
necessary to cure all patients. Further, organ transplant approaches are extremely
invasive, autoimmune rejection of transplanted organs must be carefully managed to
avoid rejection or death and combined leads to exorbitant medical bills. Thus,
researchers have explored hMSCs as a much less invasive therapeutic option for beta
cell replacement therapy.
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hMSCs were transplanted into diabetic immunodeficient mice following
which the mice’s beta cell numbers and insulin levels increased [131, 132]. Another
animal model conducted by Ho et al., induced mice with diabetes using streptozocin
to kill the beta cells and then subsequently treated them with multiple high MSC
(non-human) concentrated injections. Multiple MSC injections were used because
blood glucose homeostasis was not established after a single injection. Multiple
injections gradually stabilized blood glucose to normal levels [133].
Others have employed chemical based methods and found that hMSCs
differentiate into insulin producing cells [134-136], and those cells are able to release
insulin in a glucose-dependent manner [137]. MSC differentiation toward insulin
producing cells is mediated with additives in the cell culture procedure. Hisanga et
al. [138], used activin A and betacellulin to direct murine (rat) MSCs differentiation;
insulin producing cells were detected within 14 days of additive addition. Genetic
modification with pancreatic duodenal homeobox-1 has also been used to
differentiate hMSCs toward insulin producing cells [139, 140].
In summary, there are multiple methods, chemical and genetic modification,
in place to differentiate hMSCs toward insulin producing cells for type 1 diabetes
therapeutics. Additionally, hMSCs without directed differentiation toward insulin
producing cells have also been used to improve diabetic condition, thus implicating
hMSCs differentiate into insulin producing cells without external stimulus inside the
body. These methods all indicate that a type 1 diabetes cure with hMSCs is possible,
and present evidence that efficient cell purification is necessary for such therapeutic
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interventions. This provides exciting motivation to implement nondamaging
dielectrophoretic microdevice-based separations for hMSC purification.

2.4 Conclusions
hMSCs hold high promise as a therapeutic treatment option for type 1
diabetes due to their differentiation ability, replenishing capacity, and their trophic
activity. They have been shown to differentiate into insulin producing cells through a
variety of methods: chemical, genetic, and undifferentiated. hMSCs are easily
obtained from bone marrow as a heterogeneous population and therefore require
separation before utilization in type 1 diabetes therapeutics. Within a single hMSC
population, there are a variety of progenitor cells present (adipogenic-progenitor,
osteogenic-progenitor, chondrogenic-progenitor, etc.) and these cells have a
propensity to differentiate toward a specific cell type. Additionally, hMSCs are not
well characterized because there is not a unique set of biosurface markers available
that distinguishes hMSCs from other cell populations. To compensate, current
methodologies utilize density centrifugation paired with either FACS or MACS to
achieve hMSC subpopulation separations. These methods are disadvantageous
because of operation time, high cost, and cell antigen labeling which has been shown
to alter cell function. These multistep separation processes are not ideal for the scaleup required by clinical applications; multiple hMSCs transplantations of millions of
cells are needed for effective therapeutic treatments. Therefore, this research seeks to
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solve the following issues associated with hMSCs separations and ultimately
advance type 1 diabetes hMSC therapeutics:
1) No unique set of biosurface markers currently exists to distinguish
hMSCs from other cell populations; mappings of CD proteins overlap
with other cell systems. Instead, minimum requirements have been
established by the International Society for Cellular Therapy.
2) Morphology variations within hMSCs populations make highly
selective separations difficult.
3) FACS and MACS are expensive, low throughput, and timeconsuming separation techniques that alter cellular function.

2.4.1 Dielectrophoresis for hMSC Separation
Dielectrophoresis (DEP) is the separation technology explored in this
research to resolve issues 1-3 associated with hMSC cell purification. DEP may be
able to recognize a dielectric marker via cell membrane capacitance measurements
making it possible to discern hMSCs from other cell populations. DEP is a quick,
noninvasive separation method, with the potential to be low cost, and does not alter
or damage cells [141]. Chapter 3 provides a review of DEP and the cell separations
this technology has been able to accomplish.
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Chapter 3 Dielectrophoresis Literature Review

3.1 Brief Overview: hMSC Separation Shortcomings and Research
Objectives
The realization of hMSC-based diabetic therapeutics requires careful
characterization of the unique biological and biophysical properties to enable
separations of hMSCs from different cells or between hMSC progenitor
subpopulations. Dielectrophoretic (DEP) technology is a tool that can be used to
characterize cell biophysical properties (membrane capacitance, permittivity, and
conductivity). This body of work extends DEP to the exploration of hMSCs. DEP is
an ideal candidate for efficient hMSCs separations because it is a rapid,
straightforward method capable of purifying desired cell subpopulations from
heterogeneous cell populations without changing cell functionality. Because hMSCs
are a newly explored cell system, DEP technology can increase understanding of
their diverse functions by characterizing the cells dielectric properties – how charges
interact with the cell, membrane, cytosol, organelles, and proteins. This work
primarily explores charge behaviors around the entire cell and with proteins on the
membrane surface. Additionally, an archive that links biosurface markers to hMSC
differentiation behaviors has not yet been established. This work is an essential first
step in achieving this. Considering all of these attributes, a DEP microfluidic device

1

The material contained in this chapter will be submitted for publication.
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has the potential to improve the purification processes for hMSCs therapeutic
applications.
Therefore, as a reminder, the objectives of this research are:
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the
DEP spectra including the cross-over frequency.
Objective 1a:

Standardize hMSCs morphology with ELP-PEI to

reduce size-dependent DEP variations, and characterize the DEP
spectra.
Objective 2: Model and calculate hMSCs dielectric properties using MATLAB and
the Core-Shell Spherical DEP Polarization models.
Objective 2a: Correlate these properties with known phenotypical
molecular expressions of hMSCs.
Objective 2b: Compare dielectric properties with other cell systems.
Objective 3: Develop and optimize a new frequency sweep rate data collection
technique for rapid compilation of the frequency dependent DEP spectrum.

Since dielectrophoresis will be used to characterize hMSCs dielectric
properties, a review of DEP technology is provided in this chapter. The sections to
follow will describe the dielectrophoretic phenomena, length scales and types of cell
polarizations, types of DEP, and DEP’s current utilization.
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3.2 Dielectrophoresis Phenomena
DEP is a separation technique that utilizes nonuniform electric fields to
polarize cells based on the dielectric properties of their membrane, cytoplasm, and
organelles. The electric fields can be applied with either alternating or direct current
(AC or DC), this research utilizes AC electric fields because the applied frequency
are controlled easier. Cells will exhibit either positive DEP forces (pDEP), where
cells move to areas of high electric field density, or negative DEP forces (nDEP),
where cells are repelled from areas of high electric field density. The magnitude of
the DEP force can be changed by adjusting the electric field magnitude and shape [13]. Figure 3.1 below illustrates pDEP and nDEP in one type of electric field

&
geometry. The DEP force, FDEP , that a spherical-shaped cell (general case)
experiences in an AC field is given by [1, 4],
,

(1)

ZKHUHİmed is the medium permittivity (unitless), fCM is the Clausius-Mossotti factor
(unitless), R3 is the radius of the cell (μm), and Eo is the electric potential (V).
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Figure 3.1 Schematic of the negative DEP and positive DEP a cell will experience in
an AC electric field with quadrapole electrodes [1-3] .

3.2.1 Polarization Mechanisms
There are a variety polarization factors involved with DEP: electronic,
atomic, orientational, and interfacial [5]. Consider a cell placed in a conductive
medium with an electric field applied. The electric field will interact with the ions
available in the medium causing them to move and align around the cells (electronic
polarization). On the atomic level the ions present in the conductive medium will
move relative to one another (atomic polarization), for example NaCl (Na+, Cl-); Na+
will move relative to Cl-; this movement has previously been assumed to be almost
negligible in comparison to the movement associated with the cell in the electric
field (however, other research in our group has quantified this motion and shown it
can contribute to secondary cell phenomena). Molecules composed of multiple atoms
in the conductive medium will also contribute to the polarization induced by the
electric field. Water for instance has 3 atoms and a permanent dipole so, in the
presence of an electric field, it responds by aligning with the field gradient to reduce
potential energy [6].
Lastly, interfacial polarization is a resultant of electronic, atomic, and
orientation polarization and is described as ion movement occurring at the interface
of two phases, for cells the conductive medium is phase 1 and the cell surface is
phase 2. Interfacial polarizations are described by Maxwell Wagner, as charges that
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are built up at the particle-medium interface [7]. This interfacial polarization is
characterized by the time is takes for full particle polarization to occur, the dielectric
relaxation time, and is given by
,

(2)

where İp, İm are the permittivity of the particle (or cell) and medium respectively,
DQGıp, ım is the conductivity of the particle (or cell) and medium, respectively. Any
impedance a ion experiences during polarization is due to the dielectric properties of
the suspended cell [6].
With AC electric fields applied, cell polarizations occur at specific
frequencies and are strongly dependent on cell structure. The cell response to
frequencies is also known as the dielectric dispersion with Į- ȕ- DQG į-regions.
Since cells have different structures, this dispersion is unique to different cell
systems. The ȕ-dispersion region is important when interrogating the cell’s
membrane structure, because the electric fields penetrate the cell-conductive medium
interface to detect surface features. The ȕ-dispersion region is characterized by radio
frequencies, 0.010-10MHz, and interfacial polarizations are dominant in this region
[8]. The other polarization mechanisms are dominant at specific frequency ranges,
orientation polarization 0.010-10MHz and atomic polarization 1011-1013Hz; the
polarization length scales are different.
At radio frequencies dipolar and ionic polarizations are significant. Again,
take a spherical shaped cell suspended in a conductive medium in a nonuniform
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electric field. The electric field polarizes the cell and induces a moment, and the
resultant net force exerted on the cell is represented as the effective moment dotted
with the gradient of the electric potential [4],

&
F

&
*
p eff  E .

(2)

Figure 3.2 illustrates the dipole particle with the electric field. The expression for

*
DEP force is obtained by determining the proper expression for peff . The effective
moment is determined by solving the spherical electrostatic potential boundary value
problem using the proper boundary conditions, which gives [4],

*
peff

§ H  H med
4SH1 ¨¨ cell
© H cell  2H med

· 3
¸¸ R Eo .
¹

(3)

Substituting Equation 3 back into Equation 2 yields the DEP force Equation given in
Equation 1.
E(r + d)
Dipole

+q

+

d
E(r)
y

-q

-

r

z

Figure 3.2 Force exerted upon a small dipole by an electric field. Adapted from [4].
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3.2.2 Debye Electrical Double Layer
As a resultant of a cell’s polarization an electric double layer of charges are
formed at the cell interface also referred to as the Debye or electric double layer
(EDL). The EDL contains two layer of charges with potential difference, phase 1
(conductive medium) has a net negative charge and phase 2 (cell) has a net positive
charge or vice versa (equivalent to parallel plate capacitance). There are several
models established to describe the charge layering phenomena: Hemholtz, GuoyChapma, and Guoy-Chapman-Stern model.
This information is important because during DEP experiments the
movement of ions is the key factor to the polarization and the behavior of the ions in
the EDL is an indicator of cellular dielectric properties. The dielectric relaxation
time is cell-specific and dictates how long it will take for a cell to adequately feel the
applied electric field, also critical in cell separations. Also, to state more clearly, the
key parameters associated with dielectrophoresis are permittivity and conductivity.
These two properties are inversely related and the permittivity can be thought of as a
resistance to the surface ion polarization induced by the applied AC electric field.
The higher a cell’s permittivity the less resistant it is to the AC electric field and the
polarization will occur quicker when compared to cells of similar size with smaller
permittivity’s. Cell size is critical to interfacial polarization, the larger the cell the
longer it will take for ions to move around, align, and induce movement, this is
evident in Equation 1 for the DEP force. The Clausius-Mossotti factor is the
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indicator in the DEP force equation that is directly correlated to a cell’s polarizability
because it’s dependent on the cell’s permittivity and conductivity values.

3.3 Dielectrophoretic Particle Polarization Models
3.3.1

Geometry Overview
Now, that the different particle polarizations have been discussed let’s look at

the key equations developed to model the polarization response of cells. A particle’s
polarization can be modeled using a series of equations dependent on a cells shape,
complex permittivity, permittivity, and conductivity. A variety cell shapes can be
modeled using the DEP polarization model equations, and cell complexity can be
added to these models by adding layers that account for a cells internal structure
(membrane, cytoplasm, nucleus, etc.). The most common cell shapes modeled in this
manner are spherical, core-shell sphere, ellipsoid, and core-shell ellipsoid. The
hMSCs are our focus, and their main shape is spherical like or star-shaped, which
can be modified to spherical via ELP-PEI treatment. Thus, this section will focus on
the spherical and core-shell spherical DEP polarization model.

3.3.2 Homogeneous Sphere DEP Polarization Model
The homogenous sphere, used for polystyrene beads in Chapter 5, simplifies
the cell structure to not contain any internal organelles. For a homogeneous spherical
particle, the fCM is given by [1, 4],
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f CM

H~cell  H~med
H~cell  2H~med

H~cell

H cell 

H~med

H med 

(4)

V cell
jZ

(5)

V med
jZ

(6)

In Equations 4 – 6 H med is the permittivity of the surrounding medium (unitless),
Re[fCM] is the real part of the Clausius-Mossotti factor (unitless), H~cell is the complex
permittivity of the cell (unitless), H~med is the complex permittivity of the medium
(unitless), H cell is the permittivity of the cell (unitless), V cell is the conductivity of the
cell (S/m), and V med is the conductivity of the medium (S/m). If a particle
experiences pDEP, then fCM is positive which indicates that the DEP force displaces
the particle in the electric field gradient towards areas of high electric field density.
Vice versa is true for a particle experiencing nDEP, fCM is negative and the particle is
displaced in the electric field gradient towards areas of low electric field density.
When fCM equals zero, cross-over frequency (fxo), the particle experiences no DEP
force (

). The fxo is the point at which a cell (or particle) transitions from

experiencing pDEP to nDEP or nDEP to pDEP. The fxo is important because at this
transition point the dielectric properties of cells (or particles) can be determined,
along with other data points from the DEP spectra [9]. fCM is dependent on the
complex permittivity of the cell and the medium (Equation 5-6). If H med > H cell , then
fCM will be negative and if the H cell > H med , then fCM will be positive. The real part of
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the fCM is further dependent on the permittivity and conductivity of the medium and
cell, with four cases summarized in Table 3.1. From Equation 1, the cell size plays a
role in the DEP force experienced by the cells. As cell size changes the cell DEP
force changes.

Table 3.1. High and low frequency examination of the Clausius-Mossotti factor, fCM.
Case 1
High
If V cell > V med ,
Frequency then f is
CM
dependent on
permittivity
Low
If V cell > V med ,
Frequency then f is
CM
positive

Case 2

Case 3

If V cell < V med , If H cell >
then fCM is
H med then
dependent on
fCM is
permittivity
positive
If V cell < V med , If H cell >
then fCM is
H med then
negative
fCM is
positive

Case 4
If H cell <

H med then
fCM is
negative
If H cell <

H med then
fCM is
negative

The permittivity of a cell is a resistance to the electric field, and cells with
higher permittivities have less resistance to the electric field and are easier to
polarize. This can be thought of time take for ions in a suspending solution take to
rearrange around the cells once the AC electric field is applied. The homogeneous
sphere does not represent the complexity of a cell, so it’s not frequently used to
model cell’s DEP response. However, the homogeneous sphere of polystyrene beads
is useful in evaluating new microdevice designs, and experimental techniques,
because PS bead structure is homogeneous.
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The homogeneous spherical DEP polarization model has been used to
examine how the fCM changes as a function of frequency at varying medium
conductivities. The results of this model are in Figure 3.3, which illustrates that an
increase in solution conductivity shift fCM, model doesn’t account for cell internal
organelles.

Figure 3.3 Homogeneous sphere DEP polarization models for the fCM of hMSCs in
varying conductive mediums. Plot generated in MATLAB using Equations 4-6 [1],
where İcell = 1 İoİmed  İoİo = 8.85*10-12DQGıcell = 10-6 S/m. This model
does not account for hMSCs internal structure.
82

3.3.3 Core-Shell Spherical DEP Polarization Model
Because the spherical DEP polarization model does not account for cells
structural organelles such as the membrane and cytoplasm, and therefore, it is not an
accurate representation of cell’s DEP response spectra. A more appropriate model is
the core-shell spherical DEP polarization model, which treats cells as a layered
particle and accounts for the conductivity and permittivity of both the cell membrane
and cytoplasm. Consider a layered spherical cell suspended in a conductive medium
in a nonuniform AC electric field, the DEP force acting on the cell will be the same
as in Equation 1. The difference in this case appears in how the fCM is defined
because a third region describing the electrostatic potential on the layered cell is
added creating an additional boundary condition. Now the complex permittivity of
the cell has to account for the complex permittivity of the cell membrane and
cytoplasm. This is accomplished by replacing the cell by an equivalent homogeneous
sphere defined with the same radius. By solving the new layered spherical
electrostatic potential problem the Clausius-Mossotti Factor is now given as [1, 4],
f CM

'
H~cell
 H~med
,
'
H~cell
 2H~med

(7)

'
H~cell
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H~mem

H mem 

V mem
.
jZ

(10)

In Equation 7 H cell is the effective complex permittivity of the cell, which
'

takes into account the complex permittivity of the cytoplasm ( H~cyto ) and cell
membrane ( H~mem ), permittivity of the cytoplasm ( H cyto ) and cell membrane ( H mem ),
as well as the conductivity of the cytoplasm ( V cyto ) and cell membrane ( V mem ). Here
the size of the cell plays a very important role and the size is accounted for in the
radii. Here is where knowing hMSCs morphology, cell size, and protein expression
becomes important, because larger cells will have a different DEP response than
smaller cells. The overall goal of this research is to characterize the dielectric
behavior of hMSCs and its differentiated progeny.
Figure 3.4 illustrates that for a core-shell sphere a conductivity increase shifts
(increases) the fCM, similar trend to the homogeneous sphere case. As the cell size
changes the cell DEP force changes. The core-shell spherical DEP polarization
model was also plotted to show size effects on fCM in a medium with 0.01 S/m
conductivity, Figure 3.5. In Figure 3.5 as the size of the cell increases fCM increases.
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Figure 3.4 Schematic of core-shell spherical cell and equivalent spherical with the
core-shell spherical DEP polarization model for hMSCs fCM in varied conductive
mediums. Plot generated in MATLAB using Equations 7-10 [1, 4] where İcyto =
 İoİmem = 0.50 İoİmed  İoİo = 8.85*10-12DQGıcyto = 0.63 6Pımem = 10-6
S/m.
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Figure 3.5 Effect of membrane size difference on hMSCs fCM directly correlates to
DEP response spectra [5]. Generated using Equations 7-10 LQ0$7/$%ZKHUHİcyto
 İoİmem = 0.50 İoİmed  İoİo = 8.85*10-12DQGıcyto = 0.63 6Pımem =
10-6 S/m, and R = 10, 20, 40, 60μm.

This modeling is key in the exploration of cells (or particles) because it
predicts cellular behavior at specific frequencies. These DEP models can be
compared to the experimentally determined DEP response spectra and optimized to
determine the dielectric properties membrane/cytoplasm permittivity, conductivity,
and membrane capacitance. Once the fxo is determined based on the experimental
DEP spectra fxo can be correlated to the membrane capacitance, and then correlated to
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the membrane permittivity. Membrane capacitance, Cmem, is a function of fxo and
given by [10, 11]
,

(11)

where r is the cell radius (ȝm). Further, the membrane permittivity is proportional to
Cmem,

H mem

Cmem d
,
4Sr 2H 0

(12)

where d is the membrane thickness and İ0 is the vacuum permittivity. Therefore, the
fxo and Cmem can be used as indicators of treatment-induced hMSC changes and can
be lumped into İmem, a key dielectric property. To obtain the dielectric properties, the
membrane and cytoplasm conductivity and permttivity values are adjusted until good
aggreement is made between experimental data and theory predictions. The
experimentally determined fxo is used to estimate the experimental membrane
capacitance.
Modeling hMSCs as core-shell spherical particles is a more accurate
representation of their complexity but is not 100% accurate. There are morphological
variations within an hMSC population ( as mentioned in Chapter 2), and in order to
have reproducible DEP responses as well as detect biosurface protein markers these
variations need to be removed from the DEP measurement. To achieve this, elastinlike polypeptide (ELP) polyethyleneimine (PEI) was employed as a standardization
technique and Chapter 4 reports results.
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This research uses a quadraple microelectrode design in order to achieve DEP
motion within experiments. There are many other microelectrodes possible, and they
will be briefly discussed in the next section.

3.4 Types of Dielectrophoresis Electrode Designs
Different types of DEP are characterized by the electrode design, and specific
design utilization are dependent on the application necessary. Traditional DEP is
classified by common electrode designs implemented into experimental studies,
which are interdigitated, castellated, curved and quadrapole; insulator/contactless
DEP is alternative method to traditional DEP and it prevents cells from coming in
contact with operational electrodes, and lastly traveling wave DEP is used from
cell/fluid pumping. This section will overview these designs in more details and
show their current use in research.

3.4.1 Traditional DEP
Traditional DEP uses a couple of different electrode configurations. For each
design type the electrodes are patterned along the bottom of a microchannel or
microchamber [12]. These designs include: interdigitated, castellated, curved, and
quadrapole (design used in this research); this list in not all inclusive. Figure 3.6 (ad) illustrates these different electrode designs. The electrode design selection is made
based on specific functions needed. Traditional DEP electrode designs are typically
used for cell separations or enrichment. Each design shapes the electric field gradient
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differently, and the position where the gradient is highest is marked with a red circle
in Figure 3.6 (a-d). The advantages to using these designs are that they are fabricated
easily, and require low electric fields to induce cell movement, which is critical to
maintain cell viability. The disadvantage to these designs are that they expose cells
to AC electric fields which means the electrode material used has to be
biocompatible [12]. Typical electrode materials used are gold and titanium [8].

Figure 3.6 Common traditional DEP electrode designs (a) interdigitated, (b)
castellated, (c) curved, (d) quadrapole. Each device design is used for cell trapping
based on cell dielectric properties. Adapted from [12].

Interdigitated, castellated, curved, and quadrapole electrodes are all used for
cell trapping either in the high electric field gradient area, pDEP, or in the low field
electric field gradient area, nDEP. Table 3.2 summarizes the applications these
electrode designs have been used in.
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Table 3.2 Summary of electrode configuration applications.
Configuration
Interdigitated

Castellated

Curved

Quadrapole

Particle
Prostate circulating
tumor cells
Human neonatal dermal
fibroblast and mouse
embryonic stem cells
Viral nano-lysate
3T3 and embryonic stem
cells
Latex nanoparticles

Application
DEP immunocapture
system
Estimation of
dielectric properties
based on % trapping
HIV virus detection
DEP-based cell
pairing
DEP image
processing and
dielectric property
measurement
Murine embryonic stem
Embryoid formation
cells
for stem cell
differentiation
Mycobacterium
Alive dead cell
smegmatis bacterial cells isolation
Porcine oocytes
Healthy oocyte
selection for in vitro
fertilization
Tungsten trioxide and
Particle concentration
polystyrene nanoparticles mapping
Yeast cells
Live and dead cell
sorter
Latex microbeads
microdevice utility
for continuous cell
sorting
Polystyrene beads and
Frequency sweep rate
red blood cells
data collection utility
Red blood cells
Blood typing
Colloidal crystals
Colloidal assembly
manipulations
HeLa cells
AC electrothermal
flow trapping
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3.4.2 Insulator/contactless DEP (iDEP or cDEP)
Another type of DEP separation is insulator DEP also known as contactless
DEP (cDEP), this method uses insulating postings within the microfluidic channel to
assist separations and the electrodes are located along the edges of the microdevice,
Figure 3.7. Specifically, the electrodes are isolated from the main microfluidic
channel by a thin membrane [27], and polyermic posts are placed in the channel to
distort the field creating a gradient [28]. The posts can have varied geometries such
as diamonds, circles, and triangles. DEP force equation and Clausius-Mossotti factor
remain the same with these setups.
Some applications for iDEP/cDEP are ABO-Rh blood typing [29], separation
of yeast cell and polystyrene bead mixture [30], P. aeruginosa and S. mitis bacteria
strain level discrimination [31], particle focusing [32], and high performance particle
trapping on a silicon substrate [33].
The advantages to this method are simple fabrication, DEP force is
distributed over large area (increases throughput), low AC fields used for
separations, and single cell analysis. A disadvantages is the possibility of joule
heating [12], applied AC field releases heat increasing system temperature [34].
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Figure 3.7 Varied insulating posts design inside iDEP microdevices. (a) rounded
triangluar [27], (b) circular [33], (c) elongated [32], and (d) triangular [30].
Reproduced with permission from [27, 30, 32, 33].

3.4.3 Traveling Wave DEP (twDEP)
Pumping is another operation strategies that can be implemented using DEP
with a slightly different electrode setup consisting of rectangular parallel electrode
array pattern, Figure 3.8. This electrode design facilitates horizontal particle
movement in a nonuniform electric field, and the electric field gradient maxima
occurs at the center of the electrodes therefore cells travels in wave down the center
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of the electrodes. This electrode design functions by turning on two electrodes at a
specific frequency, and then turning one electrode off and stepping to the next
electrode (turning on the next electrode). This causes the electric field gradient to
move or travel down the electrodes, hence the name traveling wave DEP (twDEP).
The time-average DEP force equation is now dependent on the real and imaginary
part of the Clausius-Mossotti factor [35],

FDEP

2SH med R 3 ^Re> f CM @E 2  Im> f CM @¦ E 2 I `

(11)

The velocity of the cells in the electric field is critical and specific to cell being
examined, different dielectric properties affects cell movement or mobility. Velocity
is dependent on fCM and is given by [35],

X DEP

R 2 H r H 0 Re> f CM @
E
3K

(12)

twDEP has been used as an alternative to FACS and MACs cell sorting
method by van den Driesche et al., in their work they separated jurkat cells from with
S. cervisiae (yeast) and Lactobacillus casei (bacteria found in the mouth and
intestine). The separation was achieved by first determining a separation frequency
fxo for jurkat cells using a quadrapole electrode design and choosing a device
operation frequency such that target cells experienced a small nDEP force away from
the electrodes. The twDEP was applied perpendicular to the flow, so that the
untargeted bacteria were adhered to the electrodes. Hydrodynamic flow allowed the
targeted jurkat cells to be collected [36]. Figure 3.8 illustrates the device setup and
real images of cell separation.
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Figure 3.8 twDEP separation of jurkat cells from S. cervisiae and Lactobacillus
casei bacteria. Jurkat cells were separated by flowing along the twDEP field gradient
with nDEP force and the bacteria cells were adhered to the electrodes with pDEP
force. Reprint produced with permission from [36].

The main applications of twDEP is to pump cells for sorting and other cell
systems be explored using this technique are red blood cells [37],

yeast, and

microparticles [38]. Each method discussed above traditional DEP, iDEP/cDEP, and
twDEP are useful in particle manipulation and determining the dielectric properties
of biological cells. In this dissertation the quadrapole electrode design is used due to
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is simple fabrication process. The quadrapole electrode DEP microdevice used in
this work is easily networked with syringe pumps, a function generator, and
microscope to complete experimental tests.

3.5 Microdevice Dielectrophoretic Applications
3.5.1 General Applications and Stem Cell Studies
Dielectrophoretic technology has been around for awhile with the earliest
work occurring in 1974 completed by Chen and Pohl. In this work single yeast cells
were exploited in nonuniform electric fields created with platinum wires. Individual
cell characteristics, permittivity and age, were tabulated using voltage release
response. The effective polarizability varied from cell to cell, but variations were
reproducible. The voltage response spectrum was able to detect variability within the
yeast cell population indicative of subpopulations (similar to hMSCs). This dielectric
response varied with cell age condition, dead cell excess permittivity decreased,
parameters may be useful in cell studies [5]. This study is at the core of all other
DEP studies to follow over the next 40 years.
Studies have now transformed to look at many animal and human cell
lineages. In a study completed by Muratore et al., myoblast C2C12 cells were
examined because of their similarities to stem cells (i.e. they differentiate). This
work detected different membrane capacitance signatures for fibroblasts,
differentiated C2C12, and undifferentiated C2C12 cells using a symmetrical
electrode design that funneled cells during sorting to the outlet, Figure 3.9a. The
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cells were tested in 0.12S/m conductive medium, and the membrane capacitance
difference between the undifferentiated C2C12 and fibroblast cells were attributed to
surface microvilli, with SEM images adding supporting evidence, Figure 3.9b [39].

Figure 3.9 Shows the cell sorting microdevice and corresponding SEM images of
sorted fibroblasts and undifferentiated C2C12 cells. Reproduced with permission
from editor [39].
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Another DEP study by Duncan et al., explored the Cl-, K+, and Ca+2 ionic
contributions to the cytoplasm conductivity of drug resistant and nondrug resistant
leukemic cells (K562 and K562AR, respectively). K562 and K562AR were treated
with verapamil (calcium channel blocker), quinine (potassium channel blocker), and
NPPB (chloride channel blocker) and the cells spatial variation were tabulated in the
presence of AC electric fields at 0.0025S/m. The channel blocker treatments altered
K562 and K562AR DEP response indicating reductions in their cytoplasm
conductivity. As a result Cl-, K+, and Ca+2 ionic contributions to K562’s and
K562AR’s cytoplasmic conductivity were found to be K562: 0.13S/m K+, 0.08S/m
Ca+2, and 0.09S/m Cl-; K562AR: 0.16S/m K+, 0.08S/m Ca+2, and 0.25S/m Cl-. Based
on the ionic contributions it can be inferred that the physiological difference between
K562 and K562AR is associated with the presence of extra chlorides (increased
chloride channel activity). This work demonstrates that DEP is a good analysis tool
to detect ion channel activity within cells [40].
DEP is also a good research tool for stem cells studies. In some of the first
stem cell DEP research it was demonstrated that hematopoietic stem cells could be
concentrated from a mixed cell population without requiring cell manipulation [41,
42]. Adipose-derived putative stem cells were also concentrated by coupling DEP
and field-flow fractionation (FFF) [41, 43]. Flanagan et al., examined the dielectric
properties of mouse neural stem/precursor cells (NSPCs) using parallel electrodes
(50μm in width with 100μm gaps) with an AC electric field. Figure 3.10 below
shows an image of the real microfluidic device used. In this study the NSPCs were
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suspended in a sucrose buffer solution with a conductivity of 150 μS/cm and
injected in a microchannel. An electric potential of 8V was applied and the
frequency was varied from 25kHz to 25MHz using a function generator. The DEP
response of the cells was recorded in 10 to 15 second videos and analyzed. The
results of this study show that NSPCs, neurons, and astrocytes have unique dielectric
properties that were detected in the system in Figure 3.10. These unique dielectric
properties were detected by looking at the percent of cells trapped at specific
frequency, trapped cell are those attracted to the electrodes or positive DEP [44].
These results are given in Figure 3.11. The work completed by Flanagan et al., did
not calculate the dielectric properties of NSPCs, and there was no connection made
with the to the biochemistry aspect of the stem cells.

Figure 3.10 Real image of the parallel electrode microfluidic device used to examine
the dielectric behavior of NSPCs. Reproduced with permission from editor [44].
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Figure 3.11 Percent trappings results for NSPCs, neurons, and astrocytes. Each cell
type has distinct percentage of cells trapped at particular frequencies, which is an
indication of unique dielectric properties among each cell type. Reproduced with
permission from editor [44].

DEP is a versatile technology and has been implemented in other studies
looking at the effects of DEP treated hydrogen peroxide on enamel teeth whitening
[45], pesticide detection [46], water quality testing [47, 48], and DNA electrical
property determination [49].

99

3.5.2 DEP Studies to Determine Cell Membrane Capacitance
A cell’s DEP spectra can be correlated to its membrane capacitance, which is
an indicator of biosurface proteins. This is of particular interests in hMSCs DEP
separations because the biosurface proteins are attributed to hMSCs subpopulations.
hMSCs membrane capacitance up to this point has not been explored (we
accomplish this in chapter 4), so the membrane capacitance of other cell systems will
be discussed in this section.
Table 3.3 summarizes

the cell membrane capacitance of

neural

precursor/stem progenitor cells (NSPCs) with neurogenic progenitor (NP) and
astrogenic progenitors (AP); embryonic (E12.5 or E16.5) mouse NSPCs; multiple
lineages of oral squamous carcinoma cells (CaLH3, H357, OSCC1, and DOK);
adipose-derived stem cells (ADSCs); adipogenic progenitors; osteogenic progenitors;
and ADSCs differentiated to osteoblasts. These cell systems were tested in varied
conductivity solutions ranging from 0.01S/m to greater than 1S/m (cell culture
media). The oral squamous carcinoma cells were characterized based on
subpopulations identified by their adhesiveness: rapid adherent cells (RAC), middle
adherent cells (MAC), and late adherent cells (LAC). Each of these adhesive
subpopulations were correlated to tumorigenic capability with RAC > MAC > LAC
[50], which indicates that DEP can be used to detect the tumor cells from healthy
cells, useful for cancer therapeutics. Lastly, the measured membrane capacitance for
each cell system is consistent with theory, higher capacitance values are
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experimentally determined in higher conductivity mediums due to their proportional
relationship (Equation 11).
Table 3.3 Summary of cell membrane capacitance studies using DEP.
Cell Type
NSPCs-NP biased
NSPCs-AP biased
E12.5 mNSPCs
E16.5 mNSPCs
SW Treated-E16.5
mNSPCs
CaLH3
RAC
MAC
LAC
H357
RAC
MAC
LAC
OSCC1
RAC
MAC
LAC
DOK
RAC
MAC
LAC
ADSC
Adipogenicprogenitor
Osteogenicprogenitor
Differentiated
osteoblasts

Conductivity
(S/m)
0.01
0.01
0.01
0.01
0.01

Cmem
(pF)
3.3
4.3
1.6
2.8
4

0.10

>1.0
>1.0

4.1
3.4
2.9
3.3
2.9
2.3
1.6
1.3
1.1
5.1
5.1
5.8
6.6
9.0

[52]
[52]

>1.0

6.9

[52]

>1.0

5.7

[52]

0.10
0.10
0.10

Ref
[51]
[51]
[51]
[51]
[51]
[50]
[50]
[50]
[50]

To review, the advantages to using density centrifugation paired with FACS
and MACS for hMSC separation are high selectively, automated, commercial
availability, and continuous processes [53]. The disadvantages of these processes are
that long process times, high cost, large electronic systems, and the antigen labeling
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necessary to achieve target cell isolation [54]. A cell separation system that can
improve upon these disadvantages will provide an alternative method for hMSC
separation, which may be more suitable for hMSC clinical therapeutics.
With that being said the advantages of using DEP microdevices over FACS
and MACs systems are the potential for low cost (microdevices can be mass
produced), electric fields are nonharmful to biological cells [55], quick separation
times (less than 5mins) [8], decreased resources necessary to achieve separations (μl
sample volumes) [7], and the versatility within microdevices [56]. In a FACS or
MACS system the only procedure that can be accomplished is cell separation based
on biosurface markers (ideal). DEP microdevices gives cell separations added
versatility such as further bioprocessing like cell culturing [57], lysis [58],
microreactor chambers for differentiation [59], and viability screening [60]. These
steps can all be concurrently combined on a single microfluidic platform.

3.6 Conclusions
DEP is a versatile analytical technique that has been employed to study
biological cell systems. At the foundation of DEP technology is electronic
polarization that occurs due to ion movement around a cell, Maxwell-Wagner
interfacial polarization dominant at radio frequencies. Cells response to the ion
movement is not instantaneous and dielectric relaxation time is required for the cell
to respond to ion movement. This time is cell specific and was utilized in the design
of a new DEP data collection technique in chapter 5.
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Additionally, the core-shell spherical DEP polarization model provides
adequate predictions of hMSCs DEP response (Chapter 4). The DEP spectra for cells
is dependent on cell size, dielectric properties, and medium conductivity. Cells
suspended in a higher medium conductivity will experience a shift in the DEP
spectra due to the increased number of ions present in the suspending solution. The
dielectric properties can be extracted from the DEP response spectra because the
membrane is directly related to fxo and the entire DEP spectra. A variety of electrode
designs are available for DEP experiments but the design type used is dependent on
the function required by the microdevice. Our work uses the quadrapole electrode
design because its easy to fabricate. Many particle/cell systems have been studied
with DEP technology jurkat cells, leukemic cells, and mouse neural precursor/stem
progenitor cells, just to name a few. However, hMSCs have not been studied with
DEP, therefore this dissertation work extends DEP technology to this novel cell
system for separations that can be utilized for type 1 diabetes therapeutics.
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Chapter 4 Characterizing the Dielectric Properties of
Human Mesenchymal Stem Cells and the Effects of Charged
Elastin-like Polypeptide Copolymer Treatment [1]

1

T.N.G. Adams, P.A. Turner, A.V. Janorkar, F. Zhao, and A.R. Minerick

4.1 Abstract
Human mesenchymal stem cells (hMSCs) have three key properties that make
them desirable for stem cell therapeutics: differentiation capacity, trophic activity, and
ability to self-renew. However, current separation techniques are inefficient, time
consuming, expensive and in some cases alter hMSCs cellular function and viability.
Dielectrophoresis (DEP) is a technique that uses alternating current (AC) electric
fields to spatially separate biological cells based on the dielectric properties of their
membrane and cytoplasm.

This work implements the first steps toward the

development of a continuous cell sorting microfluidic device by characterizing native
hMSCs dielectric signatures and comparing them to hMSCs morphologically
standardized with a polymer. A quadrapole Ti-Au electrode microdevice was used to
quantify the dielectric properties based on the DEP frequency spectra and cross-over
frequency of hMSCs from 0.010-35MHz in dextrose buffer solutions (0.030S/m and

The material contained in this chapter was previously published in
Biomicrofluidics, 2014. 8: p. 054109.
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1

0.10S/m). The membrane capacitance and permittivity were found to be 2.2pF and
2.0 in 0.030S/m and 4.5pF and 4.1 in 0.10S/m, respectively. Elastin-like polypeptide
(ELP-) polyethyleneimine (PEI) copolymer was used to control hMSCs morphology
to spheroidal cells and aggregates. Results demonstrated that ELP-PEI treatment
controlled

hMSCs

morphology,

increased

experiment

reproducibility,

and

concurrently increased hMSCs membrane permittivity to shift the cross-over
frequency above 35MHz. Therefore, ELP-PEI treatment may serve as a tool for the
eventual determination of biosurface marker-dependent DEP signatures and hMSCs
purification.

Key Words: Dielectrophoresis, human mesenchymal stem cells, elastin-like
polypeptide polyethyleneimine, cross-over frequency, membrane capacitance,
membrane permittivity

Common abbreviations: Human Mesenchymal Stem Cells (hMSCs),
Dielectrophoresis (DEP), Alternating Current (AC), Elastin-like polypeptide (ELP),
Polyethyleneimine (PEI), positive dielectrophoresis (pDEP), negative
dielectrophoresis (pDEP)
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4.2

Introduction
Human mesenchymal stem cells (hMSCs) are an interesting cell source to

researchers because of their regenerative [1, 2] and immunological properties [3, 4].
hMSCs are isolated from the bone marrow and other locations in the body [5] due to
their beneficial properties. They have a high differentiation capacity (adipocytes,
chondrocytes, osteoblasts, etc.) [6-10], self-renew [11, 12], and secrete bioactive
molecules (trophic activity) [2, 3, 13, 14]. hMSCs trophic activity is substantial to
their function because signals are sent to surrounding cells triggering tissue repair [13]
causing apoptosis inhibition, proliferation, and matrix production [13, 14]. hMSCs
are being pursued as a therapeutic option for many chronic diseases such as lupus [15],
diabetes mellitus [16], cardiomyopathy [17], liver cirrhosis [18], and Crohn’s disease
[19].
For therapeutic treatments, obtaining hMSCs is a multistep process. hMSCs
are a heterogeneous population [20, 21] therefore following bone marrow isolation
they are centrifuged via density gradient solution (step 1), adhered to plastic cell
culture dish (step 2), and separated using trypsinization (step 3) [17]. This method is
inefficient and time consuming [22], so other techniques are employed, fluorescentand magnetic-activated cell sorting (FACS and MACS), which implement unique cellsurface antigens or other recognition elements to tag target cells. This ‘labeling’ of
cells alters cellular function, which is not desirable [22-24]. FACS and MACS require
expensive raw materials and are labor intensive. There is not a unique biosurface
marker that distinguishes hMSCs from other cell populations [21, 25], the minimum
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requirements established by the International Society for Cellular Therapy are: (1)
plastic adherence (generic cellular property [6]); (2) positive expression of CD105,
CD73, and CD90; (3) negative expression for CD34, CD45, CD11a, CD19, CD14,
and HLA-DR; and (4) adipogenic, osteogenic, and chondrogenic differentiation
potential [8, 16]. hMSCs have differing biosurface marker expressions on their
membrane [26] making it difficult to establish a unique biosurface marker for
characterization.
Additionally, hMSCs morphology has variations, which can create
subpopulations [27]. Therefore a label-free, one-step cell purification technique that
rapidly purifies hMSCs by accounting for their morphology without altering cellular
function is needed.
Dielectrophoresis (DEP) is a separation technique that has potential to
overcome the shortcomings of density gradient centrifugation, FACS, and MACS and
could provide an electrical biomarker for hMSCs. DEP technologies enable a variety
of particle polarizations with nonuniform AC electric fields on microchips [28, 29] to
achieve particle manipulation. DEP has been used to study other cell systems such as
red blood cells [30, 31], cancer cells [32, 33], white blood cells [34], and yeasts cells
[35, 36]. The red blood cell DEP studies are important because different ABO-Rh
surface antigens were distinguishable from the DEP spectra. The long-term goals of
characterizing hMSCs dielectric properties are to discern unique biosurface markers
specific to hMSC subcultures.
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Advances have been made in the study of stem cells using dielectrophoresis.
Flanagan et al. [37], looked at the affects AC electric field expsosure times have on
cell viabilty. They found that for human and mouse neural stem/progenitor cells short
exposure times (30s-1min) between 0.010-10MHz did not affect cell viability and
metabolic activity.

However, longer exposure times, 5–30mins, at the same

frequencies induced 20 to 40% decrease in cell viability and metabolic activity. These
results establish experimental parameters, and aligns with cell viability results found
in this work after 90s AC field exposure hMSC cell viability remained intact. Wu and
Morrow [38] conducted a one patient clinical study on stromal vascular fraction (SVF)
cells separated via DEP. The SVF cells were obtained, separated at 15Vpp, 0.101.0MHz and autologously transplanted to a patients hand to treat muscle atrophy.
Positive results were achieved indicating that DEP treated cells were not harmful and
they accelerated the healing process over 3 months (as compared to control). The
advantages to coupling DEP with microfluidics are microliter sample size, quick
analysis (~minutes to achieve results), little sample preparation, and minimal waste
production. Disadvantages are that extended electric field exposure times (>5mins)
negatively affect cells properties and viability [37].

4.3 Background
DEP utilizes nonuniform electric fields for cell movement based on the
polarizability and dielectric properties (permittivity and conductivity) of their
membrane, cytoplasm, and other structurally dominant organelles [39]. Cells have
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distinct dielectric dispersions that can be used as an identification tool for cell
purification. A cell’s complex permittivity is frequency dependent and characterized
E\WKHĮȕDQGȖGLHOHFWULFGLVSHUVLRQUHJLRQV ȦĮ Ȧȕ ȦȖ) [40]. At radio frequencies
(ȕ-region), 0.010–10MHz, the dielectric dispersion of cells are affected by their
membrane; high frequencies penetrate a cells surface and interogates the internal
structure. Therefore, a plethora of information can be obtained about a cell population
in the ȕ-region; many researchers complete their experiments within this frequency
range.
In the ȕ-region, Maxwell-Wagner interfacial polarizations dominate the DEP
response phenomena. Based on permittivity and conductivity, polarized cells will
exhibit either positive DEP (pDEP), cells move to areas of high electric field gradient,
or negative DEP (nDEP) force; cells move to areas of low electric field gradient [41,
42]. The DEP force is given by, FDEP

3
2SH med Rmem
Re> f CM @E 2 and this cell motion

in the electric field is defined by the Clausius-Mossotti factor, fCM, for core-shell
spherical particles [39, 41]
,

(1)

,

(2)
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,

(3)

where R is the radius of the cell cytoplasm and membrane (Rcyto and Rmem),

is the

complex permittivity, İi is the permittivity, and ıi is the conductivity where i = cell,
cytoplasm, membrane, or medium. The complex permittivity
the angular frequency (

, is also dependent on

) [41]. fCM is dependent on the complex permittivity of the

cell and the medium, equation 2. If a cell experiences pDEP then fCM (equation 1) is
positive indicating the cell is more polarizable than the suspending medium,

>

H~med , and the cell moves toward areas of high electric field density [41]. For nDEP,
the fCM is negative and the cell is less polarizable than the suspending medium, H~med >
, and the cell moves towards areas of low electric field density [41]. When fCM is
zero, known as the cross-over frequency fxo [39], cells experience no DEP force (FDEP
= 0) as they transition from nDEP to pDEP or pDEP to nDEP. This fxo is an important
component of a cell’s DEP spectra because the dielectric properties of cells can be
estimated along with other data points from the DEP spectra.
The DEP behavior of cells is quantified experimentally by measuring the pDEP
and nDEP at specific frequencies within a given buffer solution. The fxo can be
extrapolated between the two nearest pDEP and nDEP frequencies. Cells typically
display two fxo’s, which are dominated by its membrane structure. The low fxo is
determined by the cell’s size, shape, and membrane with typical values between 0.0100.10MHz (ȕ-region), but reported as high as ~4MHz [43]. The high fxo is dominated
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by the cell’s cytoplasm and is typically above 10MHz in low conductivity media [44].
For the experiments described in this work, the high fxo value falls outside of the range
of our function generator (Ȗ-region). Membrane capacitance, Cmem, is a function of fxo
and given by [44, 45]

,

(4)

where r is hMSCs radius (ȝm). Further, the membrane permittivity is proportional to
Cmem,

,

(5)

where d is the membrane thickness and İ0 is the vacuum permittivity. Therefore, the
fxo and Cmem can be used as indicators of treatment-induced hMSC changes and can be
lumped into İmem, a key dielectric property.
To eliminate variation in cell morphology and increase DEP response
reproduciblity within our hMSC sample population, elastin-like polypeptide (ELP)
polyethyleneimine (PEI) was employed. ELP-PEI is a postively charged copolymer
that directs cells morphology to a spheroidal shape with a propensity to form
aggregates. Similar to mammalian elastin, ELP is synthesized from amino acids
including valine, proline, and glycine and has been utilized to induce spheroid
formation and differentiation of H35 rat hepatocytes. ELP-PEI has also elucitated
affects of free fatty acids and cytokines in 2D and 3D rat hepatoma cell cultures [46,
47].
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In this paper, the first steps toward the development of a continuous cell sorting
microdevice were completed by characterizing the dielectric signature of hMSCs and
standardizing their morphology with ELP-PEI treatments. We demonstrate that DEP
can quantify hMSCs İmem, ımem, and Cmem based on measured DEP spectra. We also
characterize the DEP behavior of ELP-PEI treated hMSCs for comparison to the native
hMSCs. Determing hMSCs dieletric properties and removing morphology variations
is essential to increase reproducibility and magnify different membrane biosurface
markers.

4.4 Materials and Methods
Microdevice Fabrication: The microdevice in Figure 4.1b was fabricated
using prior published techniques [30] with 100ȝm wide and 200ȝm spaced electrodes.
A 2000ȝm deep by 3000ȝm wide microwell made with PDMS was sealed on top of
the quadrapole array. Figure 4.1b shows the quadrapole Ti-Au electrode microdevice
setup.
hMSC Cell Culture: Nitrogen stored bone marrow derived hMSCs were
recovered by thawing cells in 37°C water bath. 500mL alpha minimum essential
medium (ĮMEM) with L-glutamine, without ribonucleosides or deoxyribonucleosides
(Catalog # M20350, Atlanta Biologicals, Atlanta, GA) was completed with 50mL fetal
bovine serum (FBS, Catalog # S11550, Atlanta Biologicals), 3mL L-glutamine
(200mM in 0.85% NaCl, Catalog # 25030081, Life Technologies, Carlsbad, CA), and
3mL penicillin/streptomycin (Catalog # 15140122, Life Technologies).
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Thawed

hMSCs were placed in 15mL complete ĮMEM in sterile cell culture flask and
incubated overnight at 37°C, 5%CO2. After 24hrs, phosphate buffer solution (PBS,
Catalog # 6508-OP, EMD Millipore, Chicago, IL), 0.25% trypsin/1mM EDTA
(Catalog # 25200072, Life Technologies) and complete ĮMEM were warmed to 37°C.
Old complete ĮMEM was removed from the flask and attached hMSCs were washed
with 10ml PBS. 4mL trypsin was added to the flask and hMSCs were incubated at
37°C, 5%CO2 for 3-4mins for full cell detachment (monitored with microscope). After
detachment 5mL of complete ĮMEM was added to flask to inactivate trypsin, and the
hMSC suspension was placed in sterile centrifuge tubes. hMSCs were centrifuged for
10 minutes at 494 relative centrifugal force (RCF). The supernatant was removed and
hMSCs were resuspended in 5mL of fresh completed ĮMEM.

1mL of hMSC

suspension was placed in new cell culture flask with 15mL complete ĮMEM for the
next passage. hMSCs were incubated until 90% confluent (~5 days) and passaged
following the same trypsin detachment procedure. Multiple flasks of hMSCs were
cultured for DEP tests, with an extra hMSC flask continually passaged every 4-5days
for subsequent DEP testing. DEP tests were completed when cells reached 106 cell/mL
concentration (~5-7 days).
DEP Solution Preparation: 1M NaOH (Catalog #S318-500, Fisher Scientific,
Waltham, MA) solution, 3M salt stock solution, 4% bovine serum albumin (BSA,
Catalog # A7906-100G, Sigma Aldrich, St. Louis, MO)-Epure H2O pH 10 solution,
0.030S/m and 0.10S/m dextrose solutions were prepared to complete hMSCs DEP
testing.

The 3M salt stock was comprised of 1M KH2PO4 (Catalog # 7100,
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Mallinckrodt Chemicals, St. Louis, MO), 1M NaCl (Catalog # 7581, Macron
Chemicals, Swedesboro, NJ), and 1M K2HPO4 (Catalog # BDH0266-500G, VWR,
West Chester, PA) in 20mL Epure H2O. A 4% BSA pH 10 solution was utilized to
pretreat the microdevice surface. The 0.030S/m dextrose solution was prepared to
0.30M with 0.30M dextrose (Catalog # D9434-500G, Sigma Aldrich) and 9.1x10-4M
salt stock, then balanced to pH 7 with 1M NaOH (as necessary). 4% BSA was added
and thoroughly vortexed. The 0.10S/m dextrose solution was prepared to 0.28M with
0.27M dextrose and 7.5x10-3M salt stock, then balanced to pH 7 with 1M NaOH (as
necessary). 4% BSA was added and thoroughly vortexed. Final dextrose solution
conductivities were verified using a conductivity meter (AB30, Fisher Scientific).
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Figure 4.1 (a) hMSCs cartooned to emphasize the differing cell membrane biosurface
markers and thus properties.

After ELP-PEI treatment, cartooned spheroidal

morphology. (b) Quadrapole microdevice with 200ȝm spaced Ti-Au electrodes used
for DEP experiments. (c) hMSCs in device with field off, and the DEP response
observed with field on. At a single frequency, both nDEP and pDEP were observed
due to differing membrane biosurface markers within an hMSCs population.
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DEP Experimental Procedure: For DEP tests, centrifuged untreated hMSCs
were resuspended to a concentration of 1.3x106cells/mL in either 0.030S/m or 0.10S/m
dextrose solution. The microdevice was presoaked in 4% BSA-Epure H2O adjusted
to pH 10 to prevent cell adhesion. The hMSC dextrose suspension was loaded into
the quadrapole chamber using a micropipette. A function generator (Agilent 33250A,
Agilent, Santa Clara, CA) was connected to the microdevice via copper leads (Figure
4.1b). Static frequency measurements were completed using 10Vpp AC sine wave,
0.010MHz to 35MHz for 90s. More than 300 untreated hMSCs (n > 300) were tested
at each static frequency. Untreated hMSCs static DEP responses were compared to
static measurements of ELP-PEI treated hMSCs.

To achieve ELP-PEI hMSC

treatment, ELP-PEI was synthesized as described in [46, 47] and dissolved in Epure
H2O (5mg/mL) in a sterile centrifuge tube. 5mL ELP-PEI Epure H2O solution was
added to a vented cell culture flask and dried for 48hrs at 37°C. After 48hrs, excess
water was removed and the coated flask was decontaminated under UV light for
5mins. 90% confluent hMSCs were trypsinized and placed in ELP-PEI coated flask
for 24hrs. hMSC images were taken before and after ELP-PEI treatment. After 24
hours, ELP-PEI treated hMSCs were tested within the DEP microdevice using AC
fields and static frequencies.
Data Acquisition: 30 fps video recordings using LabSmith SVM Synchronized
Video Microscope 10x objective (LabSmith, Livermore, CA, USA) were collected.
DEP behaviors of the untreated hMSCs and ELP-PEI treated hMSCs were quantified
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with ImageJ (NIH, Bethesda, MD) by recording cell position and number after 90s in
the AC electric field. Percent cell responses (Rc) were calculated by tabulating the
number of cells, ni, exhibiting nDEP and pDEP behaviors (where i = nDEP, pDEP,
pDEP-nDEP) divided by the total number of cells, nT, tested.
,

(6)

Rc was plotted as a stacked column chart to show hMSC nDEP, pDEP, and
pDEP-nDEP behavior at individual static frequencies, Figure 4.3a and 4.3b. Next, Rc
was translated to a traditional DEP spectra plot (inspired by [48]) by scaling the nDEP
responses by fCM,min and pDEP responses by fCM,max calculated via Equations 1-3 for
each conductivity. The scaled equations were,

Rc ,nDEP

Rc , pDEP

nnDEP
u f CM . min ,
nT

n pDEP
nT

(7)

u f CM . max .

(8)

At 0.030S/m, fCM,min = -0.45 and fCM,max = 0.72 and for 0.10S/m, fCM,min = -0.49 and
fCM,max = 0.36. If the magnitude of the scaled Rc,nDEP was larger than the scaled Rc,pDEP
then Rc,nDEP was selected if not then Rc,pDEP was selected. The DEP spectra transitions
from nDEP to pDEP when Rc,nDEP # Rc,pDEP = 0.50 (at the fxo) as illustrated in Figure
4.3c.
Comparison to Model: The resulting DEP spectra for untreated and ELP-PEI
treated hMSCs were separately fit to the core-shell spherical DEP polarization model.
The starting literature values were İmem = 6.5 [49-51, 14, 52], ımem = 10-6 [49-51, 14],
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İcyto = 60 [49, 50, 14, 52], ıcyto = 0.63S/m [49-51, 14, 52]. These dielectric parameters
(İmem, ımem, İcyto, and ıcyto) were iteratively adjusted in Equations 1-3 starting from the
literature values, then varied to obtain the best curve fit to experimental data. R =
20ȝm was used for each optimization. Cmem was calculated from fxo to obtain
parameters for İmem via equations 4 and 5.

4.5 Results and Discussion
Static frequency measurements were completed from 0.010MHz to 35MHz to
establish hMSCs DEP response spectra to then calculate untreated and ELP-PEI
treated hMSCs dielectric properties. Static measurements were completed at 10Vpp
for 90s at each individual frequency and Figure 4.2 illustrates the hMSC spatial cell
counts and subsequent Rc at 0.010, 1.0, and 10MHz for untreated hMSCs. The
notation nDEP-pDEP indicates cells that initially exhibit pDEP and then transition to
nDEP, a behavior that is pronounced near fxo (see Figure 4.3).
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Figure 4.2 (a) Microscope images of untreated hMSCs DEP response with the field
off and at 0.010, 1.0, and 10MHz after 90s in 0.10S/m dextrose solution.

At

0.010MHz, hMSCs only display nDEP and display both nDEP and pDEP at 10MHz.
(b) Table of total cells for each image. (c) DEP responses tabulated as % cell response
(Rc) into a stacked column chart. nDEP dominates at 0.010MHz and at 10MHz pDEP
is 79% dominant.

To examine the medium conductivity dependence, hMSCs were tested in
0.030S/m and 0.10S/m at fixed 10Vpp for 90s at each individual frequency.
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Experiments were rerun until n > 300 cells and were tabulated at each frequency.
Figure 4.3a and 4.3b show the stacked column representation of hMSCs DEP response
in 0.030S/m and 0.10S/m, respectively. In 0.030S/m media, nDEP (gray) is the
dominant behavior up to ~0.65MHz, at which point the DEP behavior transitions to
pDEP (green) dominance. Individual cells experiencing both pDEP and nDEP (red)
within one experimental run are seen between 0.10–2MHz. In 0.10S/m media, nDEP
is dominant until ~1MHz and then transitions to pDEP behavior following a similar
trend as the lower conductivity but with the frequency response shifted higher. Figure
4.3c illustrates the translation of the Rc responses to hMSCs DEP spectra at 0.030S/m
and 0.10S/m, respectively. The DEP spectra curve shift is more apparent with this
plot format. Thus, hMSCs display different fxo’s dependent on the conductivity of the
suspending solution, 0.030S/m fxo = 0.62MHz and 0.10S/m fxo = 1.3MHz. The
frequency shift of 0.68MHz is consistent with other medium conductivity experiments
in the literature [39]. It was also observed that the DEP force weakened (slower hMSC
movement) as the fxo was approached.
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Figure 4.3 (a) Percent cell response Rc for untreated hMSCs in 0.030S/m dextrose
solution.

(b) Rc for untreated hMSCs in 0.10S/m dextrose solution.

For both

conductivities, nDEP dominates lower frequencies while pDEP dominates higher
frequencies. (c) Data from a and b translated into DEP response spectra for untreated
hMSCs at 0.030S/m and 0.10S/m. This format best illustrates 0.030S/m fxo estimated
as 0.62MHz and 0.10S/m fxo estimated as 1.3MHz.

The experimental data in Figure 4.3 was compared to the core-shell spherical
DEP polarization model (equations 1 - 3) as illustrated in Figure 4.4. The experimental
fxo’s were used in equations 4 and 5 to calculate Cmem and İmem of 2.2pF and 2.0, 4.5pF
and 4.1 for 0.030S/m and 0.10S/m, respectively. The İmem’s were utilized along with
starting model parameters specified in materials and methods and optimized WRİmem =
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0.79, ımem = 10-6, İcyto = 60, and ıcyto = 0.50S/m for 0.030S/m (Figure 4.4a solid curve
and Table 4.1).

0.030S/m experimental data (open green diamonds) has good

agreement with the core-shell spherical polarization model, with an overall 23% error.
For 0.10S/m, model parameters were separately optimized WRİmem = 1.1, ımem = 10-6,
İcyto = 60, ıcyto = 0.50S/m (Figure 4.4a dashed curve and Table 4.1) and agreed well
with the experimental data (open blue triangles), with an overall 17% error.

Figure 4.4 (a) Untreated hMSC DEP responses at 0.030 and 0.10S/m compared to
the core-shell spherical model. (b) hMSC membrane capacitance and (c) membrane
permittivity based on experimentally determined cross-over frequency.
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In order to elucidate the morphology contribution to the DEP response spectra,
ELP-PEI treated hMSCs were examined following the same experimental procedures
in 0.10S/m. Figure 4.5 compares ELP-PEI treated to untreated hMSCs experimental
images to DEP response spectra. Figures 4.5a and 4.5b illustrate the morphological
changes between untreated hMSCs attached to the bottom of the cell culture flask and
ELP-PEI treated hMSCs spheroidal cells and cell aggregates, which do not adhere to
the flask bottom. These images indicate that treated hMSCs formed spheroidal
aggregates consistent with liver cells, H35 rat hepatoma cells, and 3T3 mouse cells
described in previous literature [46, 47]; therefore the ELP-PEI treatment on the
hMSCs was successful in producing spheroidal morphology. Figures 4.5c and 4.5d
compare untreated and ELP-PEI treated hMSCs within the DEP microdevice with the
electric field off. With the field off, hMSC suspensions were randomly distributed
within the microwell, although cell aggregates were apparent with the treated hMSCs.
Figures 4.5e and 4.5f compare untreated and ELP-PEI treated hMSCs at 0.010MHz
after 90s in the AC field. Both the untreated and treated hMSCs display nDEP
behavior, but the treated hMSCs were more aggregated. At increased frequencies
1.0MHz (Figure 4.5g and 4.5h) and 10MHz (Figure 4.5i and 4.5j), untreated hMSCs
exhibit both nDEP and pDEP behavior while ELP-PEI treated hMSCs only exhibit
nDEP.
Figure 4.5k the corresponding DEP spectra for untreated hMSCs (open red
triangles) and treated hMSCs (open red triangles). At high frequencies (>10MHz),
ELP-PEI treated hMSCs exhibit primarily nDEP with minor pDEP behaviors.
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However, untreated hMSCs reveal nDEP behavior at lower frequencies, and pDEP at
higher frequencies with the fxo ~1.3MHz. There was not a fxo value within the tested
frequency range for treated hMSCs, so Cmem and İmem were estimated to be >0.13pF
and >0.12 with fxo>35MHz. For untreated hMSCs, cell counts were at least 300 for
each static frequency tested. Treated hMSCs were aggregated spheroids, therefore the
cell counts are denoted n’. Lower n’ numbers were tolerated at lower frequencies
where nDEP clearly dominated the responses.

Figure 4.5 Untreated hMSCs (first row) compared to ELP-PEI treated hMSC
spheroidal morphology (second row), both in 0.10S/m dextrose solution. (a) untreated
hMSCs in cell culture flask, (b) treated hMSCs after 24hrs in cell culture flask, (c)
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untreated and (d) treated hMSCs in microdevice with field off where black regions are
the quadrapole electrodes. Untreated and treated hMSCs at 10 Vpp and 0.010MHz (e
and f), 1.0MHz (g and h), and 10MHz (i and j). (k) DEP response spectra of untreated
and ELP-PEI treated hMSCs in 0.10 S/m. Untreated cells transition from nDEP to
pDEP at ~1.3MHz, while treated cells predominantly exhibit nDEP behaviors and
formed spheroidal aggregates.
The ELP-PEI treated hMSCs DEP experimental data at 0.10S/m was also fit
to the core-shell spherical DEP polarization model as shown in Figure 4.6. Because
fxo could not be directly measured, model parameters İmem, ımemİcytoDQGıcyto were
systematically adjusted from theoretical values to arrive at best fit parameters in
Figures 4.6a through 4.6d, respectively. For each individual parameter optimization,
the other three literature values were held constant as illustrated in Table 4.1.
Membrane permittivity adjustments in Figure 6a revealed that decreasing İmem from 5
[49-51, 14, 52] to 0.050 better matched the experimental data. Membrane conductivity
adjustments in Figure 4.6b from ımem 10-5 down to 10-7 [49-51, 14] had very little
impact on achieving model/data agreement. Cytoplasm permittivity adjustments in
Figure 4.6c from İmem 6 up to 100 [49, 50, 14, 52] also had very little impact on
achieving model/data agreement. Cytoplasm conductivity adjustments in Figure 4.6d
from ıcyto 0.63S/m [49-51, 14, 52] down to 6.3 x 10-3 S/m, achieved good agreement
with experimental data and may account for the nDEP behavior displayed by the ELPPEI treated hMSCs. Figure 4.6e compares the optimized model parameters for
untreated and treated hMSC. These values are simultaneously summarized in Table
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4.1. All final model parameters lie within the range of previously reported literature
values, except the membrane permittivity and cytoplasm conductivity, which were
slightly lower than the lowest reported value of 6.5 [49-51, 14, 52] and 0.63 S/m [4951, 14, 52], respectively.
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Figure 4.6 Key parameter optimizations for the core-shell spherical DEP polarization
model for ELP-PEI treated hMSCs at 0.10S/m. (a) Decreases from literature values
in membrane permittivity better capture ELP-PEI treated hMSCs nDEP behaviors. (b)
Increases or decreases in membrane conductivity do not contribute to the
experimentally observed nDEP. (c) Decreases in cytoplasm permittivity also do not
contribute. (d) Decreases in cytoplasm conductivity may contribute to the nDEP
behavior with ıcyto= 6.3 x 10-3 S/m fitting well. (e) Model prediction for both untreated
and treated hMSCs at 0.10 S/m using all optimal parameters for each. Agreement
between the model and the data is quite good with an overall 2.5% error.
Table 4.1 Summary of literature and optimized parameters for core-shell spherical
DEP polarization model for untreated and treated hMSCs in 0.030S/m and 0.10S/m.
İmem
Literature Range
(starting model
values)
[references]
Untreated
0.030S/m
Untreated
0.10S/m
ELP-PEI Treated
0.10S/m

İcyto

ıcyto (S/m)

6.5-11
(0.50)
[49-51,
14, 52]
0.79

ımem
(S/m)
10-3-10-8
(10-6)
[49-51,
14]
10-6

50-100
(60)
[49, 50,
14, 52]
60

0.30-0.88
(0.63)
[49-51,
14, 52]
0.50

1.1

10-6

60

0.50

0.050

10-6

60

6.3x10-3

In review, there was an observable conductivity dependence on the DEP
behavior of untreated hMSCs in 0.030S/m and 0.10S/m. This dependency was most
discernable near the hMSCs frequency transition region from nDEP to pDEP and the
135

fxo value, both were encompassed in the range of 0.61 and 1.4 MHz. Maxwell-Wagner
interfacial polarization mechanisms dominate in the frequency range from 0.010MHz
to 10MHz in the ȕ-dispersion region [40] such that an observed fxo is influenced by the
ionic interactions of the hMSCs membrane with the surrounding medium. As the
frequency increases in the MHz range, this interfacial polarization transitions to being
dominated by the membrane permittivity, which was more consistent with the
optimized model parameters in Table 4.1. Thus at 0.10S/m, the hMSCs membrane
was electrically more permissive to the ions driven by the AC field evidenced by the
shift in the DEP spectra to higher frequencies. These experimental findings were
consistent with the core-shell DEP polarization model optimization whereby the
cytoplasm properities did not vary, but the membrane parameters did (Table 4.1
summary). These experimental observations were corroborated with increases in the
calculated membrane capacitance, 2.2 pF and 4.5 pF at 0.030S/m and 0.10S/m,
respectively. Small deviations between the experimental data and the core-shell
spherical DEP polarization model likely occurred because the model does not account
for all of the hMSCs morphological and biosurface marker complexities.
To reduce the hMSCs morphological complexity, the cells were treated with
ELP-PEI to yield a uniform spheroidal cell shape.

The ELP-PEI treatment

concurrently caused some hMSCs to form spheroidal aggregates consistent with
previous work [46, 47]. For low frequencies, 0.010–0.10MHz, untreated and ELPPEI treated hMSCs similarly exhibited nDEP, suggesting comparable membrane
resistance at those frequencies. Above 0.10MHz, ELP-PEI treated hMSCs only
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exhibited nDEP behavior, which deviated from untreated hMSCs that transitioned to
pDEP behavior. There are a few possible scenarios to explain this behavior: (1) the
ELP-PEI may be incorporating itself into the hMSCs membrane, (2) small
concentrations of ELP-PEI could be present in the dextrose solution surrounding the
cells, and/or (3) cells aggregating into spheroids could shield membrane polarization
effects.
Within hypothesis (1) context, that ELP-PEI may have intercolated into the
hMSCs membrane, the core-shell spherical DEP polarization model key parameters in
Figure 4.6 and Table 4.1 illustrate that decreases in hMSCs membrane permittivity
were necessary to match experimental data (İmem is 0.050). A decrease in cytoplasm
conductivity from 0.63 S/m to 6.3 x10-3 S/m also supports this claim (Figure 4.7d), but
since the DEP tests were completed in the ȕ-dispersion region, its unlikely that the
DEP responses recorded were representative of the cytoplasm structure inside of
hMSCs.
Because the ELP-PEI treatment caused hMSCs to form spheroidal aggregates,
size effects were examined. Using the treated hMSCs starting model parameters
(Table 4.1) in the core-shell spherical DEP polarization model, the size would have to
reduce to 0.75ȝm to exhibit nDEP behavior similar to the observed experimental data.
This was not feasible for the treated cells and their aggregates, which had average sizes
of 17 ± 4ȝm and 43 ± 16ȝm, respectively. The increased size of the treated hMSC
aggregates would increase the exerted DEP force. However, there was no evidence
that this size increase would prevent interrogation of biosurface markers present on
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hMSCs membranes. Data did show strong media/membrane polarization behaviors,
which are prerequisites for surface biosurface marker-induced stem cell separations in
nonlinear AC electric fields. We conclude that the ELP-PEI treatment did achieve
standardization of the hMSCs morphology and simultaneously altered DEP behavior.

4.6 Conclusions
hMSCs are an important cell system due to their differentiation capacity,
trophic activity, and their ability to self-renew. Their therapeutic potential is currently
being explored through clinical trials to treat lupus, Crohn’s disease, and diabetes
mellitus. For successful and effective stem cell therapies, hMSCs purification after
bone marrow isolation could be considerably improved to increase selective recovery
of the most highly viable cells. Separation techniques like FACS and MACS are
expensive and alter cellular function and viability due to antigen tagging. Userfriendly DEP microdevices have previously demonstrated rapid cell separation and no
loss in cell viability with low voltage AC electric fields [37]. hMSCs populations are
heterogeneous with varied morphology, so the development of a continuous cell
sorting microdevice needs to concurrently control for and accurately measure (1)
hMSCs dielectric signatures and (2) cell morphology variations. The later was
accomplished in this work by morphologically standardizing the cell population with
ELP-PEI. Additionally, hMSC population heterogeneity correlates with biosurface
marker expression predisposing cells for adipocytes, chondrocytes, and osteoblasts.
Thus, after morphological standardization, precise measurements of DEP dielectric
signatures may facilitate biosurface marker-dependent cell separations.
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hMSCs have a distinct dielectric dispersion defined by internal structures, cell
membrane and cytoplasm. hMSCs membrane mostly affects the DEP response at
radio frequencies in the ȕ-dispersion region; the radio frequencies polarize the hMSCs
surface, facilitating a DEP force along the field gradient, and thus allowing
interogation of the cell membrane dielectric properties. The DEP results in this work
reveal that the conductivity of hMSCs suspending solution is critical to the membrane
polarization. Higher conductivity solutions increase the membrane permittivity
shifting the DEP spectra to higher frequencies for 0.10S/m than 0.030S/m. This
translates to a membrane capacitance increase from 2.2 pF for 0.030S/m to 4.5pF for
0.10S/m. Similarly, the membrane permittivity increases from 2.0 for 0.030S/m to 4.1
for 0.10S/m. The solution conductivity dependence was also apparent at the fxo for
hMSCs; 0.030S/m yields a lower fxo at 0.62MHz and 0.10 S/m yields a lower fxo at
1.3MHz. Frequency ranges tested did not enable measurement of the higher fxo. This
dielectric signature is unique for hMSCs because typical low fxo’s for other cell
systems fall in the range of 0.010-0.10MHz [44]. These differing DEP spectra could
be harnessed for hMSC cell separations from these other cell systems. Complicating
any separation endeavor is that the untreated hMSC DEP responses at static
frequencies varied within a single culture, thus reproducible separations need to
consider and control for biosurface marker expression.
The ELP-PEI treatment successfully standardized hMSCs population
morphology, although spheroidal cell aggregates were concurrently observed. The
ELP-PEI treatment concurrently increased the DEP response reproducibility. This
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standardization occurred because the polymer interacted with the cell membrane and
shifted hMSCs polarization behaviors. Only nDEP responses were observed from
0.010–10MHz, which was substantially different from untreated hMSCs.

The

spheroidal cell aggregates present after ELP-PEI treatment should increase the DEP
force, which is proportional to cell radius cubed.

However, the strong

media/membrane polarization behaviors observed suggest that this hMSC cell system
is a good candidate for future surface biosurface marker-induced stem cell separations.
With optimization of the ELP-PEI treatment, detection of molecular level differences
in hMSCs may be realizable to aid understanding of biological functions and cell
population purification for stem cell therapies.
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Chapter 5 Frequency Sweep Rate Dependence on the
Dielectrophoretic Response of Polystyrene Beads and Red
Blood Cells [1]
1

T. N. G. Adams, K. M. Leonard, and A. R. Minerick

5.1 Abstract
Alternating current (AC) dielectrophoresis (DEP) experiments for biological
particles in microdevices are typically done at a fixed frequency. Reconstructing the
DEP response curve from static frequency experiments is laborious, but essential to
ascertain differences in dielectric properties of biological particles. Our lab explored
the concept of sweeping the frequency as a function of time to rapidly determine the
DEP response curve from fewer experiments. For the purpose of determining an ideal
sweep rate, homogeneous 6.08ȝP polystyrene (PS) beads were used as a model
system. Translatability of the sweep rate approach to ~7ȝP red blood cells (RBC) was
then verified. An Au/Ti quadrapole electrode microfluidic device was used to
separately subject particles and cells to 10Vpp AC electric fields at frequencies
ranging from 0.010–2.0 MHz over sweep rates from 0.00080 to 0.17 MHz/s. PS beads
exhibited negative DEP assembly over the frequencies explored due to MaxwellWagner interfacial polarizations. Results demonstrate that frequency sweep rates must

The material contained in this chapter was previously published in
Biomicrofluidics, 2013. 7: p. 064114.
146
1

be slower than particle polarization timescales; sweep rates near 0.00080 MHz/s
yielded DEP behaviors very consistent with static frequency DEP responses for both
PS beads and RBCs.
Key Words: Dielectrophoresis, frequency sweep, polystyrene beads, red blood cells,
interfacial polarization, microfluidic devices

5.2 Introduction
Microfluidic and dielectrophoretic (DEP) technologies enable a wide variety
of particle polarizations with nonuniform electric fields on microchips [2, 3] to achieve
particle manipulation, concentration, separations, and property-based identification.
Particles [4-6] include bioparticles (DNA [7], virus [8], protein [9]) as well as cells
(blood cell types [10, 11], cancer [12-14], stem cells [15], and yeast [16]). The
advantages to coupling DEP with microfluidics are small sample size (on the order of
microliters), rapid analysis (approximately minutes to achieve results), minimal
sample preparation, and minimal waste production [17, 18]. Traditionally, DEP
experiments are completed at static, fixed frequencies such that maximum particle
polarization can be achieved and measured. Multiple experiments are conducted, each
at discrete frequencies over the range of interest to stitch together DEP response
spectra; this is a labor-intensive approach. Further disadvantages are that extended
field exposure times at fixed frequencies can change particle properties [15] or cell
viability [19]. Prior research has used rapid frequency sweeping to increase cell
separation efficiency [20-24], but to the best of our knowledge, frequency sweeping
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has not been explored to generate continuous DEP spectra. Therefore, a detailed study
examining the effects of frequency sweeping on particle polarization is pertinent and
timely. In this paper, we demonstrate that frequency can be swept with time in the ȕdispersion region thus enabling interrogation of cells at multiple frequencies within a
short time period. The benefits of using a frequency sweep technique are that nearly
continuous DEP response curves, when coupled with automated response analysis, can
be compiled in near real time and the number of experiments needed to obtain particle
DEP spectra are greatly reduced.
DEP enables phenotypically similar biological cells to be discriminated based
on dielectric properties including the conductivity and permittivity of the membrane,
cytoplasm, and other structurally relevant organelles. Cell components and structure
contribute to a cell’s signature dielectric dispersion [3, 16]. A particle’s complex
permittivity is frequency dependent and characterized by dielectric dispersion regions
ȖȕDQGĮZKHUHȦĮ Ȧȕ ȦȖ) specific to an applied frequency. This work explores
0.010 to 2.0 M+]LQWKHȕ-dispersion region [25] because the Clausius-Mossotti factor,
which governs sign and polarization strength, for polystyrene beads is nearly constant
over this range. Maxwell-Wagner theory describes the polarization mechanism of
SDUWLFOHVLQWKHȕ-dispersion region as interfacial polarization where moving charges
build around the interface of a charged or charge-neutral particle and exchange ions
with the suspending medium (ref. [26], pp.33-38). Interfacial particle polarization
creates an induced dipole moment such that the particle experiences disproportionate
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forces in each half cycle of the alternating current (AC) field resulting in net particle
movement (ref. [26], pp. 8-11).
Polarized particles can exhibit either positive dielectrophoresis (pDEP) or
negative dielectrophoresis (nDEP) as a consequence of the frequency-dependent
polarizability of the particle in the surrounding medium (ref.[26], p.10) [27]. Particles
that exhibit pDEP move to high electric field regions and particles that exhibit nDEP
move to low electric field regions [3, 16]. This motion up and down electric field
gradients is described by the Clausius-Mossotti factor for spherical particles [16]
f cm

H~i
where

H~p  H~m
,
H~p  2H~m

H~i 

(1)

Vi
,
Zj

(2)

is the complex permittivity of the particle (i=p) and of the medium (i=m),

which are both functions of conductivity ı permittivity İ DQG angular frequency
) [26].

Polarization is not an instantaneous event [28]; charge transport into the
interface takes a few microseconds in response to the electric field. Maxwell-Wagner
dielectric relaxation is a physical phenomena related to the transport delay of cation
and anion alignment in and around the interface of the dielectric particle [29]. At
lower frequencies (<~10 MHz), particle polarization is driven by this conductive
polarization. At higher AC frequencies, charges do not have enough time to move into
and around the interface double layer, so particles experience polarization lag time as
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a result of the rapidly modulating field and do not reach maximum polarization.
Maxwell-Wagner dielectric relaxation is charDFWHUL]HGE\DWLPHFRQVWDQWĲMW, which
is unique to each particle or cell due to the time constant’s dependence on the cell
dielectric properties. The time required for a particle to reach maximum polarization
given by (ref. [26] ,p. 27) [25, 30]
.

(3)

Typical relaxation times for particle polarization vary from pico to microseconds (ref.
[26],p. 37) [25, 30], and the calculated ĲMW for polystyrene (PS) beads in our Epure
H2O medium at 2.5x10-4 S/m is 3.5 μs. Thus, a single AC cycle is on the order of 0.01
to 2 μs; the time delay in ion transport within a static frequency field of 0.010 to 2.0
MHz is such that 2 to 350 AC cycles must be completed before the particle experiences
full polarization.
The Maxwell-Wagner dielectric timescales for charge transport into and
around the interface becomes important when the frequency is swept, i.e. changes as
a function of time.

Figure 5.1a crudely cartoons the Maxwell-Wagner particle

polarization at the interface under static frequency as well as slow and fast frequency
sweep rates. At a static frequency in the ȕ-dispersion region, the particle experiences
a constant frequency field such that the relaxation time is not a factor and the particle
fully polarizes. A particle in a field with a slowly changing frequency sweep has
relaxation time, ĲǻFS, that is less than ĲMW and thus the particle interface fully polarizes.
In contrast, a particle in a fast frequency sweep has a relaxation time, ĲǻFS, that is larger
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than ĲMW and the particle interface does not have time to fully polarize in the field. PS
beads are lossy dielectric particles treated as homogeneous spheres and are thus an
idealized particle to examine new techniques, devices or approaches to
dielectrophoretic characterizations. Our system is easily able to discern pDEP and
nDEP transitional behavior and adaptable to our new frequency sweep technique. The
homogeneous spherical DEP polarization model for PS beads İ DQGı [5

S/m) suspended in Epure H2O displays only nDEP behavior over 0.010 to 2.0 MHz.
In this study, dielectrophoretic responses of PS beads (model system) were

quantified at both static frequencies and frequency sweeps at rates ranging from
0.00080 to 0.17 MHz/s RYHUWKHȕ-dispersion frequency range of 0.010-2.0 MHz in
Epure H2O medium at 2.5x10-4 S/m.

At these experimental conditons AC

electroosmosis, normally at 100-500kHz, and electrothermal flow, normally occurs in
high conducitivity media 1 S/m or greater, was not a factor [31]. PS bead motion in
the electric field was imaged with video microscopy and analyzed using three
techniques: intensity profiles, transient response, and particle velocities.

Image

intensity analysis has been used by other researchers to quantify the pDEP and nDEP
behavior of particles representing particle concentration [32], voltage trapping [33],
cell counting [34], and noncontinuous DEP spectra [35, 36]. Our intensity analysis
method is used to develop a continuous DEP response spectra and data shows that
frequency sweep rates impact particle polarization due to dielectric relaxation
limitations. This frequency sweep technique was further extended to negatively
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charged biconcave red blood cells (RBCs), which are an important cellular system for
medical disease diagnostics [37-39].

Figure 5.1 (a) Dielectric relaxation mechanism for PS beads showing cases when i)
particle polarization occurs at a static frequency, ii) ĲMW is shorter than the slow
frequency sweep rate (ĲǻFS) allowing the bead interface time to polarize in response to
the nonuniform AC field, and iii) ĲMW is longer than the ĲǻFS for fast frequency sweep
rates and the bead interface does not have time to fully polarize. (b) Schematic of the
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quadrapole electrodes micro patterned onto a glass slide, and (c) microdevice with
PDMS fluidic layer bonded above the quadrapole electrodes silver epoxies to copper
leads.

5.3Materials and Methods
The microdevice shown in Figure 5.1c was fabricated according to previously
published microfabrication techniques [7], with the 1ȝP wide electrodes spaced
ȝP apart aligned at 90o along the bottom RI D  ȝP GHHS E\  ȝP ZLGH
microfluidic chamber as shown in Figure 5.1b. Polystyrene beads (Cat No. PP-60-10,
Spherotech, Lake Forest, IL, USA), 6.08 ȝP in diameter were centrifuged at 1300 min1

for 5 mins to separate the beads from the liquid. The PS beads were resuspended in

Epure H2O 0ȍRU[-4S/m) at a 1:10 (bead to water) volumetric dilution ratio
and vortexed. Microdevice was pre-rinsed with Epure H2O and Alconox precision
cleaner (Cat No. 1104, Alconox Inc, White Plains, NY, USA) to prevent bead
adhesion. PS bead-Epure H2O suspension was pumped to the microchamber using a
syringe. Time was allowed for inlet and outlet pressures to equalize and flow to stop.
The function generator (Agilent 33250A, Agilent, Santa Clara, CA, USA) was
connected via copper leads to produce a 10Vpp AC sine wave with frequencies
ranging from 0.010-2.0 MHz at specific frequency sweep rates 0.00080, 0.0011,
0.0030, 0.0063, 0.013, 0.021, 0.028, 0.042, 0.056, 0.083, and 0.17 MHz/s. Frequency
sweeps linearly increased the applied frequency as a function of time. Greater than
five (n>5) static frequency experiments were completed at each frequency 0.010,
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0.020, 0.030, 0.040, 0.050, 0.20, 0.40, 0.60, 0.80, 1.0, 1.2, 1.4, 1.6, 1.8, and 2.0 MHz
by applying 10Vpp for 90s. These DEP static frequency responses were compared to
each frequency sweep rate DEP responses. For the static and frequency sweep
experiments, the PS bead concentration was between 238-263 beads in the t=0 field of
view. Video recordings of experiments were taken at 30 fps at 640x480 pixels/image
using LabSmith SVM Synchronized Video Microscope with a 10x objective
(LabSmith, Livermore, CA, USA).
Video recordings of PS beads DEP behaviors were analyzed with ImageJ
(NIH, Bethesda, MD) using intensity, transient slope, and velocity measurements.
Since PS beads only exhibit nDEP over the frequency range of interest, intensity data
acquisition from images was completed by drawing a rectangular box at the device
center, ICTR, and background, IBK measured in a location with no PS beads present (See
Figure 5.2a). ImageJ Z Project function was used to average the pixel intensities in
the specified boxed region. The initial background, IBK(t=0) and center intensity,
ICTR(t=0) were subtracted from the center and background intensity at each time,
ICTR(t) and IBK(t), and then a normalized intensity was calculated by dividing by the
maximum intensity experienced by the PS beads,
(4)
This normalized intensity tracked the real-time magnitude of the PS bead DEP
response, which had two distinct regions: transient where beads moved with nDEP
toward the center, and steady-state (SS) where beads achieved tight packing at the
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device center. These two responses were analyzed separately via transient slope and
particle velocity.
The transient response of the PS beads was extracted from the steady-state
response via signal processing in which the delay and rise time were quantified. The
PS bead delay time, td, was characterized as the time required for the intensity response
to reach 50% of the final intensity response for the first time. The rise time, tr, was
determined as the time needed for the intensity response to reach 100% of the final
intensity response for the first time (ref. [40], pp. 517-518). This allowed the transient
response to be segmented and a linear trend line was fit between td and tr where td< tr.
A comparison of the transient slope for frequency sweep rates and static frequency
measurements is given in Figure 5.3c. PS bead velocities were determined from the
original video by tracking the x-, y-pixel position of individual PS beads from 0-50s.
36 EHDG ORFDWHG ZLWKLQ  ȝP RI HOHFWURGH WLSV ZHUH VHOHFWHG WR FRQWURO IRU VLPLODU
electric field gradients. This procedure was repeated for at least 10 beads in each
specific frequency sweep rate and static experimental video.
For the experiments involving human RBCs, blood type O+ was obtained from
a single donor and centrifuged at 1400 rpm for 5 mins to separate the packed RBCs
from the plasma and leukocytes. The packed RBCs were removed, then resuspended
at 1:75 v:v in 0.10 S/m isotonic dextrose buffer doped with 0.75% BSA (Cat No.
A7906, Sigma Aldrich, St. Louis, MO, USA) to prevent cell/device adhesion. This
RBC suspension was syringe-pumped to the microchamber, time allowed for flow to
stop and the 10Vpp signal applied over 0.010-0.50 MHz (range reduced to avoid pDEP
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behavior) at frequency sweep rates of 0.00080, 0.0063 and 0.056 MHz/s (n=7). RBC
static frequency experiments were completed at 0.010, 0.10, 0.25 and 0.50 MHz at
10Vpp for 90s (n=7). Video microscopy at 25x and 1 fps was obtained with a Zeiss
Axiovert Inverted Light Microscope (Zeiss, Germany). The video images were
analyzed as described above for the PS beads.

5.4 Results & Discussion
Frequency sweep rates ranging from 0.00080 to 0.17 MHz/s were explored to
see if the nDEP response of PS beads would vary and/or correspond to static frequency
measurements. The frequency range was chosen for the relatively consistent ClausiusMossotti factor, Re(fCM) for a homogeneous lossy polystyrene sphere of 0.26 to 0.48
(see Figure 5.2c) over the frequency range of 0.010 to 2.0 MHz. Static frequency
experiments were completed at fixed values in this same frequency range. Figure 5.2a
shows still images from both static frequency experiments and the frequency sweeps
at 0.20, 0.60, and 1.0 MHz. For static frequencies, the response 45 seconds after field
application is shown while for frequency sweeps of 0.0063, 0.056, and 0.17 MHz/s,
the image is shown at the time stamp when the specified frequency is reached. The
electrodes are visible as black shadows in the images and the PS beads assemble due
to nDEP forces at the central electric field gradient minima. Data was examined to
determine the sweep rate that most closely approximated the static frequency response.
Frequency sweeps 0.00080 and 0.0063 MHz/s (shown) tracked static frequency, or
true, DEP responses while the slightly faster sweep of 0.056 MHz/s begins to lag the
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true DEP responses and at 0.17 MHz/s and faster, particles were unable to achieve
sufficient polarization to respond sufficiently in the electric field.
nDEP responses were quantified via intensity analysis as described in materials
and methods for all sweeps and all static frequency experiments.

Figure 5.2b

illustrates the frequency (and time) dependent intensity for the 0.0063 MHz/s sweep
rate images shown in Figure 5.2a. This quantification of the PS bead nDEP response
was correlated to total bead packing via the calibration shown in the inset. The 188bead count at the center deviates slightly from the initial, field off, bead count of 245
because PS beads also move down the electric field gradient to regions outside of the
image field of view.

Figure 5.2 (a) nDEP behavior of 6μm PS beads suspended in E-pure H2O 2.5x10-4
S/m and 250Vpp/cm 0.0063, 0.056 and 0.17 MHz/s sweep rates from 0.010 MHz to
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1.0 MHz. (b) Raw intensity profile of PS beads in the center nDEP region (boxes
shown at 0.20 MHz) at 0.0063 MHz/s sweep rate. Inset is a calibration of intensity per
bead. (c) Clausius-Mossotti factor for the PS beads from 0.010 MHz to 2.0 MHz at
three conductivities of 2.5x10-4, 1.0x10-3, and 1.0 S/m. PS bead assembly at slower
frequency sweep rates track static frequency responses while 0.056 MHz/s illustrates
transitional behavior and frequency sweeps above 0.17 MHz/s substantially lag the
true static frequency DEP responses.

Normalized intensities, Eq. (4), were compiled in Figure 5.3a for SS (i.e. 45
seconds) static frequency nDEP responses and 0.00080, 0.0063, 0.056 MHz/s
frequency sweep rate nDEP responses. The time for sweep responses to achieve the
true nDEP static response decreases as the sweep rate decreases. Frequency sweep
rates 0.00080 and 0.0063 MHz/s are within the 95% confidence intervals (n=7) of the
static steady-state responses. Figure 5.3a inset shows that the slowest 0.00080 MHz/s
sweep rate more quickly aligns closely with the static frequency responses. Figure 3b
compares average 0.0063 MHz/s (n=8) to 0.17 MHz/s (n=7) with the dashed lines
signifying the upper and lower limits of the 95% confidence intervals for IDEP. The
confidence intervals around the transient 0.0063 MHz/s sweeps are smaller than for
0.17 MHz/s over much of the frequency range indicating greater reproducibility at
slower sweep rates. Faster sweep rates either do not reach SS or have a lag before
reaching SS (compare to Figure 5.2a) suggesting the bead interface does not fully
polarized and thus displays attenuated nDEP motion.
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The transient behavior was quantified for all static frequencies and frequency
sweeps via a transient slope analysis as compiled in Figure 5.3c. Four static frequency
measurements 0.010, 0.60, 1.0 and 2.0 MHz are shown compared to 0.00080, 0.0063,
0.028, 0.056, and 0.17 MHz/s frequency sweep rates. Static frequency transient slopes
range between 0.023-0.095 and are within the 95% (p<0.05) confidence intervals of
0.00080, 0.0063, and 0.028 MHz/s frequency sweep transient slopes. These slower
sweep rates and 0.056 MHz/s differ at p<0.001 from the fastest sweep rate of 0.17
MHz/s, which is also significantly different at p<0.001 from the static measurements
(except for 1.0x104 Hz with p<0.01).
Individual bead velocities were compiled for static as well as frequency sweeps
in Figure 5.3d. PS bead velocity corroborates the intensity profile and the slope
analysis that 0.00080 MHz/s frequency sweep rate closely tracks the bead velocity at
static frequencies. 0.056 MHz/s gives good estimations of static frequency bead
velocity at times greater than 20s. Based on intensity, transient slope, and velocity
analysis, the slow frequency sweep rate of 0.00080 MHz/s is most consistent with
static frequency DEP responses.
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Figure 5.3 (a) ȝPPS beads nDEP intensity profiles for 0.00080, 0.0063, and 0.056
MHz/s and static steady state (SS) measurements (black diamonds). Intensity analysis
captures bead assembly to the quadrapole center with transient and SS regions. The
slowest frequency sweep rate of 0.00080 MHz/s best predicts the static DEP responses.
(b) Bead assembly profiles for 0.0063 (n=8) and 0.17 MHz/s (n=7) with 95%
confidence upper and lower limits shown as dashed lines.

(c) Transient slope

comparison for static frequencies (0MHz/s) as well as frequency sweeps. (d)
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Comparison of static frequency and frequency sweep PS bead velocities from 0 to 50s.
0.00080 MHz/s results are consistently similar to the static frequency results.

There is an observable inverse relationship between the frequency sweep rate
and particle polarization, slower sweep rates result in comparable particle polarization
characteristics to static frequency responses. Dielectric relaxation is the driving force
of this relationship; the calculated dielectric relaxation time Eq. (3) for PS beads in Epure H2O at 2.5x10-4 S/m is 3.5 μs, which corresponds to ~0.28 MHz. There are two
timescales that influence this behavior: the frequency itself and the change in
frequency per time.

The Maxwell-Wagner, conductivity-driven interfacial

polarization mechanism occurs below ~0.28 MHz; above this frequency threshold the
interfacial polarization of the PS beads gradually decreases and the particle
permittivity increasingly influences the DEP force. The experimental frequencies
tested were within the range dominated by Maxwell-Wagner polarization such that
maximum particle interfacial polarization was possible.
The second timescale of interest is the frequency change per time or frequency
sweep rate, which determines how many consecutive cycles a particle experiences a
specific frequency.

At slower sweep rates, the PS beads experience a specific

frequency for a large number of cycles and thus the beads have time to polarize
because the timescale of the frequency change is slower than the dielectric relaxation
time. A particle must experience a single frequency during the sweep for a minimum
of 3.5 μs for maximum interfacial polarization to be achieved. Upon polarization, the
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particle, which its current DEP force has to overcome inertia and Stokes drag to
achieve observable particle motion down the electric field gradient. At static
frequencies, it takes roughly 5 s for maximum velocity to be attained (see Figure 5.3d,
AC field applied at t = 5s) and as much as 45s for final SS at the field gradient minima
to be reached. As the sweep rate increases, the dielectric relaxation time and the rate
of change of the frequency approach the same order of magnitude. Results suggest
that 0.056 MHz/s is a transitional sweep rate because the DEP behavior roughly
corresponds to the static behavior of the PS beads. With further increases in frequency
sweep rates, the timescale for frequency change surpasses the dielectric relaxation
timescale such that particles are unable to fully polarize resulting in an attenuated DEP
response as shown with data in Figures 5.2, 5.3a, and 5.3b.

Figure 5.3b also

demonstrates that the transient behavior of the PS beads is more reproducible at slower
frequency sweep rates, which can be attributed to the interfacial polarization timescale
of the beads. Implications of the intensity, slope, and velocity analysis compared with
static frequencies are that slow frequency sweep rates accurately predict the DEP
response of PS beads because the changes in frequency are slower than the
characteristic Maxwell-Wagner dielectric relaxation.
Thus, a frequency sweep approach can be utilized to attain accurate DEP
behavior of PS beads, provided the sweep rate is slower than conductivity mediated
interfacial polarization timescale. This result is reliable over frequency ranges where
particle polarization is dominated by the conduction of free charges from the media.
The charges are moving around the PS beads through the particle-liquid interface
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inducing a dipole, which causes PS bead movement down the electric field gradient to
the electrode center. At different sweep rates the rate of movement of the charges
varies which varies the rate of the dipole being induced, observed as dielectric
relaxation. Each sweep rate has a unique dielectric relaxation time and our results are
consistent with Maxwell-Wagner interfacial polarization theory. 0.00080 MHz/s is the
optimal sweep rate necessary to predict the true DEP behavior of PS beads because it
allows for full or partial (when the frequency is above 0.28 MHz) polarization.
Given that the sweep methodology yielded accurate DEP responses for the
ideal system of PS beads, the same methodology and frequency sweep rates were
explored with human RBCs. The three most successful PS bead frequency sweep rates
were reproduced with human red blood cells: 0.00080 MHz/s, 0.0063 MHz/s and
0.056 MHz/s. Static frequency experiments were also performed at 0.010 MHz, 0.10
MHz, 0.25 MHz and 0.50 MHz. Seen in Figure 5.4a are 25x microscope images taken
of the t=45s final static frequency frames aligned above the sweep time points that
correspond to those four static frequencies. Qualitatively, the only sweep rate that
accurately matches the static frequency behavior of the human RBCs is 0.00080
MHz/s. This behavior was further verified by the same intensity analysis as for PS
beads. In Figure 5.4b, the scaled intensity is plotted for 0.00080, 0.0063 and 0.056
MHz/s experiments (n=8) as compared to the static frequency intensities. After the
initial 10s transition for the red blood cells to polarize and overcome drag, the slowest
frequency sweep of 0.00080 MHz/s accurately predicts the static frequency behavior
and is highly reproducible, with a very narrow 95% confidence interval range (Figure
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5.4c). The fastest sweep rate of 0.056 MHz/s does not predict the static behavior of
the human RBCs and is much less reproducible, as evidenced by the large 95%
confidence interval in Figure 5.4c. From these experiments, we conclude that the
optimal frequency sweep for determining the accurate DEP behavior of RBCs is
0.00080 MHz/s. Due to the complex dielectric properties of cells, it is necessary to
carefully compare frequency sweep rates with static frequency behaviors to ascertain
optimal frequency sweep rates that accurately interrogate the cell of interest.

Figure 5.4 (a) nDEP behavior of RBCs suspended in 0.1S/m dextrose buffer and
250V/cm at 0.00080 MHz/s, 0.0063 MHz/s and 0.056 MHz/s sweep rates from 0.010
MHz to 0.50 MHz. (b) RBCs nDEP intensity profiles for 0.00080, 0.0063, and 0.056
MHz/s and static measurements. (c) 0.00080 and 0.056 MHz/s RBC assembly profiles
n=8, with 95% confidence interval upper and lower limits shown as dashed lines.
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The inverse relationship between the frequency sweep rate and particle
polarization exists for RBCs. RBC dielectric relaxation is the driving force and the
calculated dielectric relaxation time is 4.6 μs corresponding to ~0.21 MHz. By
choosing to sweep at a rate slower than this relaxation time the researchers are insured
that the response during the sweep is the same as that at a static frequency. Further
work is being done to explore the DEP response of RBCs when subjected to a wider
range of sweep conditions.

5.5 Conclusions
Traditional DEP measurements are completed at single static frequencies in
order to compile frequency by frequency, the DEP spectrum for a particle or cell
system. This method is laborious, and as illustrated in this work, requires time for
particles to fully polarize for accurate observed DEP responses.

This work

investigated the use of frequency sweeps as a means to more efficiently interrogate
multiple frequencies in a single experimental run and systematically compared the
responses to the nDEP response at fixed frequencies between 0.010 and 2.0 MHz. It
was observed that frequency sweep rates influence the DEP response of PS beads and
RBCs and further, the permissible frequency sweep rate is particle or cell dependent.
The underlying mechanism appears to be the same. At slower sweep rates,
particles have more time to polarize in the electric field and therefore a more accurate
and reproducible DEP spectrum can be obtained. At faster frequency sweep rates, the
particles are unable to achieve maximum interfacial polarization because of the
165

dielectric relaxation time scale so the observed DEP response does not match the true
DEP behavior of the particle.
For polystyrene beads at frequency sweep rates below 0.0063 MHz/s,
responses correlate closely with dielectric responses of particles subjected to a static
frequency potential. In the PS bead system, 0.056 MHz/s is the transitional sweep rate
where the particle dielectric relaxation is approximately the same order of magnitude
as the shifts in frequency within the sweep. Dielectric responses continue to track the
static frequency responses, although reproducibility is diminished. However as this
sweep rate is increased further, conductivity dominated interfacial polarizations
cannot be established and the PS bead frequency sweep data does not coincide with
static frequency measurements.
For full utility in DEP experiments, this frequency sweep rate methodology
must be translatable to cell systems. Results illustrated that only 0.00080 MHz/s
accurately predicted the static frequency DEP responses of human RBCs. Red blood
cells are substantially more morphologically and dielectrically complex than
polystyrene beads. Calculation of the dielectric relaxation time, taking into account
only the membrane permittivity and conductivity of 4.4 and 10-7 S/m, respectively [41]
yields DGLHOHFWULFUHOD[DWLRQWLPHaȝVURXJKO\FRUUHVSRQGLQJWR0+]7KLV
relaxation time is larger than the PS bead relaxation time of 3.5 μs, so the optimal
frequency sweep rate for red blood cells would be slower than that for PS beads. This
result suggests that for each new cell system of interest it is imperative to determine
the optimal frequency sweep rate to accurately and reproducibly interrogating the
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behavior of that cell. This work outlines a systematic technique to make comparisons
between frequency sweep rate and static frequency shown. For all cell systems, sweep
rates that are too fast will not allow the cell adequate time to polarize and will result
in inaccurate and less reproducible DEP responses. An optimal frequency sweep rate
can be estimated by calculating the Maxwell-Wagner dielectric relaxation time for the
particle/cell of interest, provided the cell’s permittivity and conductivity is known.
The frequency sweep rate chosen for the DEP study should then remain at frequencies
below the inverse dielectric relaxation WLPH  ĲMW) for 5-45s (longer times spent
below the threshold give better DEP predictions). This is necessary because frequency
sweep rates allow for particles/cells to be polarized incrementally with faster sweep
rates, larger frequency step size, not allowing sufficient polarization time. Slower
sweep rates, small frequency step size, allow particles to remain at lower frequencies
for longer yielding full particle polarization consistent with static polarization
measurements.
Since the cell’s permittivity and conductivity are determined from the
frequency dependent DEP spectrum, this presents a cyclical situation. However, this
work has demonstrated that frequency sweep rates slower than 0.00080 MHz/s can
yield accurate DEP response of PS beads as well as RBCs. This sweep rate may
therefore be translatable to other cell systems. In addition, at higher frequencies where
the polarization mechanism is more heavily influenced by charge permittivity effects
through the membrane and cell cytosol, it is possible that slow frequency sweep rates
can still accurately capture DEP response spectra. Lastly, this frequency sweep rate
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technique will enable researchers to obtain accurate and continuous DEP response
spectra in shorter experiment times.
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Chapter 6 Conclusions: Knowledge Gained from the
Dielectrophoretic Study of hMSCs for Type 1 Diabetes

6.1 Summary of Human Mesenchymal Stem Cells, Type 1 Diabetes, and
Dielectrophoretic Background Knowledge
More than 108,000 children have type 1 diabetes with 16,000 new cases
diagnosed each year in the U.S. [1]. There is growing evidence that links gene
mutations, viral infections, and bacteria to the autoimmune disruption that causes type
1 diabetes [2-25]. Because the immune system destroys the insulin producing beta
cells [26], insulin injections are used as a management tool [27, 28]. No cure exists
and the various complications necessitate the need for a curative therapeutic option,
which would negate the need for insulin management strategies and reduce the risk of
complications from the disease. An effective cure will preserve surviving beta cells,
produce new beta cells, and protect all from autoimmune destruction in the pancreas
[29, 30]. hMSCs have been explored as a minimally invasive therapeutic option for
beta cell replacement therapy, and there are chemical modifications [31-34], genetic
modification [35, 36], and nonstimulus methods [37, 38] available to differentiate
hMSCs toward insulin producing cells.
hMSCs have been explored because they hold high promise as a therapeutic
treatment option for type 1 diabetes due to their differentiation ability [39],
replenishing capacity [40], and trophic activity [41]. hMSCs are easily obtained from
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bone marrow as a heterogeneous population [42] and require separation and
purification before utilization in therapeutics. Within a single hMSC population, there
are a variety of progenitor cells (adipogenic-progenitor, osteogenic-progenitor,
chondrogenic-progenitor, etc.) and these cells have a proclivity to differentiate toward
a specific cell type. Since proclivity is not a 100% response, purification for individual
therapeutic options is important.
Thus far, hMSCs have not been well characterized and there is not a unique
catalog of biosurface markers available that distinguishes hMSCs or separate
progenitor cells from other cell populations. To compensate, current methodologies
utilize density centrifugation paired with either fluorescent-activated cell sorting
(FACS) or magnetic-activated cell sorting (MACS) to achieve hMSC subpopulation
separations [43]. The main disadvantages for FACS and MACS methods are
processing complexity and time, high cost, throughput, and cell antigen labeling; these
tedious multistep separation processes are not ideal for clinical scale-up [44].
Therefore, this research explored dielectrophoretic (DEP) microdevices as an
alternative. DEP first served as an hMSCs characterization technique and was used to
complete the first steps necessary for the design of a microdevice to achieve hMSCs
separations for type 1 diabetes therapeutic advancements.
DEP was used in this research because a) surmounting evidence shows that AC
electric fields are not harmful to biological cells [45], and b) separations/dielectric
signature quantification have been achieved with neural precursor/stem progenitor
cells [46], oral squamous cell carcinomas [47], adipose-derived stem cells [48], and
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ovarian cancer cells [49]. Prior research has shown that DEP is a quick, low cost,
noninvasive separation method, with non-damaging AC electric fields [50]. With a
custom DEP quadrapole electrode microfluidic device, hMSCs dielectric properties
were discerned with membrane capacitance and permittivity measurements. Further,
ELP-PEI standardization of hMSC morphology was achieved and dielectric properties
were measured within the same DEP device. The specific objectives accomplished in
this dissertation research are summarized below.

6.1.1 hMSC Dielectrophoretic Characterization – Objective 1
A strong case has been made to use DEP as a characterization tool to determine
the dielectric signature for hMSC separation. User-friendly DEP microdevices with
low voltage AC electric fields have been demonstrated to rapidly separate cells with
no loss in cell viability and virility. The hMSC populations tested in this work were
heterogeneous with varied morphology; therefore the development of a continuous
cell sorting microdevice should concurrently control and accurately measure hMSCs
dielectric signatures independent of cell morphology variations. hMSCs morphology
standardization was successfully achieved with ELP-PEI to regulate morphology
variations. Additionally, hMSC population heterogeneity correlates to biosurface
marker expression predisposing cells for adipocytes, chondrocytes, and osteoblasts.
Thus, after morphological standardization, precise measurements of DEP dielectric
signatures of individual progenitor cell subpopulations may next facilitate biosurface
marker-dependent cell separations.
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hMSCs dielectric dispersion is defined by their internal structure, cell
membrane and cytoplasm [50]. Our work has found that hMSCs membrane is
UHFRJQL]DEOHDWUDGLRIUHTXHQFLHVLQWKHȕ-dispersion region. The radio frequencies
polarize a cell’s surface, facilitating a DEP force, and allowing interogation of the cell
membrane dielectric properties [51]. hMSC suspending solution conductivity was
found to be critical to cell membrane polarization; higher conductivities increase
membrane permittivity shifting the DEP spectra inflection points to higher
frequencies. The solution conductivity dependence was apparent at the cross-over
frequency, fxo; 0.030S/m yields a lower fxo at 0.62MHz and 0.10 S/m yields a lower fxo
at 1.3MHz. This dielectric signature is unique for hMSCs because typical low fxo’s for
other cell systems fall in the range of 0.010-0.10MHz. Based on these results, these
differing DEP spectra could be readily harnessed for hMSC cell separations from other
cell systems. It should be noted that untreated hMSC DEP responses at static
frequencies varied within a single culture, thus reproducible separations targetting
hMSC subpopulations need to consider and control for biosurface marker expression.
This work also explored ELP-PEI treatment, which successfully standardized
hMSCs population morphology to spheroids with some cell aggregates observed. This
treatment concurrently increased DEP response reproducibility of the ELP-PEI treated
hMSCs over the untreated hMSCs. This standardization was facilitated by polymer
interaction with the hMSCs cell membrane, which altered membrane dielectric
properties and shifted the entire cell’s polarization behaviors within the nonuniform
AC fields. For ELP-PEI treated cells, only nDEP responses were observed from
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0.010–10MHz, which was substantially different from native hMSCs. Solution
media/membrane polarization behaviors implicate hMSCs are good candidates for
future biosurface marker-induced stem cell separations. With optimization of the ELPPEI treatment, detection of molecular level differences in hMSCs may be realizable to
aid understanding of biological functions and cell population purification for stem cell
therapies.
Therefore, objective 1, as follows, for this disseratioin was successfully
accomplished.
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the
DEP spectra including the cross-over frequency.
Objective 1a: Standardize hMSCs morphology with ELP-PEI to
reduce size-dependent DEP variations. Characterize the DEP spectra of
ELP-PEI treated hMSCs, then compare to native hMSCs in order to
identify conditions for cell separations. Subpopulation variations are
expected to be based on molecular level expression.

6.1.2 hMSC Dielectric Properties Modeled – Objective 2
hMSCs distinct DEP spectra in the ȕ-dispersion region were correlated to their
dielectric properties membrane permittivity and capacity in Chapter 4. Data indicated
that higher conductivity solutions increase the membrane permittivity shifting the DEP
spectra to higher frequencies. The experimentally determined DEP spectra for hMSCs
at 0.030S/m and 0.10S/m were modeled and optimized with the core-shell spherical
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DEP polarization model. The measured conductivity dependence was translated to a
membrane capacitance increase from 2.2 pF for 0.030S/m to 4.5pF for 0.10S/m.
Similarly, the membrane permittivity increases from 2.0 for 0.030S/m to 4.1 for
0.10S/m. Each optimization was a good fit to experimental data. These differing
membrane capacitance values are indicative of hMSCs unique dielectric signature;
these values are a consistent order of magnitude as values reported within the
literature. Thus, these unique dielectric signatures may be harnessed for hMSC cell
separations from other cell populations. It should be noted, however, that additional
research, discussed in the Future Work section 6.2, should delve into utilizing DEP to
discern individual hMSC biosurface markers in order to discern hMSC progenitor cell
subpopulations.
Therefore objective 2 for this dissertation research was successfully
accomplished.
Objective 2: From the experimentally derived DEP spectra obtained in Objective 1,
model the dielectric properties of human mesenchymal stem cells using MATLAB and
the Core-Shell Spherical DEP Polarization models. Use these models to calculate the
dielectric properties of hMSCs.
Objective 2a: Correlate these properties with known phenotypical
molecular expressions of hMSCs.
Objective 2b: Compare dielectric properties with other cell systems,
Table 6.1.
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Table 6.1 Cell membrane capacitance comparison between hMSCs and other cell
systems. Neural stem/progenitor cells (NSPCs) membrane capacitance was
characterized based on its progenitor cells neurogenic progenitor (NP) and astrogenic
progenitor (AP) [52]. Human mesenchymal stem cells (hMSCs) membrane
capacitance was characterized by work completed in this dissertation [53]. CaLH3,
H357, OSCC1, DOK are oral squamous cell carcinomas characterized into three
subpopulations based on cell adhesion: rapid adherent cells (RAC), middle adherent
cells (MAC), and late adherent cells (LAC), which correlates to the cells tumorigenic
capabilities [47]. Adipose-derived stem cells membrane capacitance was characterized
based on subpopulations determined by differentiation (osteoblasts), and progenitor
cells (adipogenic and osteogenic) [48].
Cell Type
NSPCs-NP biased
NSPCs-AP biased
E12.5 mNSPCs
E16.5 mNSPCs
SW Treated-E16.5
mNSPCs
hMSCs
hMSCs
treated hMSCs
CaLH3
RAC
MAC
LAC
H357
RAC
MAC
LAC
OSCC1
RAC
MAC
LAC
DOK
RAC

Conductivity
(S/m)
0.01
0.01
0.01
0.01
0.01

Cmem
(pF)
3.3
4.3
1.6
2.8
4

0.03
0.10
0.10
0.10

2.2
4.5
<4.5
4.1
3.4
2.9
3.3
2.9
2.3
1.6
1.3
1.1
5.1

0.10
0.10
0.10
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Ref
[52]
[52]
[52]
[52]
[52]
[53]
[53]
[53]
[47]
[47]
[47]
[47]

MAC
LAC
ADSC
Adipogenicprogenitor
Osteogenicprogenitor
Differentiated
osteoblasts

>1.0
>1.0

5.1
5.8
6.6
9.0

[48]
[48]

>1.0

6.9

[48]

>1.0

5.7

[48]

6.1.3 Frequency Sweep Rate Dielectrophoretic Experimental Method
hMSCs dielectric signature quantification in Chapter 4 was achieved using
traditional DEP data collection and analysis techniques, which translates to long
experimental days and laborious data analysis (months to collect and fully analyze
data). A rapid data collection procedure with automated data analysis is beneficial as
an alternative technique to quicken the process for DEP characterizations and
separations.
Traditional DEP measurements are completed at individual frequencies in
order to compile frequency by frequency, the DEP spectrum for a particle or cell
system [54]. This method requires time for individual particles to fully polarize and
for the dielectrophoretic test region to reach steady state. This can take upwards of
45s and is necessary in order to observe accurate DEP responses. An alternative
technique is to sweep the frequency or increase frequency via a linear ramp or with
small steps over time within a single experiment. This approach allows individual
particles to incrementally polarize as the frequency is incrementally increased, thus
greatly reducing response time. It was found that frequency sweep rates influence the
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DEP response of polystyrene (PS) beads and red blood cells (RBCs) and further, the
permissible frequency sweep rate is particle or cell dependent. At slower sweep rates,
particles have more time to polarize in the electric field yielding an accurate and
reproducible DEP response and thus quantified spectrum. At faster frequency sweep
rates, particles are unable to achieve maximum polarization due to dielectric relaxation
of the charges around the particle surface, so the observed DEP response does not
match the particle’s true DEP behavior.
For PS beads at frequency sweep rates below 0.0063 MHz/s, responses
correlate closely with dielectric responses of particles subjected to a static frequency.
However, at 0.056 MHz/s, responses began to deviate from static responses, so this
was the transitional sweep rate where PS bead dielectric relaxation was approximately
the same order of magnitude as the frequency shifts within the sweep. As the sweep
rate further increased, conductivity dominated polarizations were not established and
the PS bead frequency sweep data did not coincide with static frequency
measurements. Similar experiments were completed with red blood cells and results
illustrated that 0.00080 MHz/s accurately predicted the static frequency DEP
responses of human RBCs.
Dielectric relaxation is cell specific, so our work demonstrated that for each
new cell system it is imperative to determine the optimal frequency sweep rate to
accurately and reproducibly interrogate a cell’s DEP response. An optimal frequency
sweep rate can be estimated by calculating the Maxwell-Wagner dielectric relaxation
time for the particle/cell of interest. The applied frequency sweep rate should remain
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at frequencies below the inverse dielectric relaxation WLPH ĲMW) for ~5s to achieve
slow incremental polarization.

This ultimately yields full particle polarization

consistent with static frequency polarization measurements. This new frequency
sweep rate DEP method will enable researchers to obtain accurate and continuous DEP
response spectra in much shorter experiment times and requiring fewer cells.
Therefore, objective 3 of this dissertation work was successfully accomplished.
Objective 3: A new DEP data collection technique, frequency sweep rate, was
established for rapid compilation cell’s DEP spectrum. An optimization procedure was
identified for the operational frequency sweep rate for effective characterization of
specific cells DEP spectrum. The method was successfully verified with polystyrene
beads and red blood cells. Additional semi-automated data analysis was tested on
polystyrene beads and red blood cells; a patent disclosure has been filed on this work,
with the full patent application to be submitted in September 2014.
In summary, dielectrophoretic microdevice versatility has been demonstrated
within this dissertation research through hMSC quantification, hMSC treatment, and
the development of a new DEP data collection and quantification technique. New
knowledge has been contributed to the field including hMSCs DEP spectra, membrane
capacitance, permittivity, interactions with ELP-PEI, and the development of the new
frequency sweep rate DEP data collection/analysis technique.
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6.2 Future Work
The first steps toward the development of a continuous cell sorting DEP
microdevice was completed in this dissertation through the quantification of a
heterogeneous hMSCs population’s dielectric signature and the implementation of an
ELP-PEI morphological standardization technique. The next generation hMSC
microdevice should include an optimized DEP sorting chamber, which bifurcates into
additional microchannels and outlet collection ports.

Such a design could be

optimized to allow continuous flow for hMSCs separation, thus moving the current
system from a batch to a continuous process. This work is achievable by the utilization
of the microfabrication facility in the M&M building on campus, and would allow a
tailor made device to be developed for hMSCs.
Further investigations should be completed, with the new continuous cell
sorting DEP microdevice, to achieve hMSCs separations based their progenitor cell
phenotype. This is crucial in designing a device specifically for clinical therapeutics,
and allows cell fate prediction.
Another parameter that should be further explored is the ELP-PEI treatment. It
should be noted that only one concentration of ELP-PEI was tested. The concentration
was based upon the optimal concentration required for hepatocyte cells [55].
However, the hMSC cells displayed not only spheroidal shape, but also a tendency to
form into spheroid aggregates of multiple cells. To avoid these cell-cell interactions,
concentration optimization studies should be completed such that the minimal
concentration of ELP-PEI is present in the system to adjust individual cell
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morphologies. Additionally, further studies should be completed to assess the impact
the ELP-PEI treatment has on hMSCs differentiation capacity and trophic activity.
Although, further studies with hMSCs and ELP-PEI should be completed to
fully understand molecular level interactions together, it is important to mention that
utilizing this treatment will have a positive impact on hMSCs separation because of
the substantial shift in cross over frequency and DEP spectra. As a result of the
treatment, the nDEP behavior observed over a wide frequency range in the future will
allow separation from other cell systems. Dissolution studies and time necessary for
the ELP-PEI coating to be removed from hMSCs, should to be explored in order to
design a washing step on the microfluidic device. This step will allow ELP-PEI to be
removed before purified hMSCs are cultured and used in type 1 diabetes therapy.
Also within this body of work, the DEP data collection and analysis technique
was further improved using a frequency sweep rate method, which allows multiple
frequencies, be examined within one experimental test. This method is currently semiautomated using data analysis with ImageJ. For further improvement toward fully
automated data collection, MATLAB code should be instituted to automatically
analyze data collected with the microdevice. This rapid, fully automated system is
advantageous for separations of both hMSC from other cell types and hMSC
progenitor cell subpopulations. This is necessary to make this approach competitive
with FACS and MACS. Further, dielectric signatures may vary slightly from donor to
donor, so being able to rapidly quantify donor specific hMSC membrane capacitance
and then in situ adapt operating conditions would provide the versatility to
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concurrently separate hMSCs from other cells in heterogeneous populations. Thus,
dielectrophoretic separations have the potential to serve as a powerful separation tool
that would enable large-scale, more cost-effective type 1 diabetes autologous therapy.
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Appendix A: A Tunable Microfluidic Device for Drug
Delivery
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A.1 Introduction
The field of microfluidics, small-scale tests from nanoscale to microscale, has
grown dramatically over the past two decades as evidenced by greater than 30,000
papers published over the last 10 years on the topic [Web of Knowledge search using
‘microfluidic’ terms October 2011]. Microfluidic platforms, also known as lab-on-achip (LOC), include a set of miniaturized integrated unit operations that are touted to
lead to fast, easy, precise control in biological and chemical systems. LOCs include
the development of point-of-care (POC) medical diagnostic devices with the
advantages of increased sensitivity, lower sample volumes, lower reagent volumes,
low energy, low cost, low labor need, and less likelihood of human error (Xiao &
Young, 2011). Due to these advantages, LOCs have substantial potential to be widely
utilized in medicine for analytical and diagnostic assays, biosensors, and drug delivery.

1

The material contained in this Appendix was previously published in Advances in
Microfluidics, 2012.
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Microfluidic technology has been used for a wide variety of applications such
as forensics, cell phone facilitated micro-imaging, and analytical testing. In 2006
Bienvenue at al., compared the use of microfluidic technology with a commercial kit
that utilized dithiothreitol to extract and purify DNA from sperm samples. The sample
volume was less than 10 μL and the resulting electropherograms were very similar for
both techniques (Bienvenue et al., 2006). DNA separation has also been studied by
Aboud et al. Pentameric short tandem repeat (STR) markers were tested in a
microfluidic device on single-stranded DNA. Coupling microfluidics with pentameric
STRs improved allele resolution by 3.7 times (Aboud et al., 2010). In these cases,
microfluidics can be used as a rapid screening tool for forensic DNA analysis to help
resolve the backlog of DNA casework (Aboud et al., 2010; Bienvenue et al., 2006).
Zhu et al., combined optofluidics with cell phone technology. A cell phone was
converted to a microscope analysis tool by integrating optofluidic fluorescent
cytometry with compact optical attachments. The cell phone optical attachment
included a lens, plastic color filter, two light emitting diodes, and batteries, which
altogether weighed less than 1 lb. To test the effectiveness of this new imaging system,
the density of white blood cells were measured using the cell phone-based fluorescent
image cytometry and compared with the white blood cell density found with a
commercial hematology analyzer. The blood sample was injected into the microfluidic
chamber using a syringe pump and the cell phone recorded the fluorescent emission.
This study demonstrated that the densities found by both systems were a good match
with less than 5% error and that cell phone optofluidic fluorescent imaging cytometry
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was useful for rapid blood cell counts or screening of water quality (Zhu et al., 2011).
Research into microfluidic devices tailored for the medical field is extensive.
Weng et al., developed a suction type microfluidic device to detect the dengue virus.
This three-layer device used pneumatics, mixing, and transport to detect the virus in
30 minutes (Weng et al., 2011). Digital microfluidic devices transport biochemical
materials in the form of miniature discrete droplets (Xiao & Young, 2011) and have
been used for immunosensing, proteomics, DNA, and cell based assays (Vergauwe et
al., 2011). Dielectrophoresis (DEP) has been incorporated into microfluidic devices
for transport, separation, and blood typing (Minerick et al., 2008; Srivastava et al.,
2011; C. Wang et al., 2011). DEP phenomena is the movement of cells from an
external applied electric field and has been used to continuously separate breast cancer
cells from normal blood cells (Alazzam et al., 2011). The device developed by
Alazzam et al. can potentially be used as an early detection method for cancer.
Professor Robert Langer and other researchers at MIT investigated the idea of
a “pharmacy on a chip”. They performed controlled release studies to determine if a
microfluidic platform could act as a pulsatile release drug delivery system. Pulsatile
release is a common controlled release method used to treat people with disorders that
require drugs to be delivered at varying rates over time. A prototype microchip made
from silicon was developed. The microchip had multiple reservoirs for drug storage
and the reservoirs were covered with gold membranes. The reservoirs were filled with
sodium fluorescein and calcium chloride using ink jet printing. To release the drugs
an electric potential of approximately 1V was applied and the gold membranes were
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dissolved in 10 to 20 seconds. The results from this study revealed that storage and
on-demand delivery of drugs can be achieved from microfluidic LOC technology.
One major advantage of using microfluidic platforms for drug delivery is that small
microchips can be implanted inside the body to locally treat diseases (Santini et al.,
1999, 2000). Farokhzad et al. gave a possible application of microfluidic technology
in the field of urology (Farokhzad et al., 2006). Other researchers have implemented
the proof-of-concept that Langer demonstrated for ambulatory emergency care
treatment. A plethora of drug delivery systems that can be embedded in the body have
been researched for use in chronic and non-chronic diseases. When treating chronic
and non-chronic diseases drugs are delivered over long periods of time. These systems
are now modified to rapidly deliver drugs in emergency situations (Elman et al., 2009).
Elman et al. developed a smart microchip implant to deliver a drug bolus when disease
symptoms are detected. The device is composed of three layers: reservoir layer where
drug solution is stored, membrane layer where reservoir is sealed and location of drug
is released, and actuation layer where bubbles are formed to trigger the release of the
stored drugs. The actuation layer triggers the operation of the device. Micro-resistors
heat the drug to generate bubbles, pressure is produced, and the membranes burst
GHOLYHULQJWKHGUXJ §/ rapidly from the device to its target area in 45 seconds.
In this work vasopressin was used as the drug and it was found that 92.5% of the
solution loaded into the device was released. Devices of this nature have the potential
to accompany cardiac devices such as defibrillators and pacemakers (Elman et al.,
2009). Langer’s findings have even been extended to nanotechnology. Brammer et al.,
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has shown that silicon nanowires are a viable drug delivery system for antibiotics. It
was shown that silicon nanowires sustained drug release levels for 42 days (Brammer
et al., 2009).
Despite this wide breadth of research success, commercial implementation of
POC devices for diagnostics assays, biosensors, and drug delivery have been much
slower than originally predicted. A feature article in Time magazine in 2001
exemplified this dream touting safer and more effective drug delivery techniques
(Bjerklie & Jaroff, 2001). However, only a few notable LOC platforms have come to
market and are most advanced in the areas of bioassays (pregnancy/ovulation tests,
etc.) and gene chips. Bioassay companies include eBioscience, and Chembio
Diagnostic Systems, Inc. Notable gene profiling chips include those by Affymetrix,
Fluidigm, Gyros, and Sage. Blood chemical analyzers are marketed by PiccoloXpress,
while versatile analytical LOCs are marketed by Caliper and Dolomite Microfluidics.
Commercialization is more advanced in the diagnostics arena than in the drug delivery
area due to the complexity of sensing the concentration of the drug and controlling the
release of new drug. However, as demonstrated by the growth in foundational
research, popular news source stories, and commercialization of products, new
innovations in this area are being sought.
Cancer is a disease that touches everyone in the world; people are either
directly affected by cancer or know someone suffering from the disease. Globally,
cancer is responsible for 1/8th of all deaths, which is more than HIV/AIDS, malaria,
and tuberculosis combined (American Cancer Society, 2011). It is estimated that 1.5
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million new cases of cancer will be diagnosed in the U.S. in 2011. Cancer is growing
at an increasingly high rate and it is expected that there will be 21.4 million new cases
of cancer in 2030 and 13.2 million cancer deaths (American Cancer Society, 2011).
Gastric cancer is malignant cell growth originating in the gastro-intestinal tissue lining
and kills 650,000 people with 870,000 new cases diagnosed annually (BalcerKubiczek & Garofalo, 2009). It is the second most fatal disease in the world (BalcerKubiczek & Garofalo, 2009; National Cancer Institute, 2010) and has a poor prognosis
due in part to late stage development of any symptoms. People diagnosed with gastric
cancer often do not experience symptoms until the disease is metastatic and spreading
elsewhere in the body. This then dictates systemic chemotherapy treatment, which
traditionally is conducted with regular injections or an embedded catheter. These
methods add suffering and additional pain beyond the discomforts of chemotherapy.
Further, these methods of drug delivery have large variations in patient exposure
concentrations over the course of the treatment; survival rates for gastric cancer
suggest this approach is not entirely effective. Therefore, there is a great need for
development of new technology to treat cancer patients. The new technology should
have two goals (1) effectively treat cancer patients to eradicate disease and (2) make
cancer treatments as painless and noninvasive as possible. Here we wish to combine
four unique technologies into a microfluidic device to provide novel nanoscale drug
delivery for cancer patients via a wrist device resembling a watch. Figure A.1 shows
the global view of our chemotherapy drug delivery system and Figure A.2 shows the
how these four technologies fit together on the drug-delivery microfluidic device and
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are then discussed separately in the following sections.

Figure A.1 Global view of chemotherapy drug delivery system, (i) path of emulsified
drug from the wrist microdevice through the human body and (ii) enlarged view wrist
devices depicting the chemotherapy drug delivery system. The encapsulated
chemotherapy drug droplets travel from the wrist device to the intestines contacting
circulating tumor cells (CTCs) to treat the gastric cancer.

In Figure A.2(i), the reservoirs for each drug are centralized into larger
chambers above the layers shown in Figure A.2(iv). There is a primary and three
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secondary reservoirs for oil (one for each drug), and the same for saline. The primary
reservoir allows the flow rate of each drug to be independently controlled. This device
uses microchannels and tunable electrodispersion to form in-line emulsions of the
chemotherapy drug, which are then delivered to the patient using adjustable
dielectrophoretic pumping and painless microneedles that penetrate the dermis of the
skin. The focus of this new technology has been to specifically treat gastric cancer, but
can be adapted to treat many other types of cancer and possibly other diseases.

Figure A.2 Microfluidic drug delivery device for cancer treatment. (i) Overview of
fluorouracil drug system including drug, oil and saline storage including (a)
electrodispersion electrodes and (b) dielectrophoretic micropumping electrodes.
Microchannel dimensions are 25 μm (width) x 25 μm (height). (ii) Termination of
microchannels into the microneedle system. (iii) Top view of ECF droplet
microdevice. And (iv) Side view of multilayered system for droplet dispersion and
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flow to the microneedles. The abbreviations are S = saline, O = poppy seed oil, F =
fluorouracil, E = epirubicin, and C = cisplatin.

Chemotherapy is a common treatment option for gastric cancer. Several single
chemotherapy drugs have been used to treat gastric cancer including 5-fluorouracil,
mitomycin, doxorubicin, cisplatin, etoposide, docetexal, and methotrexate. Efficacy
of these drugs are typically measured via clinical response rates, which is the
percentage of patients that respond to cancer treatment such that cancer cells are no
longer detected. The response rates to these drugs were poor ranging from 15-35%
(Cleveland Clinic Foundation, 2010; Hershock, 2006; Levi et al., 1979). More
effective treatments use a combination of two, three or more chemotherapy drugs.
Combining two chemotherapy drugs has been examined by Levi et al. and response
rates for drug cocktails increased to 40-50% (Levi et al., 1979). McDonald et al.
combined three chemotherapy drugs fluorouracil, doxorubicin, and mitomycin and
results showed a 55% response rate (Levi et al., 1979). Rivera et al. studied docetexal,
a newer chemotherapy drug, in combination with cisplatin and 5-fluorouracil (DCF).
DCF was compared with docetexal/cisplatin (DC) and cisplatin/5-fluorouracil (CF),
and the objective response rates for DCF were 37-43%, 26% for DC, and 25% for CF.
Based on these results it can be concluded that a combination of three chemotherapy
drugs are more effective than two chemotherapy drugs (Rivera et al., 2007). Other
combination chemotherapy drugs have been studied, and their response rates were:
epirubicin, cisplatin and, 5-fluorouracil (ECF) 71%; 5-fluorouracil, adriamycin, and
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mitomycin 50% and 9%; 5-fluorouracil, leucovorin, and cisplatin 44%; 5-fluorouracil,
adriamycin, mitomycin, and methotrexate 42%; cisplatin, epirubicin, leucovorin, and
5-fluorouracil 43% docetexal, cisplatin, and 5-fluorouracil 37-43% (Hershock, 2006;
Power et al., 2010). Epirubicin, cisplatin, and 5-fluorouracil (ECF) had the highest
response rate of 71%. In summary, response rate data suggests that combination
chemotherapy drug treatment is the superior treatment option. Therefore, the
microfluidic device described here will utilize the combination of ECF. In the device
depicted in Figures A.1 and A.2 each individual drug in the ECF drug system is stored
in separate reservoirs so their dosage can be independently controlled via feedback
electronics. There is also redundancy in the microchannels and microneedles for
backup in case any of the channels become clogged over time. Within the
microchannels each drug is sheathed in a biocompatible oil in order to protect the
integrity and enhance drug efficacy over the dosage cycle.
This chapter will further explore the integration of microchannels,
electrodispersion, dielectrophoretic pumping, and microneedles in a dynamically
controllable microfluidic platform to deliver ECF to gastric cancer patients.

A.2 Technologies Utilized in the Drug Delivery Microfluidic Device
A.2.1 Microchannels and Electrodispersion
Emulsions are mixed dispersions of more than two immiscible fluids via
encapsulation of one layer by the other layer. These emulsion droplets are useful in
areas such as foods, cosmetics, pharmaceutical drug delivery, and chemical synthesis.
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Examples of foods include milk, yogurt, sauce, butter, etc. and cosmetics of lotion (oilin-water, O/W), cream (water-in-oil, W/O), hair, shaving, and bath products that are
predominantly viscous liquids (Mezzenga, 2005; S.H. Kim et al., 2011). In chemical
synthesis, droplets are being used as a new reaction platform due to their ability to
function as a batch reactor such as antimicrobial agent and preservatives (Hamouda et
al., 1999; Jensen & Lee, 2004; Mejia et al., 2009). The forms of emulsion droplets to
contain various physical and chemical compositions are effective in delivering drugs
and cosmetics in human body (Wibowo & Ng, 2001; Kiss et al., 2011).
In this drug delivery microfluidic device, flow focusing (FF) hydrodynamics
and electrodispersion technology are combined to dynamically generate oil-sheathed
drug droplets on the order of 100 nm outer diameter dispersed in saline. Poppy seed
oil is used to decrease the toxicity of the chemotherapy drug (Pai et al., 2003) while
maintaining its potency and efficacy once it reaches the target malignant cells, and
saline is used to carry the droplets into the tissue during injection. Our drug delivery
microdevice will combine both flow focusing and electrodispersion technologies in
order to achieve narrower size distribution of particles by preventing droplet
interactions and coalescence. Electric fields are added for chemotherapy drug droplet
formation to decrease the size of droplets, improve robustness of continuity of the
droplet thread formed, and increase velocity as droplets travel downstream in the
microchannel. Thus, the main focus of our study is developing FF geometry with
electrodispersion and adequate use of surfactants to generate submicron droplets (~100
nm) with highly uniform sizes to promote a quick transport into cells.
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Emulsion droplets of very narrow size distributions can be strategically
generated by harnessing hydrodynamic behaviors within microfluidic systems (Anna
et al., 2003; Martin-Banderas et al., 2005; W. Lee et al., 2009). FF geometries are used
in mixing immiscible phases or encapsulating one phase within a second sheathing
phase. Typically, hydrophobic drops are dispersed in a hydrophilic fluid or vice versa.
The drug delivery microdevice utilizes this technology in order to protect the inner
fluid (drug) by an outer fluid (oil), which is then dispersed in a continuous saline
stream. The inner phase is traditionally termed the dispersed phase while the outer
phase is termed the continuous phase when they meet at an orifice. Most microfluidic
emulsions involve a single droplet dispersed in a continuous phase such as water-inoil (W/O) and oil-in-water (O/W) (Ha and Yang, 1999; Anna et al., 2003; W. Lee et
al., 2009; Kiss et al., 2011). This concept can also be expanded to droplets that include
more than one internal droplet such as double emulsions (W/O/W or O/W/O) (Utada
et al., 2005; Seo et al; 2007; Liao and Su, 2010; S.H. Kim et al., 2011) and are the
foundation for the drug delivery microdevice described in this chapter.
During small droplet synthesis, mechanical shear stress was utilized in order
to achieve small and highly stable emulsion droplets, but this approach yielded tens of
nano- to hundreds of micro-scale droplets with large size distributions, which was
problematic (Pacek et al., 1999; Abismaïl et al., 1999). The key advantage of FF
technique is precise control in producing droplets into the range of hundreds of
nanometers (Anna et al., 2003; Thiele et al., 2010), but ambiguity remains regarding
the lower limit of droplet sizes that can be achieved, the size distribution and continuity
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of the droplet threads still remain unreported due in part to the difficulty of in-line
droplet size analysis and the length of the droplet thread (Anna et al., 2003; W. Lee et
al., 2009). The goal in this drug delivery microdevice is to generate the smallest
droplets possible because larger droplets are less stable and more likely to come in
contact with each other, which leads to droplet deformation and coalescence. Other
studies have determined that 50-150 nm droplets ensure an optimal intake in cells for
drug delivery applications (Thiele et al., 2010). In addition, larger droplets are less
stable and more likely to come in contact with each other which leads to droplet
deformation and coalescence.
Because the drug delivery microfluidic system dimensions are designed to fit
within a wristwatch-like system on a human wrist, multilayered FF and
electrodispersion is proposed for ECF chemotherapy drug emulsion and delivery,
Figure A.2(ii-iv). The total dimensions of multilayered ECF drug system is small
enough to be non-obtrusive, so that it can be worn for continuous drug delivery with
minimal discomfort as shown in Figure A.1. In the drug delivery microdevice, two
FF orifice/junction geometries are utilized in series as shown in Figure A.3. The two
junctions whereby sheathing flows of poppy seed oil and saline are added to the main
channel are 3mm long, 20 μm wide, and 20 μm deep in the microchannel, and the
continuous and dispersed phases are injected through pressure regulated membrane
deflection into the fluid reservoirs which operate as micropumps. Such designs are
also commercially available and meet the volume and portability limitations of the
proposed wristwatch system, as well as the energy demand limitations (Lima et al.,
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2004). The flow rate inputs are 0.01 μl/min of drug, 0.1 μl/min for poppy seed oil, and
1 μl/min for saline based on the reduction of the optimal flow conditions achieved by
Zagnoni et al., 2009 & 2010 to meet our channel dimensions in which the ratio of the
continuous and dispersed phase flow rate are held at 10 to achieve submicron droplets
in the downstream microchannels.
Achieving drug droplets with diameters at approximately 500 nm is feasible
via the hydrodynamic flow focusing achieved with the 4 μm wide orifice and
combined with the strategic use of surfactant chemistry (W. Lee et al., 2009). Droplet
size is determined initially by the orifice geometry; however, a surfactant mixed with
either the continuous or dispersed phase balances interfacial tension and enables
droplet sizes to be orders of magnitude smaller in comparison with those without a
surfactant (W. Lee et al., 2009). That is, adding a proper surfactant can improve
stability of the droplets and decrease the size of droplets because the surfactant
molecules reduce the interfacial tension between different fluids in a droplet, thus
avoiding the undesirable coalescence among droplets. For this chemotherapy drug
delivery application, proper surfactant selection requires biocompatibility, which must
be considered as well as long-term drug-surfactant interactions. To avoid the later,
surfactants will be dispersed in the oil phase and in the saline phase.
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Figure A.3 Microchannel design for the chemotherapy drug emulsion formation with
flow focusing and sheathing flow; appropriate scale not reflected. Dashed boxes (a)
and (b) correspond to the placement of the electrodes for electrodispersion and
dielectrophoretic micropumping, respectively. w2 is the orifice depth 4 μm, and w1 is
the width of the junction 20 μm . The aqueous drug solution flows through the
microchannel until it is dispersed into the continuous oil phase at junction 1. At the
junction 1 orifice, drug-in-oil droplets are formed and flow until they are then
dispersed into the saline phase at junction 2 to achieve an oil sheathing of the drug
droplet in the continuous saline phase. Double emulsion chemotherapy droplet is
produced via the second orifice. See Figure A.4 for the COMSOL simulation of this
fluid flow.

The droplet formation behavior is mainly determined by capillary number
(Ca), which represents the balance between the viscous forces and interfacial tension
at the surface of two fluids as defined LQ(TXDWLRQ,Q(TXDWLRQȝ is the viscosity
of the coQWLQXRXVSKDVH9LVWKHFKDUDFWHULVWLFYHORFLW\DQGȊLVWKHVXUIDFHWHQVLRQ
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Capillary number is the most appropriate dimensionless number to describe droplet
formation behavior because Reynolds number and Weber number are less significant
in FF (W. Lee et al., 2009). In addition to Ca, the flow rate ratio (ĳ), the viscosity ratio
Ȝ  DQG WKH H[SDQVLRQ UDWLR (A) in Equations 2-4 (W. Lee et al., 2009) are also
parameters to govern droplet formation because they balance viscous stresses and
exerted shear stresses which result in droplet thread trajectory and velocity profile. In
Equation 2, Qd and Qc are flow rate of dispersed phase and continuous phase,
respectively. In Equation 3, μd and μc are viscosity of dispersed phase and continuous
phase and w1 and w2 are depth of outside and inside orifice.
(1)

(2)

(3)

(4)
Accordingly, the size of droplets changes by capillary number due to viscous
force and the interfacial tension. While flow rate ratio affects the droplet formation
behavior significantly, the viscosity ratio has a relatively weak impact on the droplet
diameter compared to capillary number (Ca) since the flow rate is associated with
characteristic velocity of Ca. In addition, as the expansion ratio between the orifice
and the junction depth decreases, a longer thread of smaller droplets is achieved, which
is desired in the drug delivery microdevice. Much remains to be learned in regards to
208

the underlying physics in the system as well as the stability of the droplet threads over
long operation times. Therefore, a few assumptions were made in the FF designs of
the microdevice. These assumptions include the combination of the FF droplet
formation with the electrodispersion design to decrease droplet size, increases velocity
of droplets, as well as with regards to the continuous robustness of producing droplets
over long operation times (days) of the device.
Research has also been conducted in the related field of electrically
manipulated emulsifications (H. Kim et al., 2007; Zagnoni et al., 2009; Zagnoni et al.,
2010). Electric fields with a resonance frequency between 10Hz and 10MHz have
been used as a separation method to remove water dispersed in oil for applications in
the petroleum industry. This data is applicable to droplets in the drug delivery
microdevice since the frequency-modulated electric field utilized can be used as a
deformation tool for emulsion droplets (Zagnoni et al., 2009; Zagnoni et al., 2010).
Electric fields have also been used to focus and space nano and micro
emulsions/particles in microchannels of 50 μm (width)* 50 μm (length)* 61 μm
(height) orifice dimensions in DC fields (H. Kim et al., 2007). H. Kim et al. studied
electrospray emulsification and produced emulsion < 1 μm in diameter with ~2% of
size distribution at a field of 1.4*102 - 5.5*103 V/m, and also Arya et al. successfully
synthesized of hundreds of nm chitosan micro/Nano spheres for drug delivery
application in 2.3*105- 4.7*105 V/m. Furthermore, Mejia et al. formed wax emulsions
with high uniformity for water-proof painting, cosmetics, and adhesives that supports
the idea of utilizing electric field (2.6-2.9 kV in 500 ml wax mixture) in the production
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of fine emulsions. Compared to these literature values of the applied electric fields,
the device operating condition of 5*106-107 V/m is several orders are higher. The
electric energy acting on the particles cause the water-oil interface to charge such that
it behaves as a capacitor, which leads to a tip of Taylor cone which enables tiny
droplets and narrow size distribution ~2% (H. Kim et al., 2007).
Castellation configuration electrodes (Zagnoni et al., 2009; Zagnoni et al.,
2010) were designed for electrodispersion because this design resulted in the highest
localized electric field in the z-dimension, which has the potential to most efficiently
manipulate the droplets and minimize deformation in the x- and y- directions. These
are placed 200 μm downstream from both junction 1 and junction 2 as shown in Figure
A.3(a). This electric field energy does two things: a) it breaks apart the droplets from
hundreds of nanometers in diameter into the more effectively adsorbed size of < 100
nm and b) it spatially disperses the droplets in the continuous phase in order to
minimize coalescence as droplets travel forward in microchannel.
In order to simulate behaviors in the drug delivery microdevice, COMSOL 4.2
was used to simulate the 3D electric field gradient of the electrodispersion design in
Figure A.4, which is castellated gold electrodes of gap width 1 μm (x-direction), width
2 μm (y-direction), and thickness 20 nm (z-direction). The electrostatics module with
the electrostatic potential (Equation 5), a relationship between electric displacement
and the electric field (Equation 6), and Gauss’s law (Equation 7) were used to simulate
the electric field gradient in a fluid medium of saline.
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In Equations 5-7, E is the electric field, V is the electric potential, D is the electric
&
GLVSODFHPHQWİ0 is the permittivity of a vacuum, P is the electric polarization and was

DVVXPHGWREH]HURLQWKHIOXLGPHGLXPDQGȡV is the space charge density. Combining
Equations 5-7 with zero electric polarization gives
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Equation 8 is the governing equation used in to simulate the electric field gradient of
the electrodispersion electrode design (Figure A.3). Equation 8 is modified slightly
and employed in COMSOL as
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wx 2 wy 2 wz 2

(9)

In COMSOL, the physical properties for water were altered slightly to simulate the
saline such as 8.9 x 10-4 3DÂV G\QDPLF YLVFRVLW\ DQG  UHODWLYH SHUPLWWLYLW\ 7KH
physical properties used for poppy seed oil were dynamic viscosity 5.58 x 10-2 3DÂV
and relative permittivity of 4. Poppy seed oil is used to decrease the immediate toxicity
of the chemotherapy drug (Pai et al., 2003) as it enters the tissue, and saline is used to
carry the sheathed droplets and match tissue isotonicity during injection. Gold was the
material used for the electrodes, and PDMS was the material used to form the orifices
at the microchannel junctions (see Figure A.2 for orifice design) as reported in the
literature (W. Lee et al., 2009). The initial flow rates in the microchannels were chosen
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to be 0.01 μL/min for the drug, 0.1 μL/min for the poppy seed oil, and 1 μL/min for
the saline. These initial flow rate values were chosen based on Zagnoni et al. 2009 and
2010.
The fluid flow velocity in the FF microchannel was modeled with the laminar
flow module employing the Navier Stokes equation and the continuity equation, which
were simplified by assuming a steady-state system and an incompressible fluid as
follows:

U v   v p   P v  T v  FS

(10)

v 0

(11)

In (TXDWLRQVDQGȡLVWKHIOXLGGHQVLW\YLVWKHIOXLGYHORFLW\WLVWLPHSLVWKH
pressure, μ is the viscosity, and FS is the volumetric force on the fluid resulting from
surface tension.
Two types of fluidic conditions of water (to represent drug and saline) and oil
were employed, and the velocity of the formed emulsion droplets were calculated from
the summation of pressure driven flow velocity and electro-osmotic velocity. The
electro-osmotic flow velocity was calculated from Smoluchowski slip velocity
equation via a wall boundary condition on the microchannel and added to simulate the
velocity of the chemotherapy droplets in the field created by the electrodispersion,
Figure A.3.

The zeta potential for PDMS was assumed at -0.1V (Kirby and

Hasselbrink Jr., 2004). The boundary condition for electrical potential was an applied
DC field of 10V and ground across each pair of electrodes. The velocities without
electrodes were calculated from pressure driven flow in the x-, y-, and z-direction and
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expressed with ui. The governing equations for electro-osmotic flow used for this
simulation are Equation 12-16 below,

PE

H r H 0]
K

vEOF ,i

(12)
&

P E  Ei

where i = x,y,z

(13)

In Equations 12 and 13, μE LVHOHFWURSKRUHWLFIRUFHİr is the relative permittivity of the
IOXLG İ0 LV WKH SHUPLWWLYLW\ RI D YDFXXP ȗ LV WKH ]HWD SRWHQWLDO Ș LV WKH G\QDPLF
&
viscosity, vEOF,i is the velocity due to electro-osmotic flow (EOF), and E is the electric

field. The normal EOF velocity and the total velocity of the droplets are given as
v norm
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(14)
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The EOF velocity is related to the total velocity by,

vi ,total

2
ui  vEOF
,i where i = x,y,z

(16)

The total velocity is displayed in the simulation scale bar next to each COMSOL
diagram in Figures A.4 and A.5.
Figure A.4 shows the electric field gradient with and without the droplets. The
maximum electric field gradient without droplets is 1.1 x 107 V/m and the maximum
electric field gradient with droplets is 2.3 x 107 V/m. This difference is because when
the droplets pass in between the two electrodes, the droplets have an induced field,
which influences the applied field gradient by reducing the gap over which the
potential acts. The electric field is tuned to the resonant frequency of the droplets in
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order to break apart the ~500 nm droplets into < 100 nm droplets as well as distribute
the droplets spatially within the continuous fluid phase.

Figure A.4 COMSOL simulations of the electric field gradient as well as the velocity
profiles (without and with the E field active) at the midpoint (x, y plane at z = 10 μm
height) of the microchannel. (i) Channel level view of electrodes with cartooned drug
droplets, (ii) electric field magnitude, (iii) fluid velocity above the inactivated
electrodispersion electrodes at junction 1 (roughly 0.056 mm/s), and (iv) fluid velocity
once the electric field is activated (roughly 73.0 mm/s). The maximum observed
electric field strength during fluid flow is 2.3 x 107 V/m.

The drug delivery microdevice is designed so that it can be easily fabricated
with standard UV-photolithographic methods in a Class 100 or greater cleanroom. The
FF geometry integrated within the microchannel design is fabricated in poly
(dimethylsiloxane) (PDMS) using standard printed masks, UV soft photolithography
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techniques, and multilayer alignment of the channels from one layer to the next. The
electrodes can be fabricated on a silicon or glass support via photoresist masking
followed by deposition of a 10 nm titanium layer then a 10 nm gold layer by electronbeam evaporation.
Each layer of the molded channels can be sealed via oxygen plasma bonding
procedures. PDMS is hydrophobic so that oil wets the walls, but surface treatment
defines the required hydrophobic and hydrophilic patterns depending on fluid phases
used. The dispersed drug phases will be hydrophilic (viscosity, μc= 6 mPaÂs) and a
biocompatible surfactant will be mixed with either the continuous phase at a
concentration approximately 2.5 times greater than the critical micelle concentration
(CMC) which is a moderate surfactant concentration and is favorable to test a wide
flow rate range (W. Lee et al., 2009). The presence of the surfactant does not
substantially change the viscosity as evidenced by W. Lee et al.
A positive displacement chamber pump connected across a membrane to a
pressurized canister will be used to drive the fluids from each inlet into the FF
microchannels. Separate micropumps will connect to each solution reservoir such that
flow in each channel can be separately controlled to achieve a feedback controlled
fluidic system that can be worn on a wrist (Lima et al., 2004). Pressure drops for flows
between 0.01 and 1 μL/min are not expected to cause deformation of microchannels
due to either high-pressure injection or the PDMS elasticity used in our drug
microdevice (Soller et al., 2011). If necessary, Thermoset Polyester (TPE) would be
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the best alternative material of PDMS due to its high rigidity and suitability with
droplet microfluidics (Soller et al., 2011).
In order for a stable, efficient, and continuous small dosage of drug delivery,
optimized selection of a surfactant, microfabrication condition, and pumping system
are discussed. The unique combination of FF and electrodispersion to generate drug
droplets protected by a sheathing layer of biocompatible poppy seed oil is described.
Further, the electric field and fluid flow conditions were simulated and results used to
optimize the design. The droplets exiting the flow focusing and electrodispersion
region must then be accelerated in the drug delivery microdevice channel in order to
generate a high enough pressure difference for the fluid to exit the microneedles into
the dermis of the skin to achieve drug delivery.

A.2.2 Dielectrophoretic Pumping
Traveling wave DEP (twDEP) is incorporated into the drug delivery
microdevice in order to accelerate the chemotherapy droplets as they travel to an array
of microneedles for painless injection into the body. DEP is an efficient nondestructive
way to manipulate bioparticles (Cheng et al., 2011), and twDEP is being investigated
as a possible drug delivery technique (Bunthawin et al., 2010). The electrode
configuration consists of an array of parallel rectangular electrodes configured in an
intercalated pattern as shown in Figure A.1(ib). The intercalated configuration of the
electrodes facilitates horizontal movement of particles when a non-uniform AC field
is applied that is offset by 90° with each successive electrode. This causes the field
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maxima to travel in waves down the array of electrodes thus driving the particle
forward. Typically the spacing between the electrodes is fixed to the width of one
single electrode with the optimal width of an electrode being close to the diameter of
the target particle. The spacing between the electrodes is usually 10 μm to 50 μm and
remains constant (Lin & Yeow, 2007).
Parallel electrodes are used for collecting, transporting, and/or separating
particles. For the drug delivery microdevice, we will be using the parallel electrodes
for transporting the oil-sheathed chemotherapy droplets. To help facilitate
transportation the frequency and conductivity of medium is chosen specifically to
induce the largest positive DEP force on the dielectric particles. Positive DEP is the
movement of particles up the electric field gradient. When the AC field is applied to
the electrodes a dipole moment is induced in the particles and the time-average DEP
force, <FDEP>, is given as (Pethig, 2010)

FDEP

^

2SH m R 3 Re> f cm @E 2  Im> f cm @¦ E 2I

`

(17)

In Equation 17 Hm is the absolute permittivity of the medium, R is the radius of the
particle, fcm is the Clausius-Mossotti factor, E is the amplitude of the electric field, and

I is the phase. The Clausius-Mossotti factor is related to the polarizability of the
particle and ¦ E 2I , is the summation of the magnitude and phase of each field
component. The Clausis-Mossotti factor, fcm, for a spherical, homogeneous particle is
given as (Pethig, 2010)
f cm

H p H m
H p  2H m
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In Equation 18 Hp is the complex permittivity of the particle and Hm is the complex
permittivity of the medium defined as (Pethig, 2010)
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In Equation 19 and 20 Hp is the absolute permittivity of the particle, Vp is the
conductivity of the particle, Vm is the conductivity of the medium, Z is the angular
frequency and j is the imaginary number. It is important to note that the DEP force for
twDEP is dependent on both the real and imaginary part of the Clausius-Mossotti
factor which causes particles to experience both an in-phase force (real part) and the
out of phase force (imaginary part). Classical DEP force is only dependent on the real
portion of the Clausius-Mossotti factor, FDEP

2SH m R 3 Re> f cm @ E .
2

Further, the assumption that the oil-sheathed droplets of aqueous drug can be
represented as a first approximation homogeneous particle is acceptable because the
conductivity of the oil layer is substantially different §1 nS/m) from the supporting
saline medium that the Clausius-Mossotti factor is nearly 0.50 – 3.36*10-8i and varies
very little (4.8x10-8%) over the anticipated frequency range of interest from 1 Hz to
10 MHz (Durr et al., 2003; Felten et al., 2008). Since twDEP is being used to transport
chemotherapy droplets, it’s important to have an expression that relates the particle
electrophoretic mobility with twDEP force. The DEP force can also be written
utilizing the zeta potential ]p (Kang & Li, 2009),
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The DEP force written in this form allows it to be related to the electrophoretic
mobility of the particle given as (Kang & Li, 2009)

PE

vDEP

H r H 0] p
K

R 2H r H 0 Re> f cm @
E
3K

(22)

(23)

In equations 21-23]p is the zeta potential, Hr is the relative permittivity of the medium,
R is the radius of the particle, E is the magnitude of the electric potential, H0 is the
permittivity of free space, Re[fcm] is the real-part of the Clausis-Mossotti factor, and K
is the dynamic viscosity of the medium.
Parallel electrodes were added to the end of the microchannels, Figure A.2(ib),
to increase the velocity of the chemotherapy droplets to ensure the droplets reach the
microneedles at the end of the device with sufficient velocity to penetrate the dermis.
The desired velocity at the microneedle tips was 10 μm/s based on modeling of
transdermal delivery (Lv et al., 2006). COMSOL was used to simulate the electric
field gradient via the conservation of electrical potential between the insulating
channel walls and the velocity of the droplets via the Navier-Stokes (Equation 12) and
conservation relationships (Equation 13). Equations 5-9 developed in section 2.1 were
used to obtain the electric field gradient with and without droplets in the channel as
shown in Figure A.5. Droplets were defined as separate spherical
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Figure A.5 COMSOL simulation of traveling wave dielectrophoretic pumping
electrodes before and during fluid flow in the microchannel. The combined total length
of the electrodes including gaps is 22 μm (i) channel level view of electrodes, (ii)
normalized electric field strength from twDEP electrodes, (iii) velocity distribution in
the channel view. In (i) when the twDEP electrodes are energized at an instantaneous
half cycle with max potential of 10Vpp to ground at subsequent electrodes. The
maximum observed electric field strength before fluid flow is 7.2 x 106 V/m, and the
maximum electric field strength during fluid flow is 1.1 x 107 V/m. The droplet fluid
velocity was 70 mm/s in this DEP pumping region at z = 10 μm.

fluids with the laminar flow module in COMSOL. The material selected in COMSOL
for the particles was oil as previously described in section 2.1 and modified water to
represent saline. It can be seen in Figure A.5 that the electric field gradient decreases
by 65% when the droplets are present because of the change in the electric charge of
the dielectric oil layer. Further, the droplets align along the centerline of the electrode
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configuration because the DEP force is directed toward the symmetric centerline. This
phenomenon is observed because electric field interact with droplets and induce force
due to the dielectric property difference between immiscible phases (water and oil)
since free charges can accumulate on the interface between inner and outer fluid. The
droplet equilibrium height is 10 microns above the bottom of the channel. DEP forces
are predicted to be on the order of 152 pN for the 10 Vpp field over the 22 μm
electrodes.
The electrophoretic mobility was used to simulate the velocity of the
chemotherapy droplets in the field created by the dielectrophoretic pumping
electrodes. In this drug delivery microdevice system, the droplet is a chemotherapy
drug coated with poppy seed oil in a continuous phase of saline. In order to look at
electric field effect, electrophoretic mobility was an added term.
In Figure A.5, the fluid velocities increased by over 5000 times from
0.021mm/s to 109 mm/s by implementing dielectrophoretic pumping at 10 Vpp via
the electrode designs in the COMSOL simulation. Comparing without and with
dielectrophoretic pumping (Figure A.4(iv) and Figure A.5(iii), respectively), the
velocities with electrodispersion and DEP pumping electrodes remarkably changed as
demonstrated in Figure A.6. These increases in velocity are necessary to move the
drug droplets forward to the microneedles for injection.
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Figure A.6 The top of each simulation shows x-y plane, top view, and bottom of each
simulations shows z-x plane to display overall velocity profile. COMSOL simulation
of fluid velocity without (i) and with (ii) dielectrophoretic pumping electrodes.
Interdigitated dielectrophoretic pumping electrodes were added to the end of the
microchannel to increase the velocity of the chemotherapy drug droplets to ensure
sufficient velocity for microneedle injection. (i) The maximum fluid velocity inside
the microchannel without electrodes was 0.025 mm/s reached at junction 2, (ii) the
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maximum fluid velocity with electrodes was 109 mm/s also at junction 2. The
magnified sections for (i) and (ii) show that the fluid velocity substantially increases
from 0.0056 mm/s to 35 mm/s at the end of the microchannel once the pumping
electrodes are added.

A.2.3 Microneedles
The skin is a common area for drug delivery, and offers advantages over other
non-invasive drug delivery techniques. Drug delivery through the skin avoids drug
metabolism by enzymatic reactions and the gastro-intestinal system, has the potential
for continuous drug delivery (Migalska et al., 2011), and facilitates reaching
circulating tumor cells (CTCs) that metastacized from their origin. Hypodermic
needles are commonly used as the dominant method for transdermal drug delivery for
gastric cancer treatment. Needles are painful, inconvenient and require professional
administration for each dose (P.M. Wang et al., 2006). Another problem is that drugs
are delivered all at once which causes an immediate spike in drug concentration
profiles, which then rapidly diminishes. This can cause physiological instabilities,
other dosage-related side-effects and can potentially fail to completely eradicate the
tumor and/or CTCs (Zahn et al., 2004). To overcome these drawbacks, this work
proposes a novel drug delivery microdevice amenable to feedback control; the device
integrates microchannel hydrodynamic flow focusing, electrodispersion to decrease
drug droplet size, dielectrophoretic pumping, and microneedles together in one
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microdevice to deliver chemotherapy drugs in the form of droplets to a gastric cancer
patient.
The skin has four layers: (1) the stratum corneum, principal barrier composed
of corneocytes, (2) epidermis, (3) dermis, and (4) subcutaneous tissue (EscobarChavez et al., 2011). The four layers of the skin are barriers to transdermal drug
delivery and microneedles are used as physical enhancers for transdermal drug
delivery. They are designed to increase the permeability of the skin up to four orders
of magnitude, so that drug passage through the stratum corneum and outer most layer
of the epidermis becomes simple (Escobar-Chavez et al., 2011; K. Lee et al., 2011).
Microneedles allow for drugs to be delivered across the skin in four ways: (1) “pokewith-patch”, this method uses a solid microneedle array to penetrate the skin creating
micropores, the microneedle array is removed and drugs are delivered through the
micropores via a transdermal patch, gel or solution; (2) “coat-and-poke”, this method
coats an array of microneedles with a drug and inserts the coated microneedles into
the skin; and (3) “poke-and-release” embeds the drug molecules into the structure of
polymer, biodegradable microneedles and inserts them into the skin; and (4) “pokeand-flow”, uses hollow microneedles to insert liquid drugs into the skin (Migalska et
al., 2011). There are advantages and disadvantages to each approach and these vary
with the application. Micropores created by microneedle penetration last for more than
a day when left covered and they last for less than 2 hours when left uncovered.
Microneedles that dissolve under the skin are perceived as the safest with the least
chance of prolonged irritation (K. Lee et al., 2011). Methods 1, 2, and 3 are best suited
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for applications where a one-time dose or daily dose of drug is desired. However, for
the chemotherapy drug delivery microdevice, method 4 is optimal. The microneedles
would remain inserted in the skin and held in place via a wristband as shown in Figure
A.1.
Microneedles can be inserted into the skin easier than hypodermic needles
because stress on the skin is inversely proportional to the area of the top (Zahn et al.,
2004). Microneedles require sharpness to overcome stress forces on the skin surface
as well as strength against fracturing, bending, and buckling, sufficient flow rate, and
biocompatibility of the needle material (Nguyen & Wereley, 2006). The insertion
force can be lowered by utilizing kinetic energy such as vibration which can reduce
the force by as much as 30% (Nguyen & Wereley, 2006), and provides an increase in
infusion flow rate (P.M. Wang et al., 2006). Retracting the microneedles after insertion
by approximately 100-300 Pm also achieves a much greater flow rate (P.M. Wang et
al., 2006).
Microneedles have been shown to increase the transdermal delivery of many
molecules

including

aminovulinic

acid,

anthrax,

bovine

serum

albumin,

desmospressin, erythropoirtin, meso-tera(N-methyl-4-pyridyl)porphine tetra tosylate,
ovalbumin, plasmid DNA, low molecular weight tracers to proteins, and nanoparticles.
Insulin is the most widely studied drug with microneedles and enhanced skin
permeability has been reported in vivo and in vitro (Donnelly et al., 2011; EscobarChavez et al., 2011). Recently researchers have looked into using microneedles
fabricated from maltose to deliver methotrexate to rats via iontophoresis to treat
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cancer. The result of this study was a synergistic 25-fold increase of drug delivery
(Escobar-Chavez et al., 2011).
Microneedles are a painless drug delivery method and create larger transport
pathways for larger molecules; our device extends this to nanometer droplets. The
painless characteristics of microneedles allow them to overcome the limitation of
hypodermic needles. Advantages of microneedle technology are that the transport
mechanisms are not dependent on the diffusion into the tissue, placement in the
epidermis allows for drugs to reach target areas more readily, while only penetrating
the stratum corneum without piercing nerve endings thus reducing pain, infection, or
other injury. The microneedles are nontoxic, minimally invasive, can be massproduced for a range of materials such as silicon dioxide and polymers, are easily
disposable/interchangeable, and can be made from biodegradable materials. Some
disadvantages to using microneedles are local inflammation and skin irritation.
Another disadvantage is that the microneedles may break and be left under the skin;
to avoid this, the diameter of the microneedle should be smaller than the diameter of a
KDLU 50 μm (Escobar-Chavez et al., 2011). In comparison hypodermic needles are
inconvenient, not easily self-administered, and have poor targeted delivery because
they have to be manually injected (P.M. Wang et al., 2006).
Our microdevice uses an array of microneedles, Figure A.7, to deliver drug-inoil microdroplets, applying the “poke-and-flow” method. Figure A.7(i) shows the
design of a single microneedle wherein the diameter of hole in the microneedles is
approximately 40 μm which is sufficiently large to allow delivery of the oil sheathed
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drug droplets without disruptive shearing effects while simultaneously being large
enough to avoid breakage in the skin. Figure A.7(ii) is color coded to show the array
of microneedles for each of the chemotherapy drugs with blue representing epirubicin,
red representing cisplatin, and green representing fluorouracil. Each microneedle is
connected to its own flow-focusing channel as shown in Figure A.2. Figure A.7(iii)
shows a photograph of an array of microneedles (Baek et al., 2011) fabricated from
polylactic acid. The fluid emulsion velocities are approximately 35 mm/s as they leave
the DEP pumping electrode region. Once the emulsions enter their final descent, to the
microneedles the midchannel linear velocity decreases to approximately 30 to 40 mm/s
as the channel expands followed by velocity increases within the microneedle tip, as
constrained by the continuity equation.
Several methods are used to fabricate hollow microneedles and most are made
from silicon or silicon-based materials. This drug delivery microdevice requires a
relatively straight channel with minimal bends so that the microdroplets are not
sheared and are delivered to the dermis intact. The pyramid-shaped microneedles were
chosen because fabrication is simple and thus it has the best shape to achieve tip
sharpness and strength (Moon & Lee, 2003). The pyramid microneedles can be
fabricated by an inclined LIGA process combining lithography, electroplating, and
molding techniques. This process utilizes X-ray’s directed towards a protective
electroplated gold mask over a poly(methyl methacrylate) (PMMA) substrate on a
silicon wafer (Moon & Lee, 2003).
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As discussed in this section, optimal material, design, and operating conditions
were gleaned from the literature. This information was combined to simulate electric
field and hydrodynamic flow behaviors in each section of the microdevice. The design
was iteratively optimized based on these simulation results and then integrated
together into the drug delivery microdevice.

Figure A.7 Microneedle design to deliver chemotherapy emulsion to cancer patient,
(i) pyramid-shaped hollow microneedle for delivery of 3 chemotherapy droplets
(epirubicin, cisplatin, and fluorouracil) and the COMSOL simulation of the fluid
velocity in the microneedle, (ii) microneedle array, and (iii) real image of a
microneedle array. The initial velocities of the fluids in the microchannel were 4.2*104

m/s drug, 4.2*10-3 m/s poppy seed oil, and 4.2*10-2 m/s saline, and the exiting

velocities from the microneedles is approximately 40mm/s. In (iii) microneedles are
made out of poly-lactic acid (Baek et al., 2011).
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A.3 Integration of Technology into Fully Conceived Device
This microfluidic drug delivery device will operate in sequence as described
in sections 2.1 through 2.3. First, three different chemotherapy drugs, Epirubicin,
Cisplatin, and Fluorouracil, will be separately dispersed into oil and then subsequently
into saline by proven flow-focusing microchannel technology. Current state of the art
results in this field suggest droplets formed will be approximately 500 nm in diameter.
This design utilizes two stages of interdigitated electrodes on the bottom surface of the
microchannel leaving the flow focusing junction in order to electrodisperse the
droplets into <100nm droplets and to evenly disperse them spatially as they flow
downstream to reduce coalescence. The oil-sheathed drug droplets are then pumped
down the microchannel using traveling wave DEP technologies before flowing into an
array of microneedles inserted into the dermis layer of the skin. This entire system is
packaged inside of a small unit that can be worn on the wrist. The reservoirs for each
drug, poppy seed oil, saline, and pressurized air to pump from the reservoirs can be
individually replaced based on usage. Further, integrated electronic feedback control
and monitoring (not described here) can be utilized to monitor chemotherapy drug
delivery into the dermis and subsequently the blood stream of a cancer patient. The
main components of this microfluidic device were optimized from literature data and
COMSOL simulations.
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A.4 Conclusions and Perspectives for Future Integrated Microdevice
Technologies
There is a great need for new technologies to effectively treat all forms of
metastasized cancer. Gastric cancer provides a poignant example because patient
symptoms typically do not arise until the cancer has progressed to stage IV. Any new
technologies developed should increase the comfort level of patients as well as
concurrently improve treatment efficacy or even eradicate the disease. The goal of this
work was to develop a novel drug delivery system to effectively treat gastric cancer
patients with minimal pain or lifestyle interruptions while undergoing treatment.
In addition, this work links together technologies that have been progressing
in isolation from each other. For example, electrodispersion integrated with flow
focusing and surfactant stabilization is a novel technique with the potential to produce
droplets less than 100 nm in diameter. Smaller droplets are desired in diverse
applications such as nanoparticle synthesis or pharmaceutical packaging.

One key

advantage of this combined technique is that it can be integrated into lab-on-a-chip
devices provided the capillary number and volumetric flow rate ratio are optimized
and the surfactant required for optimizing interfacial tension increases the long-term
stability of droplets.
Traveling wave DEP is an advantageous technique for transport of droplets in
microchannels, which has minimal power requirements and thus is ideal for portable
microdevices operating on batteries. Incorporating traveling wave DEP electrodes into
the drug delivery microdevice described increased the velocity of the droplets for
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optimal microneedle injection rates.

Further, this technique has proven to be

minimally disruptive to a particle, which is a key advantage with this adaption of the
technology in the drug delivery microdevice.
Microneedles have been explored in many forms as physical enhancers for
drug delivery. Within the drug delivery microdevice, the microneedle array was
adopted to reduce pain and facilitate continuous delivery of the Epirubicin, Cisplatin,
and Fluorouracil chemotherapy drug cocktail into the dermis. Based on evidence from
previous studies, the pain level can be greatly reduced and the chemotherapy droplets
reach their target areas in a more efficient manner thus reducing side effects.
For future work this drug delivery microdevice wrist system could be improved
by incorporating a biosensor, in-line feedback control, and wireless reporting to
measure the concentration and metabolites of the chemotherapy droplets in the blood
stream, dynamically adjust dosage, and keep the primary care physician informed of
progress. This will allow for real-time drug and treatment monitoring. The advantages
of adding in this technology would be decreases in patient drug side effects, uniform
maintenance of the critical drug concentration delivered to the gastric tumor and
CTCs, increased treatment effectiveness, and increased patient comfort.
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